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Abstract 
Type 1 diabetes (T1D) results from autoimmune destruction of insulin-producing pancreatic 
β cells, involving CD4+ and CD8+ T cells. Currently, there is no treatment for T1D, and 
disease management relies on insulin replacement therapy associated with major 
complications. Therefore, there is an urgent need for an effective T1D therapy without the 
need for systemic immunosuppression. The ideal immunotherapy would be safe, cheap and 
specifically inactivate or eliminate pathogenic islet-specific T cells and/or increase islet-
specific regulatory T cells (Tregs). To this end, I have investigated the utility of liposome 
delivered antigen-specific therapy for T1D. 
Using the non-obese diabetic (NOD) mouse model of T1D, the Hamilton-Williams lab has 
shown previously that liposomes co-encapsulating a CD4-targeted islet antigen and NF-kB 
inhibitor induced antigen-specific induction of regulatory CD4+ T cells in mice and delay 
disease progression. As islet-specific glucose-6-phosphatase catalytic subunit-related 
protein (IGRP) is a major CD8-T cells diabetogenic antigen in NOD mice, I now aimed to 
test the efficacy of an IGRP-specific immunotherapy targeting CD8+ T cells for inducing 
tolerance and protecting from disease. 
For this current model, I have used liposomes co-delivering the CD8 epitope IGRP206-214 and 
NF-kB inhibitor calcitriol to treat NOD mice. Liposome delivered peptide was presented by 
antigen-presenting cells to T cells as IGRP-specific CD8+ transgenic 8.3 T cells proliferated 
in draining lymph nodes after treatment. IGRP-specific 8.3 T cells expanded at day 4 and 
then contracted by day 10 following delivery of IGRP206-214 only and IGRP206-214 /D3 
liposomes. Furthermore, the upregulation of activation and anergy markers such as CD44, 
LAG-3 and PD-1 on the 8.3 T cells following the liposomal treatment was observed. In 
contrast, endogenous IGRP-specific CD8+ population did not increase in frequency or 
upregulate of activation markers after one liposomal treatment. However, after two 
treatments the endogenous IGRP-specific cells significantly upregulated CD44 and PD-1. 
Consistent with the cells gaining a tolerogenic phenotype, IFN-g production was suppressed 
in endogenous IGRP-specific CD8+ T cells following IGRP206-214 /D3 but not IGRP206-214 only 
liposome treatment. These data suggest that endogenous IGRP-specific CD8+ T cells get 
activated in response to the liposome delivered antigen, but they gain an unresponsive 
phenotype. 
I then tested the efficacy of the therapy firstly using an accelerated transfer model of 
diabetes. IGRP206-214/D3 subcutaneous liposomal treatment significantly delayed the 
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transfer of diabetes compared to control mice and IGRP206-214 only liposome treatment. We 
then tested the efficacy of this treatment in spontaneous disease using both pre-diabetic 
NOD mice and mice treated at the onset of hyperglycaemia. T1D progression was delayed 
in all animals treated with IGRP206-214/D3 compared to control groups both in the prediabetic 
and disease onset regimens. This demonstrates that immunotherapy targeting a single 
dominant CD8 epitope is effective but codelivery of immunomodulator calcitriol was required 
to enforce tolerance. 
I next sought to improve this therapy by combining the IGRP-targeted liposomes with the 
CD4 T cell chromogranin-A (BDC2.5mim/D3) targeting liposomes our lab has previously 
shown protect from disease by induction of a population of IL-10 producing antigen-specific 
Tregs. I then co-delivered IGRP206-214/D3 and BDC2.5mim/D3, hypothesising that this multi-
epitope delivery will offer more robust tolerance by inducing production of Tregs and 
simultaneously inactivating pathogenic CD8+ T cells. Treatment at hyperglycaemia delayed 
the disease progression but did not improve the outcome compared to a single treatment 
with IGRP206-214/D3 liposome, whilst no disease protection was achieved in pre-diabetic 
mice. Furthermore, co-delivery of IGRP and BDC2.5mim liposomes actually increased the 
expansion of CD8+ IGRP-specific cells and prevented induction of a regulatory response 
suggesting that this combination may, in fact, impede effective tolerance induction. 
In summary, our IGRP-specific liposomal treatment results in inactivation and anergy of 
pathogenic CD8+ T cells evidenced by increased expression of PD-1 and LAG3 as well as 
significant reduction of IFN-g production. While we did not find good evidence for complete 
deletion of the IGRP-specific T cells, the expansion of these cells was blunted, and this may 
have been mediated by depletion of the cross-presenting CD8+ T cell population. While 
multi-epitope liposomal delivery did not induce antigen-specific Tregs or synergise to 
increase disease protection, disease development was still delayed when treated at the 
onset of hyperglycaemia. Further investigation is required to improve the efficacy of this 
treatment. These data establish a model in NOD mice for analysis of diabetogenic antigen 
presentation and response to antigen-specific liposome immunotherapy to complement 
studies of immunotherapy to prevent or treat diabetes. 
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 Introduction 
Type 1 diabetes (T1D) is a T cell mediated disorder in which tolerance to b-cell antigens 
fails, leading to hyperglycaemia and a number of complications including neuropathy, 
nephropathy, retinopathy and cardiovascular disease. Both central and peripheral tolerance 
mechanisms fail during disease development and both genetic and environmental factors 
have been described to play role in its progression. The genetic susceptibility is shared 
amongst other autoimmune disorders and T1D patients have been known to succumb to 
other autoinflammatory or autoimmune disease such as celiac disease [1]. The loss of 
tolerance to pancreatic islet proteins can occur much earlier than clinical manifestation. 
Increased risk of the disease development is associated with the production of 
autoantibodies which target insulin, IGRP (islet-specific glucose-6-phosphatase catalytic 
subunit-related protein), zinc transporter8, glutamic acid decarboxylase (GAD65) and IA2 
(also known as PTPRN) [2]. The presence of one autoantibody bears a risk of the disease 
development of approximately 6 per cent in 5 years compared to 60 per cent when four or 
more autoantibodies are present [3]. 
T1D patients present with insulin deficiency symptoms, such as sudden weight loss, 
polyuria, polydipsia, elevated levels of glycosylated haemoglobin and hyperglycaemia. 
Some patients experience momentary improvement in insulin secretion falsely perceived as 
the disease improvement. This phenomenon is termed ‘clinical honeymoon’, during which 
an adequate glycaemic control is preserved, and patient is in the partial remission stage. 
Preserving pancreatic β cells function and as such production of insulin is important for the 
disease management and provides a therapeutic window for potential intervention and 
treatment. Glycosylated haemoglobin (HbA1c) has been used as a measure of glycaemic 
control, however, in the context of remission, more sensitive measure of β cell function is 
required. Proinsulin derived C-peptide is secreted by β cells along with insulin  [4] and 
provides such a measure and is now widely accepted as a marker for β cell function [5]. 
(Figure 1-1). 
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Figure 1-1. Model of type 1 diabetes progression revised from that originally proposed by 
Eisenbarth.  
Dotted line represents increased β cell function during childhood. This explains higher C-
peptide responses in older patients with a new onset compared to the younger ones. 
Antigenic epitopes are not revealed as a single event and loss of tolerance to multiple islet 
antigens occurs prior to overt diabetes. Immune therapy may reverse or stabilise the 
impairment in β cell function. Adapted from [6]. 
Currently, disease is managed mainly using exogenous insulin, however, this approach is 
not curative, and patients’ quality of life is still affected dramatically. Insulin replacement 
therapy remains the safest and most effective disease management strategy. Therefore, 
any therapies proposed need to withstand stringent safety regulations, particularly with 
paediatric patients in mind. 
The causative factors remain difficult to identify due to the multifactorial nature of the 
disease. It is, however, widely accepted that both genetic and environmental factors play an 
important role in the disease initiation and progression. A high-degree of genetic risk is 
required for individuals to develop the disease. In monozygotic twins’ concordance is over 
50 per cent and the risk of the disease development is approximately 6 per cent for 
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individuals with affected siblings. The development of anti-islet autoantibodies and disease 
onset may occur many years later in twin sibling of the affected individual, highlighting the 
involvement of environmental factors. 
 Genetic Associations with T1D 
 
The strongest association with autoimmunity susceptibility is linked to the HLA region on 
chromosome 6p21. HLA-DR and HLA-DQ is within the major histocompatibility complex 
(MHC) II and are responsible for approximately 40 percent of genetic susceptibility 
eventually resulting in T1D. HLA class II is very closely associated with the disease and 
heterozygous DR3/4-DQ8 haplotypes DRB1*0401-DQB1*0302, DRB1*0301-DQB1*0201 
and DQA1*0301, DQB1*0302 are responsible for susceptibility, whereas DQA1*0102-
DQB1*0602 and DRB1*1501 have a protective effect [7]. Approximately 30-50 percent of 
T1D sufferers possess high risk DR3/4-DQ2/8 haplotype and siblings of diabetic patients 
sharing this haplotype have a very high risk of developing the disease by the age of 15 [8] 
Moreover, MHC class I has also a certain degree of involvement in the risk for T1D [9]. 
Outside of the HLA locus, where T cell specificity is established, other regions with less 
prominent associations are also linked to disease development. These include regions 
encoding insulin, CTLA-4, protein tyrosine phosphatase 22 (PTPN22), and interleukin-2 
receptor alpha (IL-2Rα). The pleiotropic effects of these genes are thought to be associated 
with defective T cell function and immune regulation [10, 11]. 
 
 Environmental Associations with T1D 
 
Concordance rates in monozygotic twins are approximately 40 percent. Whilst this confirms 
the strong link with the genetic susceptibility, it also suggests that other factors may play an 
important role in the disease progression. The ongoing search for environmental triggers 
continues, however, it is now evident that certain events/insults may initiate the process in 
the genetically predisposed individuals. Some of the environmental associations that have 
been implicated include direct or indirect infection of the pancreatic tissue with a virus such 
as coxsackie virus B4 (CVB4). Release of pro-inflammatory cytokines TNF, IL-8 or IL-6 and 
chemokines as a response to virus may bear devastating effects on the pancreas [12]. 
Vitamin D insufficiency appears to have a negative effect on pancreatic β cells. Hayes et al., 
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suggested that vitamin D may be involved in thymic negative selection; therefore, its reduced 
amount potentially influences the development of autoimmunity [13]. On the contrary, the 
‘hygiene hypothesis’ has been proposed, suggesting that infections with a variety of 
pathogens, and subsequent alteration of the microbiota and immune system may prevent 
T1D onset. However, infection by many of these organisms have been eliminated in modern 
day healthcare, supporting the idea of increased hygiene resulting in increased T1D 
incidence [14].Furthermore, the seasonal impact on the disease progression has been 
described, noting elevated levels of soluble IL-6 and C-reactive protein during European 
winter months which was correlated to increased incidences of disease onset [15]. Whilst 
some environmental triggers remain a subject of many controversial discussions, the 
importance of them cannot be ignored. Identifying the environmental factors in T1D 
pathogenesis may provide an opportunity to target affected populations with genetic 
susceptibility [12]. 
 The NOD mouse model of T1D 
Animal models offer an invaluable insight into the genetic and immunological 
mechanisms of disease progression and possible treatments. In T1D, the most widely 
studied rodent models are the nonobese diabetic (NOD) mouse and the biobreeding 
(BB) rat [16]. These animals spontaneously develop diabetes and serve as excellent 
models to study T1D [17]. Recent advances allowed creation of transgenic and knock-
out models as well as conditional knock-outs and knock-in vectors and have enabled 
researchers to address a much wider range of mechanistic aspects of T1D pathogenesis 
[18]. 
NOD mice were developed in 1974 by Shionogi Research Laboratories and are currently 
the most widely studied T1D animal model. In this particular model insulitis development 
is initiated at the age of 3-4 weeks and is characterised by the infiltration of CD4+ and 
CD8+ lymphocytes in the pancreatic islets. This is followed by the destruction of β cells 
and eventual loss of insulin production. The disease first occurs at approximately 12-14 
weeks depending on the animal facility. The age of onset varies dramatically, with 
spontaneous disease development occurring up to the age of 30 weeks in mice [19]. 
The MHC-II alleles associated with disease development are structurally similar in both 
humans and NOD mice and several other genetic pathways are shared. Moreover, in 
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both cases the disease development is primarily T cell mediated. These similarities have 
been exploited in the search for potential therapeutic answers [20]. 
Whilst NOD mice have been invaluable in studying the tolerance mechanisms and the 
development of treatments, the issue of the great differences between human and 
murine immune systems is still prominent and the treatments that have been successful 
in mice are not always applicable to humans. Dose and time point of intervention have 
proven difficult to translate into humans [21]. Furthermore, post treatment analysis 
presents with certain complications due to a lack of biomarkers in human peripheral 
blood, whereas drug efficacy in mice can be analysed more extensively using whole 
organs [22]. 
 
 Autoantigens in T1D 
The extensive search for the self-antigens that cause disease development continues 
today. The initial characterisation of T1D as an autoimmune disorder followed after 
identification of autoantibodies in the human patients serum [23]. Interestingly, antibody 
production by B cells merely indicates the presence of autoimmunity. It is, however, 
antigen presenting ability that appears to be the main connection to the disease 
development [24].  
The autoantibodies target specific islet-antigens including insulin, proinsulin, glutamate 
decarboxylase (GAD65), IGRP, IA2 (also referred to as PTPRN) and zinc transporter 8 
(ZNT8) [25] and a recently described tetraspanin-7 [26, 27]. The majority of newly 
diagnosed subjects have one or more of these autoantibodies present. The process of 
autoantibodies and T lymphocytes developing reactivity towards additional islet antigens 
is referred to as epitope spreading and is associated with disease chronicity [28]. As 
mentioned above, the development of autoantibodies specific for several autoantigens 
is linked to increased disease progression [29].  
 
1.5.1 Insulin 
The insulin gene (INS) region located on chromosome 11p15, with genetic link between 
identified between one of the insulin genes (IDDM2) and T1D. IDDM2 maps to a variable 
number of tandem repeats (VNTR) upstream of the insulin gene (INS) [30]. T1D is 
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associated with the shorter class I VNTR alleles (26-63 repeats), whereas longer class 
III (140-210 repeats) exert protection from T1D. This protective effect is associated with 
higher levels of thymic INS expression [31]. Insulin is also a primary T1D autoantigen 
[32]. Destruction of the pancreatic tissue leads to insulin deficiency and the disease 
development. In NOD mice amino acids 9-23 of the insulin B chain (B9-23) has been 
identified and linked to immunogenic epitope formation [33]. In younger patients the 
presence of insulin autoantibodies correlates with aggressive disease progression. The 
patients that progress to the disease prior to reaching 5 years of age have detectable 
insulin antibodies level of 2000 nU/ml or greater [28]. Insulin is also the primary 
autoantigen in NOD mice. This was exemplified by the study where replacement of 
insulin genes with a mutated insulin protein lacking the primary epitope resulted in 
avoidance of insulitis and diabetes [32]. Krishnamurthy et.al identified proinsulin as the 
main autoantigen in NOD mice and established that anti-proinsulin immune responses 
are required for the activation of other T cells specific for different autoantigens, such 
as IGRP discussed below. 
 
1.5.2 IGRP 
Islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) is 
recognised as a major diabetogenic autoantigen in NOD mice. It is a membrane 
embedded glycoprotein structurally similar to the other glucose-6-phosphatases 
(G6Pases) [34]. A large proportion of islet-infiltrating CD8+ cells are specific for an IGRP 
derived epitope. Furthermore, IGRP peptide or IGRP mimetope administration has been 
described to have a suppressive effect on disease progression [35]. IGRP-specific CD4+ 
T cell transfers postponed diabetes onset, leading to the hypothesis that this subset 
functions as Tregs, although this has not yet been defined [34]. As mentioned above, 
whilst insulin has been identified as a T1D primary autoantigen, IGRP plays important 
role in establishing the link with proinsulin, whereby the immune responses are 
interdependent [36] Furthermore, Krishnamurthy et al. investigated IGRP involvement 
in the mechanisms of central and peripheral tolerance. By crossing NOD-IGRP mice 
that are characterised by the overexpression of IGRP in the antigen presenting cells 
with NOD8.3 mice that are in turn highly diabetogenic IGRP206-214 T cell receptor (TCR) 
transgenic, the study concluded that NOD-IGRP/NOD8.3 mice received complete 
protection from diabetes [37]. In humans, a susceptibility locus IDDM7 was identified 
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overlapping with the IGRP locus [38]. Yang et al. have identified CD4+ IGRP-specific T 
cells in T1D patients and healthy controls with DR0301 or DR0401 haplotypes. CD4+ T 
cells aid CD8+ T cells maintenance and priming, therefore IGRP-specific CD4+ T cells 
could potentially be required for IGRP-specific CD8+ T cell cytotoxicity [34]. 
 
1.5.3 Chromogranin A 
 
Chromogranin A (ChgA) is a secretory protein located neuroendocrine tissues and 
pancreatic b cell islets [39] and has been described by Stadinski et al., as an antigen source 
for diabetogenic BDC CD4+ T cell clones [40]. Unlike H2-Kd restricted CD8+ T cell clones 
such as  in NOD 8.3 or G9C8 mice, transgenic BDC2.5 mice have an H2-Ag7 restricted TCR 
[41] from NOD CD4+ T cells. Furthermore, the peptide WE14, a cleavage product of ChgA 
with a weak antigenic activity has been described to increase it antigenic potential following 
post-translational modifications. ChgA has been identified as a major diabetogenic antigen 
in human T1D and aforementioned post-translational modifications may be responsible for 
generation of neo-antigens in T1D [42, 43] 
 
 Immunological Tolerance 
The immune system’s primary role is to protect the host from a wide range of pathogens, 
without initiating an attack towards self and resulting in autoimmunity. Two main 
mechanisms termed central and peripheral tolerance exist to provide this protection.  
 
1.6.1 Central Tolerance 
Elimination of autoreactive T lymphocytes with high affinity to self-antigen occurs via 
clonal deletion in the thymus during negative selection. Positively selected lymphocytes 
with intermediate or low affinity undergo positive selection [44]. It is noteworthy, 
however, that some high-affinity lymphocytes differentiate into Foxp3 positive regulatory 
T cells [45]. Autoimmune regulator transcription factor Aire expressed by medullary 
thymic epithelial cells (mTEC) plays pivotal role in the central tolerance. Its major 
involvement in the negative selection of autoreactive T lymphocytes is driven by 
expression of tissue-specific antigens [46]. Aire deficient mice exhibit severe multi-organ 
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autoimmunity supporting the importance of its involvement in induction of immunological 
tolerance [47]. Similarly, in humans, defects in Aire gene lead to multi-organ 
autoimmunity termed autoimmune polyorgan endocrinopathy candidiasis ectodermal 
dystrophy syndrome (APECED) [48].  
However, in certain circumstances such as genetic defects or unavailability of particular 
peptide-MHC complexes in the thymus, central tolerance fails resulting in the escape of 
autoreactive T lymphocytes [49]. 
 
1.6.2 Peripheral Tolerance  
To aid elimination of autoreactive T cells that escape central tolerance, peripheral 
tolerance is required. Furthermore, these mechanisms are essential to regulate 
lymphocytes after their exposure to self-antigens in the periphery. Deletion and anergy 
are identified as the cell-intrinsic mechanisms of peripheral tolerance. The incorrect 
peptide-MHC recognition leads to active removal or inactivation of pathogenic 
autoreactive T cells as well as induction of regulatory machinery that suppresses 
effector T cells. However, in conditions such as T1D these processes fail resulting in 
autoimmunity [49]. 
 
1.6.2.1 Deletion 
Deletion is a result of an impaired interaction between the T cell and antigen-presenting 
cell (APC) displaying cognate antigen. In order for the T cell activation to occur, 
recognition of self-peptide-MHC on APC followed by another signal such as CD80/CD86 
is required, where failure in formation of successful complex results in either deletion or 
functional unresponsiveness [50]. Self-reactive T cells are eliminated via apoptotic 
mechanisms using Fas receptor as well as Bim, the Bcl-2 and Bcl-xL mitochondrial 
death pathway [51]. Moreover, prior to initiation of apoptosis T cells undergo limited 
proliferation [52]. Whilst the aforementioned TCR/MHC-Ag is well described in the 
activation of CD4+ cells, a slightly different picture emerges with CD8+ T cell activation. 
The strength of TCR/MHC-Ag interaction and availability of antigen may determine 
whether CD8+ T cell will become anergic or get deleted [53]. Later studies in vivo 
confirmed this using clone 4 T cells and showed that the constant exposure to high 
doses of peptide led to anergy, whereas low doses initiated clonal deletion [54]. 
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1.6.2.2 Anergy 
Activation of T cells occurs upon TCR and costimulatory molecule signalling resulting in 
secretion of IL-2. This in turn activates PI3K/AKT-mTOR survival pathway via IL-2R 
complex. In the absence of costimulatory molecule signalling such as IL-2, TCR 
signalling and IL-2 expression are reduced, and T cells can become hypo-responsive or 
anergic [55-57]. Anergy can be induced using mTOR inhibitor such as rapamycin after 
activation with anti-CD3 and anti-CD28 [58]. Other inhibitory receptors such as cytotoxic 
t-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) also play an 
important role in tolerance and the establishment of an anergic state.  
PD-1 and its ligands PD-L1 and PD-L2 can inhibit negative T-cell responses and have 
involvement of prevention of autoimmunity [59]. Mice lacking PD-1 (Pdcd-/-) develop 
autoimmune disorder, which resembles lupus [60]. Furthermore, PD-1 signalling can 
promote conversion of naïve T cells to regulatory T cells and inhibit pathogenic cytotoxic 
T cells [61, 62]. Similarly, to PD-1, CTLA-4 plays important role in peripheral tolerance 
due to its involvement in T cell homeostasis. It is an inhibitory costimulatory molecule 
which binds to CD80 and CD86 with high affinity reducing co-stimulation [63]. 
 
1.6.3 Cell-extrinsic mechanisms 
The balance between effector and regulatory T cells is paramount for extrinsic regulation 
of peripheral tolerance. Regulatory T cells, identified primarily as the CD4+CD25+Foxp3+ 
population, have received much attention in the recent years. Green et al. showed that 
this population accumulate in pancreas and pancreatic lymph nodes rather than spleen 
or other lymph nodes and can provides protection from the disease preventing 
differentiation of CD8+ T cells in cytotoxic T lymphocytes [64]. 
Regulatory T (Treg) cells are the population of lymphocytes that exert both regulatory and 
inhibitory effects on T effector cells and are important players in the maintenance of 
peripheral tolerance. Defects in both functionality and numbers of Treg have been implicated 
in the development of autoimmunity, such as T1D [65]. Whilst several Treg phenotypes have 
been identified, including CD4+CD25+FoxP3+ Treg, CD8+ Treg, CD8+CD28- FoxP3- Treg 
and Interleukin-10 secreting Tr1 cells, CD4+CD25+FoxP3+ Treg cells remain of interest to 
many researchers due to their essential role in tolerance induction in many experimental 
models [66]. These cells can be categorised into two subsets; naturally occurring (nTreg) 
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and inducible (iTreg). The former are thymic derived and account for 5-10% of the CD4+ 
population in the periphery and as previously mentioned their defects in this population may 
result in autoimmunity. They are characterised by the expression of CTLA-4 (cytotoxic T 
lymphocyte-associated lymphocyte 4), FoxP3 (forkheadbox P3) transcription factor and 
GITR (glucocorticoid-induced TNFR family related gene). iTreg cells are peripherally 
induced and their suppression is associated with cytokines such as IL-10 [67, 68]. 
Furthermore, Treg have great affinity to IL-2, which is required for Treg development and 
function. This was exemplified by several studies showing lack of CD4+CD25+ Treg 
cells in IL-2KO mice as well as severe autoimmunity associated with it [69]. 
 
 Immune cells in T1D 
 
1.7.1 T cells 
 
It is widely accepted that T1D is a T cell mediated disorder involving both CD4+ and 
CD8+ T cells, which has been evidenced by their presence in the pancreatic islets of 
patients [70]. Mice deficient in both CD8+ T cells and MHC class I do not develop disease 
[41] and a significant reduction in disease progression can be observed when pancreatic 
β cells do not express MHC class I [71]. Moreover, effector CD4+ T cells play 
indispensable role in the disease development. Some diabetogenic CD4 clones such as 
BDC-2.5 clone have been used to initiate disease [72]. It was previously demonstrated 
that transgenic NOD mice that lack expression of I-Ag7, but express different MHC class 
II molecule, do not develop diabetes [73]. CD4+ T cell mediated β cell death is strongly 
linked to the production of inflammatory cytokines such as IFN- γ, TNF-α and IL-1 [74]. 
Based in the CD4+ T cells ability to recognise insulin, they can be categorised into two 
groups: Type A and type B. The former group responds to both insulin protein and B9-23 
peptide, whereas the latter only recognises B9-23 peptide. Type A specific CD4+ T cells 
get deleted in the thymus, but B type cells escape thymic deletion and result in 
pathogenic responses [75-77].  
Whilst CD4+ and CD8+ T cells are major players in T1D pathogenesis, the involvement 
of other cells cannot be ignored. Whilst the mechanisms involved in T1D 
immunopathology remain unclear, several cell subsets have been identified to play a 
major role in the disease development and progression. 
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1.7.2 B cells  
 
B cells are believed to play an important role in T1D pathology. The presence of 
autoreactive MHC class II positive B cells is required for disease progression [78]. 
Furthermore, their antigen presentation ability is necessary for the interaction with T 
cells [79],[24]. In the pancreas B cells aid activation of T cells and epitope spreading via 
presentation of new islet epitopes after processing of apoptotic β cells [80] B cell-
deficient NOD mice appear to be protected from the disease, however, not from the 
development of insulitis [81]. Depletion of B cells and subsequent decline in the disease 
progression was associated with the expansion of CD4+CD25+Foxp3+ Treg cells [82]. 
 
1.7.3 Macrophages 
 
Macrophages are known to be involved in the development of T1D. They have been 
detected in the pancreatic infiltrates in NOD mice and blocking the trafficking of 
macrophages into the pancreas offered protection from the disease. [83]. Furthermore, 
their role in the disease progression has been linked to IL-12 production and 
involvement in differentiation of cytotoxic CD8+ T lymphocytes [84, 85]. Recently, the 
importance of pancreatic tissue resident macrophages in T1D initiation and progression 
in NOD mice was highlighted. It was demonstrated that upon depletion of islet 
macrophages, T cell trafficking into islets is reduced resulting in the diminished antigen 
presentation [86]. 
 
1.7.4 Natural killer Cells  
 
Natural killer (NK) cells are important regulators of the immune system, offer protection 
against viruses and initiate responses during infection and tumorigenesis. They produce 
large amounts of pro-inflammatory IFN-γ and have previously been identified in the 
pancreata of both T1D subjects and mouse counterparts [87]. Recent study further 
emphasised pathogenic role of pancreatic NK cell, whereby large amounts of IFN-γ were 
produced after Treg depletion in BDC2.5 TCR transgenic mice promoting CD4+ effector 
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T cells [88]. Some studies identified protective properties of NK cells in T1D, however, 
this is beyond the scope of this discussion [89, 90]. 
1.7.5 Dendritic Cells 
 
Dendritic cells (DCs) are a diverse population of professional antigen presenting cells 
(APCs), which play a major role in shaping the immune system and regulating tolerance. 
Their ability to capture, process and present antigens to antigen-specific T lymphocytes 
has been exploited in order to further investigate their therapeutic potential [91]. 
Phenotypically DCs can be categorised into conventional (cDCs) and plasmacytoid 
(pDCs) and further classified into mature (mDCs) and immature (iDCs). In mice, 
conventional DCs are identified by expression of CD11c and MHC class II. Furthermore, 
they can be divided into CD8α+ DCs and CD8α- DCs  [92]. Although the precise 
mechanisms of peripheral tolerance maintenance by DCs remain elusive, their ability to 
induce tolerogenic responses associated with their maturation state [93]. Immature 
tolerogenic DCs express low levels of MHC class II and costimulatory molecules such 
as CD80, CD86, and CD40. On the contrary, mature DCs induce inflammatory 
responses [94]  are able to present exogenous self-antigen to naïve CD4+ T cells and 
cross-present tissue-derived antigens to CD8+ T cells [95], therefore DCs are becoming 
primary targets for the development of antigen specific immunotherapies [96]. 
Furthermore, immature DCs were shown to induce tolerance following antigen 
presentation to both CD4+ and CD8+ T cells in an autoimmune disease mouse model 
[50]. Activated DCs can also express regulatory molecules such as PDL-1 and 2, IL-10 
[96] and indoleamine  2.3-dioxygenase (IDO) causing starvation of T cells and induction 
of Tregs [97].  
It has been shown that removal of tolerogenic CD11b+CD11c+ DCs in NOD mice results 
in the accelerated development of diabetes [98]. On the contrary, generation of 
tolerogenic DCs in vitro after co-culture with a range of immunomodulatory compounds 
such as IL-10 and vitamin D and transfer into NOD mice was able to protect from disease 
[99]. Approaches designed to prevent DC maturation have included immunosuppressive 
agents such as tacrolimus, rapamycin and cyclosporine that can promote tolerogenic 
DCs populations maturation in vitro [100, 101]. 
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1.7.6 NF-κB in T1D 
 
The nuclear factor κB (NF-κB) is a transcription factor with a pivotal role in the regulation of 
cell proliferation, inflammation and apoptosis. NF-κB translocates to the nucleus following 
activation by a variety of stimuli including tumour necrosis factors (TNFs), cytokines, growth 
factors, viruses, bacterial products and oxidative stress. NF-κB comprises of five easily 
dimerising proteins p50/p105, p52/p100, RelA, RelB and RelC [102] located in the 
cytoplasm in conjunction with IκBα inhibitory proteins [103]. The phosphorylation, 
ubiquitination and degradation of inhibitors occurs in the proteasome resulting in activation 
of NF-κB molecules and their translocation to the nucleus for transcription of many innate 
immune response mediators to be initiated [102].Tumour necrosis factor (TNF-α) is a major 
proinflammatory cytokine and regulator of potent pro-inflammatory cascade and leucocyte 
recruitment to the site of inflammation. Strong links between TNF- α and T1D have been 
identified. Rapid disease development was observed in neonatal NOD mice following 
treatment with TNF-α, whereas inhibition of this factor caused complete ablation of T1D. 
[104]. Targeting NF-κB associated mediators such as TNF-α to downregulate activity has 
promising therapeutic potential. Several studies have confirmed dysfunctional regulation of 
NF-κB pathway in T1D both humans and mice [105-108]. Upregulation of NF-κB causes 
initiation of pro-apoptotic mechanisms leading to β cell death [109], therefore, the use of NF-
κB inhibitors has a great therapeutic potential [107]. 
 
1.7.7 Vitamin D3 
 
Vitamin D3 [1,25(OH)2D3], also named calcitriol, is a pleiotropic hormone involved in 
regulation of calcium homeostasis as well as has anti-proliferative effects on tumour cells 
[110]. The mechanisms of its immunomodulatory effects still require further elucidation. It 
was, however, found that in patients affected by sarcoidosis (multi-organ inflammatory 
disease), macrophages were able to synthesise calcitriol from its precursor. Furthermore, 
activated lymphocytes possess vitamin D receptor (VDR) [111]. It was further suggested 
that production of calcitriol by monocytes has an immunomodulatory effect on neighbouring 
T and B cells. Moreover, calcitriol appears to have a suppressive effect on NF-kB pathway 
in T cells, macrophages and monocytes [112]. 
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The presence of VDR has been identified in tissue resident DCs [113]. In monocyte-
derived DCs (mo-DCs), large quantities of VDR are expressed when the cells are 
immature, but this is reduced as they mature and differentiate [114]. It was shown that 
treatment with calcitriol impaired moDCs presentation ability to T lymphocytes. This is 
due to the fact that calcitriol reduces expression of MHC class II, CD40, CD80, CD86 
[115] as well as maturation proteins CD1a and CD83 [116]. Moreover, it has a negative 
impact on the synthesis of the pro-inflammatory cytokines IL-6, IL-12 and IL-23 [117]. 
Therefore, upregulation of VDR on DCs increases their tolerogenic potential [118]. 
Treatment with VDR agonists induces CD4+CD25+Foxp3+ Tregs and inhibition of the 
NF-kB pathway and, therefore reducing insulitis and arresting progression of T1D in 
NOD mice [111, 119-121]. 
 
 Current T1D management 
 
Over the last several decades many clinical trials for T1D have been conducted; 
however, there is still no cure. T1D patients depend on exogenous insulin, though this 
does not address the tissue destruction or the disease development. Many attempts 
have been made to prevent autoimmune attack, prevent destruction of pancreatic β cells 
and allow their regeneration via multiple therapeutic approaches [122]. These include 
blocking of cytokine with a purpose of downregulation of innate immune responses, 
antigen specific therapies, adaptive immune cells depletion and Tregs boost (Table 1-1). 
Despite many positive outcomes from preclinical work, no approaches were effective in 
restoring robust tolerance [123]. This failure may be a result of differences in response 
in humans as well as timing and dosage of the therapeutic agents. Furthermore, some 
treatments such as anti-CD3 or rituximab trials resulted in the delayed β cell destruction 
[124-126]. Although the complete disease reversal is the most desired outcome, it is not 
necessarily the most realistic one. Therefore, many clinical trials concentrate on 
prolonging insulin secretion, reduction of complications and restoration of normal levels 
of C peptide [127]. 
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Table 1-1. Some therapeutic approaches for T1D and their outcomes [122]. 
 
Action Therapeutic agent in 
clinical trial 
Effect 
Cell subset deletion Anti- CD3 mAb 
(Teplizumab), targeting T 
cells 
In phase I and II 
remission for up to 8 
months was shown. 
Phase III independence 
from insulin up to 12 
months in 5% of treated 
patients [124, 128] 
Anti-CD20 (Rituximab), 
targeting B cells 
Phase II showed 
reduction in insulin 
dependency for 12 
months, higher C peptide 
and lower HbA1c [129] 
Cyclophosphamide and 
anti T lymphocyte 
globulin, haematopoietic 
stem cell transfer 
Over 2 years remission 
with significant side 
effects [130] 
Cytokines targeting TNF receptor C-peptide levels 
preserved and decrease 
in HbA1c and insulin 
dependence. Increased 
lymphoma risk [131] 
Antigen-specific tolerance Oral insulin No effect on C-peptide 
[132, 133] 
DiaPep277, hsp60 
peptide 
C-peptide levels 
preserved [134, 135] 
Gad-alum 
(subcutaneously) 
Treated group showed 
slower C-peptide decline 
[136] 
Tregs boost Low dose IL-2 and 
Rapamycin 
Β cell dysfunction was 
caused [129] 
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 Antigen-specific Immunotherapy 
 
Antigen-specific immunotherapy (ASI) remains one of the most attractive approaches for 
preventing and treating autoimmunity due to its specificity, safety and potential to restore 
tolerance without global immunosuppression. The concept of using autoantigens to prevent 
or treat a number of autoimmune disorders has been explored for a number of decades. 
Vaccines provide an early example of an antigen-specific immune response, exemplified in 
using allergens for desensitisation and tolerance induction. In T1D, however, the ASI 
approaches has had limited success. This could be due to the fact that aetiology of T1D 
remains poorly understood and its heterogeneity contributed to difficulty in designing and 
translating the therapy from animal models to humans. Current therapies under 
investigation, however, are centred around immunomodulatory drugs. Whilst 
immunosuppression remains their main mechanism of action of these agents, it is now 
widely accepted that they act via a number of pathways and have versatile effects on the 
immune system. An example of such a compound is rapamycin, a potent 
immunosuppressive agent that inhibits the mammalian target of rapamycin (mTOR) 
pathway, prevents proliferation and expansion of antigen-specific effector T cells and their 
ability to respond to IL-2 [137]. Interestingly, the mTOR pathway also plays an important role 
in the regulation of differentiation of T helper cells and expression of Foxp3 [138]. This 
exemplifies the intricacy and delicate balance between effector and regulatory T cells 
populations required for tolerance induction in the autoimmune disorders (Figure 1-2).  
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Figure 1-2. Diagram showing a role of mTOR pathway in the balance required for immune 
regulation.  
The presence of Tregs (blue) outweighs the presence of effector T cells (red) for tolerance 
maintenance. However, in case of inflammation the increase in effector T cells is preferred. 
Induced Tregs can also proliferate and increase their ability in response to mTOR activation 
under inflammatory conditions. Adapted from [139]. 
Despite immunosuppression being used in a number of autoimmune disorders such as RA, 
IBD, psoriasis, lupus and MS it can be associated with serious complications including 
increased infections, viral reactivation and tumour development [140]. Aside from the 
adverse effects other major concerns include the prolonged treatment that requires 
administration by professional staff, lack of specificity and most importantly suppression but 
not cure of the underlying disease causes [141]. Figure 1-3 below provides a demonstration 
of comparison between treatment with immunosuppressants and antigen-specific treatment 
where preservation of b- cell mass as a clinical outcome is measured. When agent such as 
Rituximab are used, the benefits are only observed throughout the treatments and fade after 
the treatment seizes. In contrast, the longer lasting effects of antigen-specific tolerance 
inducing agents allow for shorter treatment times [142].  
Many individuals diagnosed with T1D are paediatric patients and therefore safety of any 
immunosuppressive agents remains a major concern. It has been previously suggested that 
mTOR activation
mTOR inhibition
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some of the therapies such as administration of Tacrolimus or Sirolimus 
immunosuppressants inhibit b-cell regeneration [143]. Therefore, mastering the art of 
creating a combination therapy with immunomodulatory potential and multiple action and 
targets that can induce regulatory populations or deletion and/or anergy of effector 
populations without side effects is of vital importance. For instance treatment with anti-CD3 
antibody was proven to be effective in both NOD mice and humans [144, 145], the insulin 
requirements were reduced and C-peptide preserved for up to 5 years [146, 147]. Anti-CD3 
therapy resulted in the induction of T cell anergy and generation of non-antigen-specific 
Tregs and received a lot of attention as a potential combination therapy candidate. However, 
there is still no long-term remission seen despite multiple treatments. The reports from 
Phase III clinical trial in early onset human subjects revealed that the levels of C-peptide 
were not preserved and HbA1c as well as insulin dose did not differ between treated and 
placebo control groups [148].  The ultimate goal for T1D therapy is to achieve specificity 
without immunosuppression. For instance, this can be achieved through the induction of 
antigen-specific Tregs as well as potential to initiate the treatment before significant 
reduction in b-cell mass occurred [149]. 
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Figure 1-3. Diagram showing a comparison between immunosuppression (top) and 
tolerance induction (bottom) approaches in T1D. 
The b-cell mass is used as a read out of treatment efficacy. The effect of the 
immunosuppressive agents only lasts for a duration of the treatment whilst and treatments 
aiming to restore tolerance are shorter in duration and have longer lasting effects. Adapted 
from [142]. 
The number of diabetogenic antigens is ever growing and whilst in NOD mice insulin B chain 
9-23 has been deemed an initiator of T1D, the case in humans is not as straight forward. 
Human T cells recognise several preproinsulin (PPI)/insulin epitopes  and antibodies against 
these can be detected long before the clinical disease onset [150]. Pancreatic lymph nodes 
CD4+ T cells recognise HLA-DRB*0401 restricted Insulin A 1-15 peptide, whilst certain CD8+ 
T cells have specificity for PPI15-21 bound to the HLA-A*0201 molecule [151-154]. In NOD 
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mice Ins B9-23-specific CD4+ and Ins15-23-specific CD8+ T cells have been found to infiltrate 
the pancreatic tissue from approximately 4 weeks of age, but this infiltration was reduced by 
12 weeks of age [75, 155]. Early attempts to induce tolerance used a major diabetogenic 
antigen insulin. After oral and intranasal insulin administration some degree of reduced 
effector function of insulin-specific T cells was observed, however, treatments failed to 
significantly delay or prevent T1D in human subjects [133, 156-158]. One of the reasons for 
the lack of success is that in human patients, disease progression is associated with 
continuous accumulation of other antigens termed ‘epitope spreading’. Also it has been 
highlighted that in pancreatic islets of T1D patients T cells target pro-insulin epitopes B:9-
23 and C:19-35 [159] Furthermore, there is still no sufficient evidence in humans to support 
the role of insulin as the disease initiating antigen [160]. In NOD mice, however, intranasal 
insulin therapy was successful in preventing T1D [161, 162] and when administered with a 
low dose of anti-CD3 antibody the disease development was delayed in new onset mice 
[163, 164]. This once again highlights the fact that to date, despite the lack of effective 
therapy for T1D, the combination approaches have had more success than 
immunosuppressive agents alone.  
 
  Liposome Based immunotherapy 
Nanotechnology has been in use for quite some time as both a therapeutic and 
diagnostic tool. Nanoscale liposomes (Figure 1-4) are designed in such way that a 
bilayer is formed such that the hydrophobic ends of the lipids compose the interior and 
hydrophilic ends the exterior phase of the liposome. These can be neutral or carry 
negative or positive charge. Furthermore, liposomes can be oligo or multilamellar and 
vary in their diameter [165]. Recently, autoantigen loaded liposomes were used with 
some success in an antigen specific immunotherapy for T1D in NOD mice. The insulin 
peptide entrapped in the phosphatidylserine liposomes were used for the induction of 
tolerogenic dendritic cells and weakened the proliferation of autoreactive T cells [166]. 
Previous studies indicate that liposomes can successfully deliver their payload to APCs 
[167]. Our group has previously shown that liposomes containing natural NF-kB inhibitor 
curcumin used for treating obese mice, were successful in delivering their content to the 
inflammatory DCs, macrophages and B cells. The treatment resulted in improved 
glucose tolerance, highlighting beneficial potential of liposomes in T1D [168]. Whilst the 
use of liposomes results in passive targeting due to their phagocytic nature, tailorable 
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nanocarrier emulsion (TNE) that include CLEC9a antibody provides more precise 
targeting of CD8α+ DCs known for their cross-presentation ability [167, 169]. This 
immunomodulatory approach can result in the induction of Tregs and elimination of 
cytotoxic T lymphocytes. 
 
  
 
Figure 1-4. Structure of a liposome. 
Hydrophilic molecules (blue sphere) can be encapsulated within the aqueous core, whilst 
hydrophobic molecules (pink cylinders) within the bilayer. Adapted from [170]. 
 
  Significance of the project and study proposal 
 
Currently, there are no successful immunotherapeutic approaches to treat or prevent T1D. 
The multifactorial nature of the disease and the complexity of antigen-specific 
immunotherapy have hindered a positive result to date. This project aims to develop a pre-
clinical model of antigen-specific immunotherapy with a translational potential. Our group 
has previously shown successful antigen delivery to dendritic cells for rheumatoid arthritis 
therapy. Therefore, current research paves the way for an antigen-specific therapeutic 
approach for the treatment and prevention of T1D. As T1D patients are often young children, 
the acceptable therapeutics should have a very high safety profile. We believe this therapy 
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will offer a safer option to treat young children, rather than immunosuppression, the effects 
of which still remain largely unknown in the long term. 
The diagram below offers a summary of a proposed delivery system consisting of liposomes 
encapsulating an NF-kB inhibitor and diabetogenic peptides to dampen and eventually 
eliminate effector T cell responses and restore robust tolerance in NOD mice. Furthermore, 
this study aims to explore the effects of the delivered liposomes on the dendritic cells, their 
phenotype, maturation status, and presentation ability. 
 
 
Figure 1-5. A schematic representation of the of the study concept focusing on the liposomal 
content processing and presentation by the DCs to CD8+ and CD4+ T cells.  
Antigenic peptides (green and yellow) are encapsulated within the aqueous core of the 
liposomes are delivered to the DCs, processed and presented via MHC I or MHC II 
complexes to CD8+ or CD4+ T cells respectively. The NF-kB inhibitor (pink cylinders) is 
required for maintaining DCs in there tolerogenic immature state. We hypothesise that the 
effector function of pathogenic antigen-specific T cells will be reduced as a result of 
liposomal treatment. The study will evaluate CD8+T cell responses after a single epitope 
treatment and further discuss effects of multi-epitope co-delivery.
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 Animals 
 
Mice were purchased from the Animal Resources Centre (ARC) (Canning Vale, Australia) 
or bred at the Translational Research Institute Biological Research Facility (TRI-BRF) 
(Brisbane, Australia). Animals were housed at the specific pathogen-free TRI-BRF facility 
with food and water available ad libitum. Female animals used in all experiments were aged 
between 8 and 10 weeks unless otherwise stated and sacrificed via cervical dislocation. 
All experimental procedures were performed in accordance with and approved by the 
University of Queensland Animal Ethics Committee, ethics number 217/15.  
 
2.1.1 NOD/Lt mice 
 
The non-obese diabetic (NOD) mouse is an inbred strain serving as a model of human 
autoimmune diabetes. The strain was originally developed in 1974 and is characterised by 
spontaneous disease development, insulitis and infiltration of CD4+ and CD8+ T 
lymphocytes in the pancreatic islets [171]. NOD/ShiLtJArc mice later referred to as NOD 
were purchased from ARC (Canning Vale, Australia).  
2.1.2  8.3 TCR transgenic mice 
 
The TCR transgenic 8.3 mouse strain produces CD8+ T cells specific for IGRP due to a fixed 
TCR-αβ arrangement.  It was developed from the NY8.3 H-2Kd restricted, cytotoxic CD8+ T 
cell clone, which was isolated from the islets of a diabetic NOD mouse [172]. NOD-8.3 Thy 
1.1 mice were bread at TRI and generated by inter-crossing transgenic NOD-8.3 and NOD-
Thy 1.1 (The Jackson Laboratory) [173]. 
2.1.3 BDC2.5 TCR transgenic mice  
BDC2.5 mice are H2-Ag7-restricted TCR transgenic mice that carry re-arranged TCR a and 
b from the diabetogenic CD4+ T cell clone BDC2.5 isolated from spleens and lymph nodes 
of NOD mice. [41, 174]. NOD BDC2.5 Thy1.1 transgenic mice were bred at TRI-BRF and 
generated by inter-crossing NOD BDC2.5 transgenic mice and NOD thy1.1 congenic mice 
obtained from Jackson laboratories. 
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2.1.4 NOD.SCID mice 
 
Severe combined immunodeficiency (SCID) strain was originally introduced onto the NOD 
background by introducing autosomal recessive mutation Prkdcscid. This mutation results in 
the impaired differentiation of T and B progenitor cells and subsequent lymphopenia. NOD-
SCID mice (strain NOD.CB17-Prkdcscid/Arc) were purchased from ARC. 
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  Reagents 
 
2.2.1  Phosphate buffer saline (PBS) 
 
NaCl (80g), KCl (2g), Na2HPO4x2H2o (11.5g), KH2PO4 (2g) (Sigma Aldrich; cat S9625, 
V016080, V019160 and V016150 respectively) were dissolved in 1L of Milli-Q water for 10x 
stock solution. The stock was sterilised and stored at room temperature then diluted to a 1X 
solution with sterile Milli-Q water prior to use.  
 
2.2.2 Flow cytometry buffer 
 
1L of buffer was prepared using 100ml of 10x PBS, 20 ml of 100mM EDTA, 2.5g of bovine 
serum albumin (Bovogen Biologicals) and total volume adjusted to 1L with deionised water. 
2.2.3 Complete RPMI 
 
Cell culture medium was prepared by adding 50 ml of heat-inactivated foetal bovine serum 
(Bovogen Biologicals, cat SFBS-F), 5ml of penicillin-streptomycin-glutamine (Gibco, cat 
10378-016) and 5ml of sodium pyruvate (100mM) (Gibco, 11360-070) into 500 ml of RPMI-
1640 (Gibco, cat 21870-076). This was performed sterilely in the biosafety cabinet in and 
later stored at 4° C. 
2.2.4 Ammonium-Chloride-Potassium (ACK) lysis buffer  
 
Erythrocyte lysis buffer was used to eliminate red blood cells from single cell suspensions 
and lymphocytes staining. 10x stock solution was prepared by diluting NH4Cl (82.9g/L), 
KHCO3 (10g/L) and EDTA (372mg/L) (Sigma Aldrich, cat A0171, 237205, and ED4S 
respectively) in 1L of Mili-Q water, pH was adjusted to 7.2-7.4. For working solution stock 
was diluted 1:10, filter sterilised and stored at 4°C. 
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2.2.5 Liposomes 
 
Liposomes encapsulating IGRP peptide and calcitriol were prepared in-house using thin-
film hydration techniques and quantified using HPLC by Dr Meghna Talekar or Dr Bijun 
Zeng. In order to dissolve lipid, egg phosphatidylcholine (140mg) and cholesterol (60mg) 
were combined in a round bottom (RB) flask along with chloroform and ethanol (9:1 ratio). 
Following this the IGRP206-214 peptide (30μg/ml) and/or calcitriol (400ng/ml) were added. 
Rotary evaporator was used at 40° C to produce a thin film of lipid and desired agent in the 
RB flask. Rehydrated solution was freeze-thawed for three cycles followed by high-
pressured homogenization in The Emulsifex-C3 (Avestin) at 12000 psi for 15 cycles (9.6 
sec/cycle/8ml). Any un-encapsulated compounds were separated via diafiltration. The size 
of the particles was measured using Malvern Zetasizer Nano ZS (Malvern, Worcestershire, 
UK). Once prepared, liposomes were stored at 4°C and used within 4-6 weeks. 
2.2.6 Peptides 
Peptides used in this study are as follows: 
• IGRP206-214 peptide (VYLKTNVFL) 
• BDC2.5 mimotope (AHHPIWARMDA) 
• HEL (AMKRHGLDNYRGYSL) 
• LLO91-99 (GYKDGNEYI) 
All peptides were purchased from GL Biochem (Shanghai) Ltd. (Shanghai, China). 
Lyophilised powder was dissolved in the ultra-pure distilled water (Invitrogen) to 5mg/ml and 
stored as 20 μl aliquots at -30° C. The final concentration of peptides within the liposomes 
was 400ng/ml unless otherwise indicated. 
2.2.7 Calcitriol 
1,25-dihydroxyvitamin D (calcitriol) (Dishman, Netherlands) was dissolved in ethanol to a 
concentration of 10 mg/ml and stored at -30° C. The concentration of calcitriol used in this 
study was 30µg/ml. 
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2.2.8 Antibodies 
Anti-mouse monoclonal antibodies used for staining are described in the table below. 
Table 2-1. Antibodies used for flow cytometric analysis. 
Antigen Fluorochrome Clone Catalogue 
No. 
Dilution Company 
CD3 APC 145-2C11 100312 1:200 BioLegend 
CD4 PE-Cy7 GK1.5 100422 1:200 BioLegend 
CD5 APC 53-7.3 17-0051-82 1:200 eBioscience 
CD8 FITC, APC 53-6.7 100706, 
100712 
1:200 BioLegend 
CD11c APC IV418 117310 1:200 BioLegend 
CD11c BV605 N418 117333 1:200 BioLegend 
CD11b BV421 MI/70 101236 1:200 BioLegend 
CD25 APC PC61 102012 1:200 BioLegend 
CD44 BUV395 IM7 740215 1:400 BD 
Biosciences 
CD62L BV421 MEL-14 104436 1:200 BioLegend 
CD69 PerCP/Cy5.5 H1.2F3 104522 1:200 BioLegend 
CD90.1 
(Thy1.1) 
PerCP/Cy5.5 OX-7 202516 1:200 BioLegend 
CD279 PE/Cy7, BV605 29F.1A12 135220 1:300 BioLegend 
F4/80 FITC BM8 123108 1:200 BioLegend 
FoxP3 Alexa 700 FJK-16S 56-4776-41 1:100 eBioscience 
Granzyme B Pacific Blue GB11 515407 1:200 BioLegend 
IFN-γ FITC, APC XMG1.2 505806 1:200 BioLegend 
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IL-17 BV421 TC11-
18H10.1 
506916 1:200 BioLegend 
LAG-3 
(CD223) 
APC C9B7W 125210 1:100 BioLegend 
Streptavidin BV605 - 405229 1:400 BioLegend 
Streptavidin BV421 - 405225 1:400 BioLegend 
Streptavidin PE - PJRS25 1:1000 Prozyme 
TIM3 
(CD366) 
APC B8.2C12 134008 1:50 BioLegend 
Cell Viability 
Zombie Aqua UV - 423101 1:500 BioLegend 
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 Procedures 
 
2.3.1 Single cell suspension preparation for flow cytometry  
Tissues were passed through 70-micron cell strainer to create single cell suspensions. 
Lymphocytes were stained in FACS buffer (PBS containing 2% FCS and 2mM EDTA) in the 
dark at 4°C using the fluorochrome conjugated antibodies (Table 2-1). 
 
2.3.2 Lymphocyte isolation from peripheral blood  
Retro-orbital bleeding was performed on anesthetised animals using heparinised capillary 
tubes. Depending on the weight of the animal, up to 200 μL of blood was collected into FACS 
buffer, centrifuged for 4 mins at 1500 rpm, treated twice with 1ml of ACK buffer, washed with 
4 ml of FACS buffer and stained with tetramer and surface antibodies as described. Flow 
cytometric analysis was performed on BD LSRII and BD Fortessa-X20 at the Translational 
Research Institute’s core facility. 
 
2.3.3 Tetramer preparation and antibody staining 
 
Biotinylated monomer (100 μL stock at 2mg/ml, 200μg of MHC protein) was supplied by the 
NIH tetramer facility and stored at -80° C. Once defrosted, 31.8 μL of Streptavidin-PE 
(1mg/ml; Prozyme, cat PJRS25) was added at room temperature every 10 minutes for a 
total of 10 times and mixed thoroughly. Samples were kept in a dark in between additions 
of streptavidin. H-2Kd IGRP tetramer was tested using IGRP-specific 8.3 cells, whilst I-Ag7 
MHC class II tetramer was tested using BDC2.5-specific CD4+ T cells from BDC2.5 
transgenic mice. Tetramers were stored at 4°C in 20μL aliquots for future use. Lysteriolysin 
O (LLO) was used as an irrelevant MHC class I peptide control and hen egg white lysozyme 
(HEL) as an irrelevant MHC class II peptide control. Tetramer staining was performed at 
room temperature in the dark for 15 minutes followed by surface antibody staining performed 
at 4 degrees for 20 minutes at the concentrations indicated in Table 2-1.  
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2.3.4  In vitro stimulation for cytokine detection 
 
Single cell suspensions were prepared in cRPMI and plated in 96 well plates in a volume of 
100 μl (cell concentration 5x106 cells). To stimulate cytokine production cells were cultured 
in a volume of 200μl for 4-5 hours at 37°C and 5% CO2 with phorbol 12-myristate (10ng/ml; 
Sigma-Aldrich), ionomycin (5ng/ml) (or peptide; 1μg/ml) and Golgi Plug™ (BD Biosciences; 
1µL/mL), whilst unstimulated controls received Golgiplug only. Following the stimulation 
cells were washed with cold FACS buffer and stained with surface antibodies as previously 
described.  This was followed by fixation and permeabilisation using BD Cytofix/CytoPerm 
reagents and stained with intracellular markers. Tetramer staining was performed prior to in 
vitro stimulation. 
2.3.5 Pancreatic lymphocyte isolation 
 
Pancreata were harvested into cold complete RPMI (cRPMI) and cut up into small pieces 
for the digestion. They were placed in the pre-warmed to 37° C cRPMI containing 2mg/ml 
Collagenase III (Worthington Biochem) and 20 ug/ml DNase I (Roche/Sigma-Aldrich) and 
incubated at 37° C for 20 min with regular mixing. After the incubation was complete, cells 
were spun at 4°C at 1500rpm, washed with PBS (+2% FCS) and passed through a 70-
micron cell strainer. Following that, the cells were re-suspended in 4ml of cRPMI, slowly 
overlayed onto 4ml of Histopaque (Sigma Aldrich) and centrifuged at 2200 rpm (slow ramp 
and brake). Afterwards, interface cells were collected, washed and stained for a variety of 
surface and intracellular markers as per normal staining protocol in FACS buffer.  
 
2.3.6  Foxp3 staining procedure 
 
Foxp3/Transcription Factor staining buffer set (eBioscience) was used for intracellular Foxp3 
staining. Fixation/Permeabilisation concentrate was diluted with diluent at a ratio of 1:3 and 
200 μL was added to cell suspensions following the surface staining step. Cells were fixed 
at 4°C for 60 minutes, washed with permeabilisation buffer diluted in distilled water 1:10. 
Antibody master mix was prepared in permeabilisation buffer and staining was performed at 
room temperature, in the dark for 45 minutes. Cells were washed with FACS buffer and 
resuspended ready for flow cytometric analysis. 
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2.3.7  Isolation of dendritic cells for flow cytometry 
 
Organs were collected into cRPMI and processed with digestion medium containing 2mg/ml 
of Collagenase D and 20 μg/ml DNAse I. Organs were incubated at 37° C for 15 minutes. 
Following that, normal single cell suspension protocol was followed, and staining performed 
in FACS buffer as previously described. 
2.3.8  Adoptive Cell Transfer 
 
Transgenic NOD 8.3 female mice 8-10 weeks old were used as donors of IGRP-specific 8.3 
cells in adoptive transfer experiments. Cells were purified on autoMACS separator using 
CD8a+ T cell separation kit (Miltenyi Biotec, Germany). Cell purity was confirmed to be 95% 
or above and 3x106, 105 or 104 cells were transferred intravenously into NOD recipients, as 
indicated. 
 
2.3.9  Liposome labelling and uptake assessment  
 
Lipophilic membrane dye 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine 
perchlorate (DiD) (Thermofisher) with red fluorescence excitation and emission spectra 
(APC channel) was added to the liposomes for labelling (4μg/ml). Alternatively, a dye with 
orange-red fluorescence (PE channel) 1,1'-Dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine perchlorate (DiI) was used (4µg/ml). Following addition of the 
dye to the liposomes, the mixture was gently vortexed and incubated for 1-hour in the dark 
at 4° C.  After the incubation liposomes were vortexed and injected subcutaneously in the 
flank or intravenously into tail vein. Liposomal uptake was assessed using flow cytometry 
24 hours post injections. 
 
2.3.10 CTV labelling 
 
Cells were labelled with 5μM Cell trace Violet (Invitrogen) in the pre-warmed PBS at 106 ml-
1 and incubated for 20 minutes at 37°C. The reaction was terminated with ice-cold complete 
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RPMI, washed and re-suspended in sterile PBS for adoptive transfer. Proliferation/CTV 
dilution was later assessed using flow cytometry. 
 
2.3.11  Immunisation  
 
Mice were immunised intraperitoneally with 10μg/mouse of peptide, 100μg/mouse of 
polyinosinic-polycytidylic acid potassium salt (Poly I:C) (Sigma-Aldrich, USA) and 
100µL/mouse of Incomplete Freund’s Adjuvant (IFA) (Sigma-Aldrich, USA). Emulsion was 
made using Precellys homogeniser using three 45s cycles at 5000 rpm. 1 ml emulsion was 
prepared using 500µL IFA, 20µL peptide (stock concentration 5mg/ml), 100µL Poly I:C and 
380µL sterile PBS. Entire procedure was performed in sterile conditions.  
 
2.3.12 Cytotoxic T Lymphocyte Assay  
 
Immunotoxicity was evaluated using cytotoxic T lymphocyte assay as previously described 
[175]. Spleens from 7-week-old NOD mice were collected into sterile RPMI, single cell 
suspensions prepared and split into two tubes at approximate concentration of 20x106 
cells/ml for labelling. Half of the cell suspension was used as targets pulsed with IGRP206-
214 peptide (final concentration 1µg/ml) for 30 minutes at 37°C. Following this, peptide cell 
suspensions were washed twice with RPMI and once with sterile PBS and labelled with 
10µL of CTV (1µL/ml), whilst non-pulsed cells were labelled with 1µL of CTV and incubated 
for 15 minutes at 37°C. The inhibited by adding ice cold RPMI, washed twice, resuspended 
in sterile PBS, counted and mixed at 1:1 ratio. Prior to injecting the cells were analysed using 
flow cytometry to establish the exact ratio of the CTVhigh and CTVlow for future calculations 
of percentage of lysis. The cells were injected via tail vein into NOD recipients and following 
a 15-18-hour period, mice were sacrificed, spleens and pancreatic lymph nodes collected, 
and cytotoxic function analysed using flow cytometry.   
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2.3.13 Accelerated diabetes model 
 
Splenocytes harvested from diabetic NOD mice (3x106) were transferred into NOD-SCID 
recipients (8-10 weeks of age) and diabetes testing was performed twice weekly using 
FreeStyle Optimum blood glucose monitor (Abbott, USA). Mice were deemed diabetic after 
two consecutive readings of >16 mmol/L. Urine analysis was performed using urine glucose 
strips Diastix (Bayer, Germany). 
 
2.3.14 Histopathology and Insulitis Assessment 
 
Pancreata from 13-14-week-old mice were collected, fixed in 10% neutral buffered formalin 
(Sigma-Aldrich, St. Louis, MO) and embedded in paraffin blocks. 5 µm sections were stained 
using haematoxylin and eosin and the levels of insulitis were assessed as follows: 0=no 
infiltration/no insulitis, 1= peri-insulitis 2= mild insulitis (<50% of islet infiltration), 3= severe 
insulitis (>50% of islet is affected by pathological change), 4 = complete insulitis (>75% of 
islet show evidence of extensive destructive insulitis). A minimum of 20 islets were counted 
using double-blind approach and data are represented as an average percentage from 5 
mice/group. All tissue preparation, staining and slide scanning was performed by TRI 
Histology and Microscopy core facilities. 
 
2.3.15 Absolute cell number calculation 
 
Prior to flow cytometric analysis 20 μL of Flow-Count Fluorospheres (Beckman Coulter) 
were added to each sample in order to later determine absolute counts of cells using 
flourospheres properties such uniform size and fluorescence intensity. The formula below 
was used for calculations: 
𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒	# = #	,-	./001	.,234/5	67	.74,8/4/9#	,-	:02,9,1;</9/1	.,234/5	67	.74,8/4/9 	𝑥	#	𝑜𝑓	𝐹𝑙𝑢𝑜𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠	𝑝𝑒𝑟	𝜇𝐿	(𝑘𝑛𝑜𝑤𝑛)	𝑥	𝑎𝑚𝑜𝑢𝑛𝑡	𝑎𝑑𝑑𝑒𝑑	(20µL)	  
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2.3.16 Data analysis 
 
Flow cytometry data was analysed using FlowJo 10 software (Treestar) and statistical 
analyses were performed using Graphpad Prism 7 software. One-way or two-way Anova 
with Turkey’s multiple comparison test were used for means comparison. Kaplan-Meier 
curve together with log-rank (Mantel-Cox) test were used to analyse survival and disease 
incidence. Significance was determined as ns/not significant p>0.05, * p≤0.05, ** p≤0.01, *** 
p≤0.001, and **** p≤0.0001. 
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IGRP-specific T cells responses to liposomal 
delivery of peptide antigen. 
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 Introduction 
The loss of tolerance in autoimmune diabetes is both CD4+ and CD8+ T cell dependent. 
CD8+ T cells play important role in the disease progression, pancreatic infiltration and tissue 
damage [176]. Early studies demonstrated significant CD8+ T cell infiltration in pancreata of 
diabetic patients [177]. The evidence in NOD mice shows that adoptive transfer of CD4+ T 
cells into NOD-SCID recipients was less efficient in diabetes induction than both CD8+ and 
CD4+ T cells transferred together [178]. Furthermore, lack of MHC I on b-cells and antigen 
presenting cells resulted in disease protection highlighting the importance of CD8+ T cells in 
disease development [71, 179]. It has been previously reported that a large proportion of 
CD8+ T cell islet infiltrates recognize a variety of H-2Kd restricted epitopes of islet-specific 
gucose-6-phosphatase catalytic subunit-Related Protein (IGRP) including IGRP206-214 [172, 
180, 181]. 
Antigen-specific immunotherapy for T1D considered to be the most desirable approach due 
to its believed low-toxicity, high specificity and safety. Several therapeutic attempts focused 
on islet antigens known to play a role in disease progression were designed to restore 
tolerance to these antigens; however, the success rate remains very low [182]. Non-specific 
immunosuppressive approaches have also been undertaken to improve the outcomes of 
T1D. Some treatments including CTLA-4 Ig [183], IL-1 receptor antagonist [184] and 
Rituximab (anti-CD20) [126] showed some promising results in delaying β-cell function 
decline. However, these therapies were unable to prevent further destruction of pancreatic 
β-cells, which is one of the major aims of any T1D treatment. Many clinical trials 
concentrated on prolonging insulin secretion and restoration of normal levels of C peptide 
[127]. The delivery of antigenic peptide has previously been described to target pathogenic 
T cells either by their deletion, inactivation or induction of Tregs leading to successful 
restoration of tolerance in murine models [185, 186]. Whether antigen-specific therapy aims 
to eliminate the effector cells or initiate regulatory mechanisms by expanding Tregs, several 
important issues must be addressed. These include the nature of antigen delivered, its 
dosing and delivery route as well as consideration of potential combination therapy 
requirements [187].  
During the design of antigen-specific immunotherapy, a vital role of antigen presenting cells 
needs to be appreciated. Antigen presenting cell tolerogenicity, activation status and 
location play important roles in tolerance induction. Upon acquisition of an activated 
phenotype, dendritic cells (DCs) are involved in the inflammatory processes, whereas an 
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immature/tolerogenic phenotype is associated with regulatory mechanisms [188]. Previous 
studies have described immature DCs to influence the induction of Tregs and their 
involvement in protection from T1D.  Similar to Tregs that are known to be dysfunctional in 
type 1 diabetics and NOD mice [189, 190], DCs also have been described to have impaired 
function and are lower in numbers. These defects in Tregs and DCs may be a barrier to 
tolerance induction [191]. Therefore, some immunotherapeutic approaches focused on 
rectifying these defects by using patient-derived DCs, modifying them in vitro and re-
introducing them back to the patients in a form of vaccine [192]. This method allows the 
introduction of a variety of immunosuppressive or immunomodulatory agents [193-195] 
and/or antigens and is currently being trialed in type 1 diabetes patients [196]. While an 
important proof-of-principal, several concerns have been raised particularly the practicality 
of generating clinical grade DCs as well as cost [192]. To address this, an alternative 
approach to DC modulation has been proposed using injection of synthetic biodegradable 
nanoparticles encapsulating a variety of immunomodulatory compounds that are taken up 
by DCs. This method was proven to be successful when administered to young NOD mice 
yielding partial protection from T1D [197]. More recently, however, several nanoparticle-
based approaches led to delay or prevention of T1D development in murine models. 
Delivery of microsphere vaccines incorporating antisense oligonucleotides against CD40, 
CD80 and CD86 into NOD resulted in generation of diabetes suppressive DCs in both pre-
diabetic and new onset mice [198]. Another nanoparticle approach using peptide-MHC 
complexes targeted low-avidity CD8+ T cells and resulted in induction of CD8+ regulatory 
population [199]. This system was further utilised by the same group focusing on expansion 
of antigen-specific regulatory CD4+ T cells and regulatory B cells resulting in reversal of 
hyperglycaemia in NOD mice and prevention in NOD-SCID model [186]. 
Here we are proposing a similar approach using liposomal nanoparticles encapsulating 
antigenic peptide IGRP206-214 and calcitriol, an active form of vitamin D3 with 
immunomodulatory potential [114]. The latter is a pleiotropic hormone that regulates calcium 
homeostasis and is known to exert anti-proliferative effects on tumour cells and suppress 
NF-κB pathway activation in T cells, macrophages and monocytes. Use of vitamin D 
receptor agonists have been previously described to induce Tregs, reduce insulitis and 
inhibit T1D progression in NOD mice [110-112, 119, 120]. We hypothesise that whilst 
IGRP206-214 peptide will enable termination of the effector function of pathogenic IGRP-
specific CD8+ T cells, the calcitriol will prevent the maturation of DCs and maintain their 
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tolerogenicity [114, 200, 201]. This chapter will explore the effects of these nanoparticles on 
the IGRP-specific CD8+ T cells.  
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 Results 
3.2.1 Liposomes encapsulating antigenic peptide and calcitriol successfully deliver their 
content to antigen presenting cells 24 hours after delivery. 
Prior to investigating the effects on T cells of liposomes encapsulating diabetogenic antigen 
IGRP206-214 and NF-κB inhibitor calcitriol the uptake patterns of these nanoparticles were 
characterised. Liposomes containing IGRP206-214/calcitriol (referred to as IGRP206-214/D3 
hereafter) were labelled with a lipophilic tracer DiD (Thermofisher, 4μg/ml) and delivered 
intraperitoneally, intravenously or subcutaneously to 8-10 weeks old NOD/Lt recipients 
(peptide 3μg/mouse; calcitriol 40ng/mouse delivered in a volume of 100μl). Spleen, skin 
draining (inguinal), pancreatic and mesenteric lymph nodes were collected 24 hours post 
treatment and antigen presenting cell subsets were analysed using flow cytometry.  
Lymphocytes were gated based on forward and side scatter characteristics and APCs such 
as B cells (CD19+ MHC-II+), MHC-II+ CD11c+ dendritic cells (DCs) and MHC-II+ CD11c- 
non-DCs (Figure 3-1) were identified. Other cell types such as monocytes and 
macrophages also successfully took up the liposomes (data not included). DiD labelled 
liposomes were successfully taken up by conventional CD11c+ DCs in spleen after 
intravenous and intraperitoneal delivery, pancreatic and mesenteric lymph nodes after 
intraperitoneal delivery, and inguinal lymph node after subcutaneous delivery (Figure 3-2 
A). Uptake by B cells and non-DCs antigen presenting cells followed a similar pattern 
(Figure 3-2 B, C). These data indicate that most liposomal uptake occurs in CD11c+ DCs 
and B cells and the site of uptake directly correlates to the delivery route with intravenous 
delivery resulting in the highest uptake in spleen whilst subcutaneously delivered liposomes 
are taken up by the APCs in the skin draining lymph nodes. In pancreatic lymph node, 
however, most of the uptake occurs when liposomes are delivered intraperitoneally, 
however, the translational potential of the intraperitoneal route in human subjects is very 
limited. Therefore, the effectiveness of other two routes will be further explored. 
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Figure 3-1. Example of flow cytometry gating strategy to identify splenic DiD+ DCs and other 
(non-DCs) antigen presenting cells. 
Mice were treated intravenously with DiD labelled IGRP206-214/D3 liposomes and uptake 
assessed after 24 hours. Lymphocytes were identified based on forward and side scatter 
characteristics, followed by exclusion of dead cells and identification of B cells and non-B 
cells based on MHC class II and CD19 markers. B cells were then identified as lipophilic dye 
(DiD) positive and negative and non-B cells further identified as DCs and non-DCs using 
MHC class II and CD11c. DiD uptake was then assessed in both of these populations.  
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Figure 3-2. DiD labelled IGRP206-215/D3 liposomes are successfully taken up by antigen-
presenting cells in spleen, pancreatic, mesenteric and inguinal lymph nodes 24 hours after 
delivery.  
Mice were treated intraperitoneally, intravenously into tail vein or subcutaneously into flank 
with IGRP206-214/D3 liposomes or PBS and sacrificed after 24 hours. Data combined from 
two separate experiments (i.p. n=8, i.v. n=8, s.c n=7, PBS n=6). Mesenteric lymph node was 
collected and analysed once only. A. Uptake by dendritic cells (DCs) (MHC-II+CD11c+), B. 
Uptake by B cells (MHC-II+CD19+). C. Uptake non-DCs antigen presenting population 
(MHC-II+ CD11c-). SEM is shown for each group, statistical analysis was performed using 
one-way Anova p value *≤0.05, **=0.009, ***=0.001, ****<0.0001. 
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To further evaluate the liposomal uptake by different subpopulations of DCs and to 
investigate whether the liposomal content such as the presence or absence of antigen or 
calcitriol would impact the uptake or change the phenotypic characteristics of cells, another 
24-hour uptake experiment was performed using intravenous delivery of liposomes or PBS. 
Liposomes containing IGRP206-214 only, IGRP206-214/D3, D3 only were labelled with a 
lipophilic dye Dil (PE channel) and delivered i.v. to the 8-week-old female NOD recipients. 
After 24 hours after delivery mice were sacrificed and the spleen and pancreatic lymph 
nodes collected. The particular focus of this experiment was to assess the uptake ability and 
phenotypic characteristics of the cross-presenting CD8+ DCs. Although the exact 
mechanisms relating the MHC class I presentation remain unclear, the important role of 
cross-presentation in the induction of tolerance as well as in adaptive immune responses to 
tumours and viruses has been previously described [202-205]. The results show that the 
proportion of total CD11c+ DCs decreased in the IGRP206-214 and D3 only treated groups 
compared to PBS in SPL but were unchanged in the pancreatic lymph nodes. The absolute 
numbers of DCs increased in IGRP206-214 and IGRP206-214/D3 treated groups compared to 
PBS in the spleen and but decreased in the PcLN compared to both PBS and the control 
D3-only liposome treated group (Figure 3-3, A). The proportion of cross-presenting 
CD8+DCs remained unchanged in the spleen and PLN but the absolute numbers showed a 
two-fold decrease in the PcLN in both the IGRP206-214 and IGRP206-214/D3 treated groups in 
comparison to PBS and D3-only liposome treated mice (Figure 3-3, B). In spleen the 
proportion of D11c+CD11b+ DCs increased in IGRP206-214/D3 treated group. The 
corresponding absolute numbers were increased in both IGRP206-214 and IGRP206-214/D3 
liposome treated mice compared to both the PBS and D3-only groups. No changes in 
CD11c+CD11b+ DCs proportion or count were found in the PcLN (Figure 3-3, C). In 
summary, these data indicate that twenty-four hours after liposomal treatment the frequency 
of total CD11c+ splenic DCs is reduced. It can be speculated that this reduction is caused 
by change in DCs phenotype, migration to other lymphoid tissues or indeed killing of DCs.  
Dil uptake was observed in the spleen of all treated groups compared to PBS in total 
CD11c+, CD8+ and CD11c+CD11b+ DCs. In the PcLN, a significant uptake of DiL was only 
observed in CD11c+CD11b+ DCs. The absolute counts of Dil+ total CD11c+ and 
CD11c+CD11b+ DCs revealed no difference in uptake of liposomes encapsulating both 
antigenic peptide and calcitriol compared to liposomes containing only one of these 
compounds. The above data indicate that liposomes successfully deliver their payload to 
the DCs. As mentioned above, the frequency of DCs in PcLN did not change following the 
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treatment, however, absolute numbers of total and CD8+ DCs were reduced in groups 
treated with antigen-containing liposomes. This could be indicative of the CD8+ T cell-
mediated killing of DCs in PcLN. This could further explain the low uptake occurring in PcLN. 
 
Figure 3-3. Frequency of DC subsets 24 hours after liposome treatment. 
The proportion and absolute numbers of A. Total CD11c+ DCs B. CD11c+ CD11b- CD8+ 
DCs (of total CD11c+DCs) C. CD11c+ CD11b+ DCs (gated on MHC class II+ non-B cells) in 
spleen and pancreatic lymph nodes. Mice were treated with IGRP206-214 only, D3 only, 
IGRP206-214/D3 liposomes or PBS. SEM is shown for each group, statistical analysis was 
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performed using one-way Anova, p value: ns (not significant) when p>0.05, *≤0.05, **=0.009, 
***=0.001, ****<0.0001, n=5. 
 
Figure 3-4. DCs successfully take up liposomes 24 hours after intravenous delivery.  
The proportion and absolute cell numbers of DiI+ cells in (A) Total CD11c+ DCs (B) CD11c+ 
CD11b- CD8+ DCs (of total CD11c+DCs) (C) CD11c+ CD11b+ DCs (gated on MHC class II+ 
non-B cells) in spleen and pancreatic lymph nodes. Mice were treated with IGRP206-214 only, 
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D3 only, IGRP206-214/D3 liposomes or PBS. SEM is shown for each group, statistical analysis 
was performed using one-way Anova, p value: ns (not significant) when p>0.05, *≤0.05, 
**=0.009, ***=0.001, ****<0.0001, n=5. 
The expression of co-stimulatory and co-regulatory markers such as CD86 and PD-L1 
following liposome uptake was also analysed in this experiment. The key co-stimulatory 
molecules CD80 and CD86 are mediators of T cell activation and survival [206]. Changes in 
both CD80 and CD86 levels of expression are associated with DC maturation and are 
correlated with suppressive functions of Tregs [207]. It has previously been suggested that 
these co-stimulatory molecules differ in their affinities to their T cell ligands CD28 and CTLA-
4, are not necessarily expressed on the surface of DCs simultaneously and have opposing 
functions on Tregs and in turn on tolerance and immune responses [207, 208]. This was 
demonstrated when CD86 blockade resulted in enhanced Treg suppression, whereas CD80 
blockade had the opposite effects by weakening Treg responses [207]. In summary, CD80 
plays a role in inhibition of cytotoxic T lymphocytes whereas CD86 has a stimulatory role 
and silencing of CD86 on DCs leads to dampening of effector T cell responses and induction 
of tolerance [209]. In the context of T1D, CD86-/- DCs pulsed with b-cell antigen and 
delivered to prediabetic NOD mice resulting in delayed disease onset, suppression of 
insulitis and an increase in IL-10 and TGF-b1 production. Interestingly, treatment with CD80-
/-DCs resulted in increased IFN-g production and not IL-10 or TGF-b1 by T cells [208]. 
Another important co-regulatory molecule, B7-CD28 superfamily member is program death 
ligand-1 (PD-L1/CD274). The relationship between co-stimulatory and co-regulatory 
molecules DC-T cell interaction determines whether activation and proliferation of effector T 
cells will occur or on the contrary the induction of Tregs particularly associated with high PD-
L1 expression [210, 211]. 
PD-L1 expression was increased on total CD11c+ DCs in the spleen but not PcLN in all 
liposome treated groups compared to PBS and the absolute numbers showed a similar 
pattern. In the PcLN, a significant reduction in the number of PD-L1+ total DCs in IGRP206-
214 and IGRP206-214/D3 treated groups compared to D3 only and PBS was noted (Figure 3-5, 
A). Interestingly, PD-L1 was significantly increased on CD8+DCs in the spleen following D3 
only treatment compared to all other treatment groups. The same pattern was observed in 
the absolute numbers of PD-L1+ in CD8+ splenic DCs. In  PcLN, whilst no significant changes 
were observed in frequency of PD-L1+CD8+ DCs, the absolute numbers showed decrease 
in PD-L1 expression in IGRP206-214 and IGRP206-214/D3 treated groups compared to PBS and 
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D3 only (Figure 3-5, B). PD-L1 expression was high in the steady state on CD11c+CD11b+ 
DCs and wasn’t further upregulated by liposome treatment in the spleen or PcLN, with latter 
showing an increase in the absolute number in all liposome treatments compared to PBS. 
The expression of the co-stimulatory marker CD86 was upregulated in splenic total DCs in 
the D3 only treated group. In the PcLN, CD86 was increased with D3 only and IGRP206-214 
only treatment but not by IGRP206-214/D3 containing liposomes (Figure 3-5, D). There was 
no change in CD86 expression on CD8+DCs in both SPL and PcLN, whereas splenic 
absolute numbers showed an increase in D3 only treated group compared to PBS and 
IGRP206-214/D3 treated groups (Figure 3-5, E). No changes were observed in 
CD11c+CD11b+ DCs in spleen or PcLN.  
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Figure 3-5. Intravenous treatment with IGRP206-214, D3 and IGRP206-214/D3 liposomes results 
in upregulation of PD-L1 and D3 only treatment increases CD86 on total CD11c+ DCs 24 
hours after treatment.  
Proportion and absolute numbers of PD-L expression on A. Total CD11c+ DCs B. CD11c+ 
CD11b- CD8+ DCs (of total CD11c+DCs) C. CD11c+ CD11b+ DCs (gated on MHC class II+ 
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non-B cells). Proportion and absolute cell numbers of CD86 expression on D. CD11c+ DCs 
E. CD11c+ CD11b- CD8+ DCs (of total CD11c+DCs) F. CD11c+ CD11b+ DCs (gated on MHC 
class II+ non-B cells). Mice were treated with IGRP206-214 only, D3 only, IGRP206-214/D3 
liposomes or PBS. SEM is shown for each group, statistical analysis was performed using 
one-way Anova, p value: ns (not significant) when p>0.05, *≤0.05, **=0.009, ***=0.001, 
****<0.0001, n=5. 
Combined, these data show that upon successful liposomal uptake by dendritic cells, the 
expression of co-regulatory molecule PD-L1 is increased on total splenic DCs in all liposome 
treated groups. Furthermore, the expression of PD-L1 is significantly elevated in D3 only 
treated group on CD8+ cross-presenting DCs. Interestingly, CD86 expression on total 
splenic DCs suggests that D3 only treatment may increase the ability of these DCs to 
activate T cells, though further confirmation is required. Whilst this experiment needs to be 
repeated and subcutaneous delivery wasn’t assessed here, these data suggest that there 
might be a possibility of DC-T cell interaction due to differences between D3 only and 
IGRP206-214/D3. Following on, the response of antigen-specific T cells to the delivered 
antigen in terms of their proliferative ability and activation status needs to be measured to 
assess the tolerogenic properties of the liposomes. 
 
3.2.2  Proliferation of IGRP-specific 8.3 T cells in ILN in response to subcutaneous delivery 
of antigen-containing liposomes. 
 
In order to test whether IGRP206-214 peptide delivered within liposomes is able to activate 
IGRP-specific 8.3 T cells, we transferred 3x106 enriched and CTV-labelled 8.3 T cells into 
NOD recipients and treated subcutaneously with liposomes encapsulating 3µg/mouse of 
IGRP206-214 peptide in the presence or absence of calcitriol as well as calcitriol alone. After 
4- or 10-days post treatment initiation mice were sacrificed, inguinal (ILN), pancreatic (PcLN) 
and cervical (CLN) lymph nodes collected and cell proliferation patterns and proportion 
analysed using flow cytometry. CD8+ 8.3 T cells were identified using the congenic marker 
CD90.1. Treatment with liposomes containing IGRP206-214 and IGRP206-214/D3 resulted in 
vigorous proliferation of 8.3 T cells in the ILN and increased proliferation in CLN compared 
to D3 only or PBS treated groups at day 4 (Figure 3-6 A-B). It has been previously reported 
that diabetogenic T cells get primed in the pancreas and pancreatic lymph node by 
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endogenously produced IGRP antigen [212]. In line with these findings, the PBS and 
calcitriol only treated groups showed proliferation in the absence of exogenous antigen only 
in the PcLN (Figure 3-6 A, B). In all analysed tissues the 8.3 cells continue to proliferate 10 
days after treatment with an increased proportion of divided cells in IGRP206-214/D3 treated 
groups in the ILN and CLN compared to PBS and D3. These data show successful antigen 
recognition by the IGRP-specific Thy1.1 CD8+ T cells as evidenced by increase in 
proliferation of this population in response to liposomal treatment containing IGRP206-214 
peptide and lack of or minimal proliferative abilities in response to PBS or liposomes 
containing D3 only respectively. After 4 days from initiation of subcutaneous treatment with 
IGRP206-214/D3 and IGRP206-214 only liposomes, the proportion of divided IGRP-specific 8.3 
cells substantially increased in the skin draining lymph nodes. The level of proliferation was 
low in the superficial cervical lymph nodes at day 4 in all treated groups, however by day 10 
in IGRP206-214/D3 treated animals increase in proliferation compared to PBS controls was 
noted.  The overall increase in proliferation including the PBS treated groups was observed 
in the PcLN. Interestingly, treatment with IGRP206-214 only containing liposomes resulted in 
lower proliferation at day 10 in the ILN compared to IGRP206-214/D3 treated group, suggesting 
an immunomodulatory effect of vitamin D3. These data demonstrate that whilst 
subcutaneous liposome delivery results in successful antigen presentation in the skin 
draining lymph nodes. A reduction in proliferation was observed in the ILN by day 10 which 
could be due to reduced antigen availability and/or migration of activated antigen-specific 
cells to the sites where antigen is present such as the pancreas or PcLN. 
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Figure 3-6. Subcutaneous treatment with antigen-containing liposomes results in 
proliferation of CTV-labelled CD90.1+ 8.3 T cells in inguinal and pancreatic lymph nodes 4 
and 10 days after delivery.  
CTV labelled 8.3 cells (3x106) were transferred into 8-10-week old female NOD recipients 
and mice were treated subcutaneously with IGRP206-214 (Day 4, n=8; Day 10, n=9), IGRP206-
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214/D3 (Day 4, n=8; Day 10, n=9), D3 only liposomes (Day 4, n=6; Day 10, n=8) or PBS (Day 
4, n=1; Day 10, n=4). A. Representative histogram plots showing IGRP-specific 8.3 T cell 
proliferation 4 days and 10 days after subcutaneous delivery of liposomes or PBS. Gated 
on CD8+CD90.1+ cells. Numbers represent percentage of the divided cells measured by 
the dilution of CTV B. Proportion of divided and undivided 8.3 IGRP-specific CD8+ T cells 4 
and 10 days after subcutaneous treatment with liposomes or PBS. Results were analysed 
using two-way Anova, p value: ns (not significant) when p>0.05, *≤0.05, **=0.009, ***=0.001, 
****<0.0001, Data combined from two individual experiments. 
A significant proportion of 8.3 cells in the ILN underwent proliferation in response to liposome 
derived antigen, some cells remained undivided at day 10. This could be explained by 
diminishing antigen availability in the ILN by day 10 due to high antigen demand by the large 
number of transferred IGRP-specific cells. Furthermore, after 4 days no accumulation of 
CTVlow cells in the PcLN is observed, suggesting possible deletion or migration of this 
population. In summary, these initial observations of potent proliferative ability of 8.3 T cells 
in response to the exogenous diabetogenic peptide IGRP206-214 warrant further investigation 
to the outcome on tolerance with this antigen-specific liposomal delivery model. 
3.2.3 Liposomal short-term treatment leads to short-lived expansion followed by 
contraction of IGRP-specific CD8+ effector T cells. 
In addition to the proportion of divided cells after the 4-or 10-day treatment above, both 
proportions and numbers of 8.3 T cells after the treatment were assessed. A short-lived 
increase in the proportion of IGRP-specific 8.3 effector cells 4 days after subcutaneous 
delivery in all liposome treated groups in the skin draining lymph nodes followed by 
significant reduction at day 10 in ILN and CLN. The initial increase in 8.3 cell proportions 
was not seen in the PcLN, however after 10 days a significant reduction in cell proportion in 
all of the liposome treated groups compared to PBS was observed with the largest reduction 
in the IGRP206-214/D3 treated mice. Interestingly, the proportion of 8.3 cells was also reduced 
compared to PBS following treatment with D3-only containing liposomes suggesting both 
the peptide and the calcitriol are impacting 8.3 cell activation. A similar pattern was seen in 
the absolute counts of IGRP-specific 8.3 cells at day 4 (Figure 3-7 A, B). This finding is 
consistent with the uptake and proliferation data (Figure 3-2 and Figure 3-6). After 10 days, 
a significant decrease in both the cell count and proportion of cells was observed in all lymph 
nodes of liposome treated mice suggestive that liposome treatment does not cause 
expansion of pathogenic IGRP-specific 8.3 cells but may result in their subsequent deletion 
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and/or exhaustion. It is noteworthy that a major limitation at day 4 was that only one animal 
received PBS treatment and therefore no statistical comparison with this group can be 
made.  
 
Figure 3-7. Subcutaneous delivery of liposomes causes expansion after 4 days and 
contraction after 10 days of CD90.1+ 8.3 cells in the ILN. 
A. Proportion and B. Absolute numbers of 8.3 IGRP-specific CD8+ T cells. Following 
adoptive transfer of 3x106 purified CTV-labelled 8.3 cells into 8-10-week-old NOD recipients, 
mice were treated with 3µg IGRP206-214; 3µg IGRP206-214/40ng calcitriol; 40ng calcitriol only 
liposomes or PBS and analysed after 4 or 10 days. CD90.1 was used as a congenic marker 
to identify 8.3 CD8+ T cells. Data combined from two individual experiments. SEM is shown 
for each group, statistical analysis was performed using one-way Anova p value: *≤0.05, 
**=0.009, ***=0.001, ****<0.0001. 
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3.2.4 Liposomal antigen- specific treatment results in the transient expansion and 
subsequent reduction of IGRP-specific effector T cells  
 
Previously, the transfer of 3x106 Thy1.1 CD8+ T cells resulted in proliferation in response to 
the delivered antigen, however even after 10 days many cells remained undivided 
presumably due to insufficient antigen delivery for the large number of transferred cells. In 
order to mimic a scenario closer to physiological conditions, 1 x 105 purified and CTV-
labelled 8.3 cells were adoptively transferred into female NOD recipients followed by 
subcutaneous or intravenous treatment with IGRP206-214 only, IGRP206-214/D3 liposomes or 
PBS and sacrificed 4- or 10-days post treatment. The responses of endogenous IGRP-
specific CD8+ T cells were also examined using IGRP206-214 H-2Kd tetramer staining. 
Representative flow cytometry plots showing the proportions of 8.3 and IGRP-specific 
endogenous CD8+ T cell populations in the spleen, ILN and PcLN after 4 and 10 days are 
shown (Figure 3-8 A) together with examples of proliferation plots (Figure 3-8, B). IGRP206-
214-driven expansion of the transferred 8.3 cells in the spleen was seen four days after i.v. 
liposome treatment and in the ILN following SC treatment. In line with previous observations, 
the proportions of transferred antigen-specific CD8+ T cells in the PcLN was comparable to 
PBS across all treatment groups. Interestingly, the proportion of divided cells was increased 
substantially compared to when 3x106 cells were transferred confirming that reduced 
antigen availability limits cell division after a transfer of large number of cells. In the spleen, 
8.3 cells were almost completely divided following i.v. treatment with IGRP206-214/D3 
liposomes by day 10, though there is no data for i.v. treatment in the previous experiment 
for comparison. However, in the ILN all liposome treated groups showed increased 
proliferation compared to PBS and in the IGRP206-214/D3 group cells were almost fully divided 
by day 10. In the PcLN, a large proportion of divided cells was seen in all treatment groups 
at both 4- and 10-days post-treatment (Figure 3-8, C). In summary, these data provide 
evidence of successful antigen recognition by the 8.3 T cells evidenced by their successful 
proliferation in response to the delivered IGRP206-214 peptide. 
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Figure 3-8. Examples of flow cytometry and CTV proliferation plots after 4 and 10 days post- 
IV and SC delivery of liposomes in IGRP-specific 8.3 and endogenous CD8+ T cells. 
Following adoptive transfer of 1x105 purified CTV-labelled 8.3 cells into 8-10-week-old NOD 
recipients, mice were treated with IGRP206-214; IGRP206-214/D3 or PBS both subcutaneously 
and intravenously. A. Representative flow cytometry plots showing the proportion of 
endogenous and transferred IGRP-specific CD8+ T cells in SPL, ILN and PcLN 4 days and 
10 days after i.v. and s.c. delivery of liposomes (gated on total CD8+ T cells). B. 
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Representative histogram plots showing IGRP-specific 8.3 T cell proliferation 4 days and 10 
days after delivery of liposomes, numbers show the percentage of divided cells. C. 
Proportion of divided and undivided 8.3 IGRP-specific CD8+ T cells 4 and 10 days after 
treatment with IGRP206-214 (Day 4, n=4; Day 10, n=4), IGRP206-214/D3 (Day 4, n=4; Day 10, 
n=4), liposomes or PBS (Day 4, n=5; Day 10, n=5) in SPL, ILN and PcLN. The PBS group 
was pooled from mice receiving either i.v. or s.c. PBS treatment. Data analysed using two-
way Anova, p value *≤0.05, **=0.009, ***=0.001, ****<0.0001. 
  
80 
 
To further investigate the response of IGRP-specific CD8+ T cells to the exogenous antigen 
delivered within the liposomes, their phenotype was assessed. After adoptive transfer of a 
reduced number of 8.3 cells (100,000 cells) and liposome treatment, the 8.3 cell frequency 
and absolute count (Figure 3-9 A-B) as well as activation status measured by CD44, LAG-
3 and PD-1 expression was determined (Figure 3-9, C-E.). Similar to the proliferation data 
discussed earlier, there was no difference in proportion of 8.3 cells in the PcLN between 
liposome and PBS treated groups due to the presence of endogenous antigen. Upregulation 
of CD44 by 8.3 cells was observed in the spleen and ILN after i.v. and s.c. treatments 
respectively with a further increase in the spleen after 10 days across all of the treatment 
groups including PBS. The latter could be explained by the recirculation of the 8.3 cells from 
other sites (e.g. the PcLN or pancreas). Interestingly, in the ILN of the s.c. treated groups at 
day 10 we observed a reduction in 8.3 cell CD44 expression compared to day 4 (Figure 3-9, 
C.). This could imply a deletion or relocation of activated cells in response to antigen 
recognition [213]. In the PcLN the majority of IGRP-specific 8.3 cells were CD44hi including 
in the PBS treated group with a slight further increase by day 10.  
Recent studies have identified lymphocyte-activation gene 3 (LAG-3) as an important 
regulator of T cell function. This transmembrane protein bares high homology to CD4 and 
binds to the MHC II molecule with much higher affinity than CD4 [214, 215]. LAG-3 
expression has been identified on T lymphocytes including, CD8+, CD4+, γδ and Tregs as 
well as NK cells, B cells and plasmocytoid DCs (pDCs) [216-219]. LAG-3 is a negative 
regulator of activation and proliferation similar to PD-1 and CTLA-4 [220]. It also has been 
described to be involved in Treg suppression [218] and maintenance of CD8 tolerance as 
well as CD8 exhaustion in viral infections [221, 222]. I observed a significant increase in 
LAG-3 expression (Figure 3-9, D) by day 10 in the spleen of mice treated i.v. with IGRP206-
214/D3 liposomes. In the ILN LAG-3 was increased at day 10 compared to PBS in all 
liposome subcutaneously treated mice and intravenously treated IGRP206-214/D3 group. In 
the PcLN LAG-3 was high across all groups including PBS. PD-1 expression (Figure 3-9, 
E., data only available for s.c. treated mice) was significantly increased in the IGRP206-214/D3 
and IGRP206-214 only treated animals in all tissues 4 days post-treatment but by day 10 PD-
1 expression was undetectable. This could be explained by the antigen scarcity at day 10 
and possible deletion of PD-1 high cells. In summary, these data show upregulation of CD44 
an increase in LAG-3 expression 10 days after treatment compared to day 4, suggesting 
that IGRP-specific 8.3 cells are gradually acquiring an exhausted phenotype. Interestingly, 
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PD-1 expression is increased at day 4 with a gradual decline by day 10, supporting the idea 
of initial expansion and activation followed by reduction of pathogenic PD-1 high cells. 
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Figure 3-9. Proportion and activation status of transferred IGRP-specific 8.3 cells in SPL, 
ILN and PcLN after 4 and 10 days of s.c. and i.v. delivery. 
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Following adoptive transfer of 105 purified CTV labelled 8.3 cells into 8-10-week-old NOD 
recipients, mice were treated with IGRP206-214; IGRP206-214/D3 both subcutaneously and 
intravenously and PBS.A. Proportion of 8.3 cells. B. Count of 8.3 cells. C.  Proportion of 
CD44hi 8.3 cells D. proportion of LAG3+ 8.3 cells and E. Proportion of PD-1+ 8.3 cells 4 
and 10 days (s.c. only) post-treatment with liposomes i.v. or s.c. SEM is shown for each 
group, statistical analysis was performed using one-way Anova, p value: ns (not significant) 
when p>0.05, *≤0.05, **=0.009, ***=0.001, ****<0.0001. 
3.2.4.1 Endogenous IGRP-specific CD8+ T cells fail to expand and upregulate activation 
markers in response to liposomal delivered antigen. 
Whilst CD90.1 transferred 8.3 cells offer a useful read-out of proliferation and activation 
status after antigen specific treatment, the endogenous IGRP-specific CD8+ T cells are the 
target population for tolerance induction. We used MHC class I H-2Kd IGRP tetramer to 
identify the endogenous IGRP-specific population. As for the 8.3 cells above, I then analysed 
their frequency and activation status using CD44, LAG3 and PD-1 markers.  
Here I demonstrate that at day 4 no change in proportion of IGRP-specific CD8+ T cells or 
expression of CD44, LAG3 or PD-1 was observed in all analysed tissues.  A slight increase 
in both proportion and number in PcLN after IGRP206-214/D3 treatment at 10 day was 
observed while no significant changes in proportions or numbers were identified in the 
spleen. In the ILN the absolute number of endogenous IGRP-specific CD8+ cells was 
increased 10 days after IGRP206-214/D3 treatment, though no change in the proportion was 
seen. Furthermore, there was no increase in expression of CD44, LAG3 or PD-1 by 
endogenous IGRP-specific cells following liposome treatment in any analysed tissues 
(Figure 3-10, A-E). These data demonstrate that despite the increase of tetramer+ 
endogenous CD8+ T cells in the inguinal lymph node after s.c. IGRP206-214/D3 treatment, no 
cell activation was noted. Therefore, their responses to the delivered antigen and possible 
competition for the antigen between endogenous and transferred cells need to be further 
investigated. 
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Figure 3-10. Endogenous IGRP-specific CD8+ T cell population shows a weak response to 
the liposomal delivered antigen.  
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Following adoptive transfer of 105 purified 8.3 cells into 8-10-week-old NOD recipients, mice 
were treated with IGRP206-214; IGRP206-214/D3 both subcutaneously and intravenously and 
PBS. A. Proportion and B. Absolute numbers of IGRP-specific endogenous CD8+ T cells 
(CD8+ CD90.1- tetramer+ cells) and their activation status showing expression of C. CD44, 
D. LAG-3 and E. PD-1 in SPL, ILN and PcLN after 4 and 10 days of s.c. and i.v. delivery. 
PD-1 expression on endogenous CD8 population is for subcutaneous treatment Day 4 only 
due to a very low cell number of tetramer+ cells at day 10. SEM is shown for each group, 
statistical analysis was performed using one-way Anova, p value: ns (not significant) when 
p>0.05, *≤0.05, **=0.009, ***=0.001, ****<0.0001. 
3.2.5 Endogenous and transferred IGRP-specific CD8+ T cells do not compete for the 
delivered antigen 
In the current model where 8.3 cells were transferred prior to treatment initiation, there has 
been no clear evidence of activation of endogenous IGRP-specific T cells. Therefore, in 
order to investigate whether both transferred and endogenous IGRP-specific populations 
are competing for the delivered antigen, an experiment was performed without 8.3 transfer. 
Mice were treated with liposome i.v. as before and 4 days later the mice were sacrificed. No 
expansion or increase in PD-1 expression by endogenous IGRP-specific CD8+ T cells was 
observed 4 days after treatment (Figure 3-11). These data suggest that competition was 
not the reason for the endogenous cells’ limited response. Here I demonstrate that despite 
successful recognition of antigenic peptide IGRP206-214 by IGRP-specific CD90.1 CD8+ T 
cells, the liposomal treatment hasn’t detectably activated the endogenous IGRP-specific 
population. As the markers I selected may have missed a response by the endogenous 
population, I next examined the more functional readout of IFN-g production. 
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Figure 3-11. Endogenous IGRP-specific CD8+ T cells do not expand or upregulate PD-1 4 
days after intravenous liposomal treatment in the absence of 8.3 cell transfer. 
Female NOD mice aged 8-10 weeks were treated intravenously with IGRP206-214; IGRP206-
214/D3, D3 only liposomes or PBS and 4 days later the spleen and PcLN collected. A. 
Proportion of IGRP-specific CD8+ T cells (of total CD8) in spleen and PcLN and B. 
Expression of PD-1 by IGRP-specific CD8+ T cells. Results were analysed using Anova, p 
values were >0.05, not significant. 
3.2.6 IFN-g production is reduced in the endogenous IGRP-specific population following 
the treatment with IGRP206-214/D3 liposomes. 
One of the hallmarks of tolerance in the autoimmunity setting is a reduction in IFN-g 
production. Therefore, we tested IFN-g production by endogenous IGRP-specific T cells in 
the context of IGRP-specific liposomal therapy ex vivo. Female NOD mice were treated s.c. 
or i.v. with liposomes or PBS and the spleen and PcLN analysed 5 days later.  Tetramer 
staining was performed prior to PMA/Ionomycin stimulation and IFN-g production was 
analysed on IGRP tetramer positive CD8+ T cells. There was a significant reduction in IFN-
g+ IGRP-specific CD8+ T cells in the spleen in mice treated with IGRP206-214/D3 liposomes 
(both s.c. and i.v.) compared to PBS treatment (Figure 3-12). Furthermore, in the group 
treated with IGRP206-214 only liposomes i.v. IFN-g was increased significantly comparing to 
IGRP206-214/D3 treatment in both the spleen and PcLN confirming the immunomodulatory 
effects of calcitriol. The production of IFN-g in the PcLN in IGRP206-214/D3 treated groups 
were not statistically lower than in PBS, although the tendency was for it to remain low. 
These data confirm that despite IGRP-specific endogenous CD8+ T cells not proliferating or 
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showing increased expression of the activation markers CD44 and PD1 in response to the 
liposome-delivered antigen, their IFN-g production is significantly reduced.  
 
Figure 3-12. IFN-g is reduced in IGRP-specific endogenous CD8+ T cells following both i.v. 
and s.c. delivery of IGRP206-214/D3 liposomes. 
Mice were treated s.c. or i.v. with IGRP206-214, IGRP206-214/D3 liposomes or PBS and 5 days 
later IFN-g production was measured after in vitro IGRP206-214 peptide stimulation. SEM is 
shown for each group, statistical analysis was performed using one-way Anova, p value: ns 
(not significant) when p>0.05 *≤0.05, **=0.009, ***=0.001, ****<0.0001. 
 
3.2.7 Increasing the IGRP peptide dose delivered by the liposomes tips the balance in 
favour of activation and IFN-γ production. 
 
Chronic exposure to antigen as well as exposure to high concentrations of antigen can lead 
to pathogenic immune responses [223]. As it has been demonstrated that cells first undergo 
proliferation upon the initial antigen exposure prior to tolerance induction. However, it needs 
to be appreciated that uncontrolled expansion of effector cells could result in inflammatory 
cytokine production that drives pathogenic responses causing the therapy to have a 
negative outcome. Alternatively, during chronic infection or inflammation it has been 
reported that exposure to high doses of antigen may induced an exhausted phenotype and 
loss of robust effector functions [224, 225]. Therefore, it is important to investigate the 
optimal peptide dose in the context of our IGRP peptide antigen and liposome-based 
therapy. 
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In order to investigate some of these issues in our therapy, we doubled the amount of IGRP 
peptide encapsulated in liposome from 30 μg/ml to 60 μg/ml (3 or 6 μg/mouse). In addition 
to animals treated with liposomes containing 3µg IGRP206-214/D3, 6µg IGRP206-214/D3, 3µg 
IGRP206-214 only and PBS, we included control empty liposome (EL) treatment group in 
spleen and pancreatic lymph nodes. Mice were treated i.v. or s.c. and 5 days later we looked 
at cell proportions, exhaustion markers and inflammatory cytokine production of both 
transferred 8.3 T cells and endogenous IGRP-specific T cells (Figure 3-13, A-C). 
Interestingly, in the spleen there was a significant expansion of transferred 8.3 cells in the 
group treated with 6μg IGRP206-214/D3 after both s.c. and i.v. treatments compared with the 
standard 3ug liposomes. This could be due to an increase in activation or survival of antigen 
experienced cells and their trafficking from the site of injection (ILN). This increased 8.3 cell 
expansion could also potentially be due to contamination by free peptide not encapsulated 
within the liposome or in the case of s.c. delivery due to small amounts of peptide reaching 
the spleen resulting in the increased activation. The 8.3 cells in mice treated with 6μg 
IGRP206-214/D3 compared to 3µg IGRP206-214/D3 had higher expression of PD-1 and 
produced significantly more IFN-γ compared to the other groups, particularly in the spleen 
following i.v. delivery. A similar pattern was observed in the inguinal lymph nodes in 
response to s.c. treatment. In the pancreatic lymph node, the proportion of 8.3 cells and PD-
1 expression was similarly high across all groups. The proportion of IFN-γ producing 8.3 
cells in the spleen of mice treated s.c. with 3μg IGRP/D3 was observed to be at similar levels 
to PBS treated controls, whereas a significant increase in 6µg IGRP206-214/D3 i.v. and 
IGRP206-214/D3 s.c. treatments occurred compared to PBS controls. IFN- γ was also 
increased in pancreatic lymph nodes in groups treated with 6μg IGRP206-214/D3 i.v. 
compared to both PBS and IGRP206-214/D3 i.v. treatment. Interestingly, IFN-g was 
significantly lower in IGRP206-214/D3 treated group compared to IGRP206-214 only in PcLN 
highlighting the potentially important role of the immunomodulator in the suppression of pro-
inflammatory cytokine production. In the skin draining lymph nodes IFN-γ production did not 
increase after treatment with 3μg IGRP206-214/D3 compared to PBS, whereas a significant 
increase in IFN-g was noted after IGRP206-214 only and 6µg IGRP206-214/D3 compared to PBS 
and 3 µg IGRP206-214/D3 treated groups. Together, these data indicate that increasing the 
peptide dose results in more potent activation and the ability to produce IFN-γ by 8.3 T cells. 
Intriguingly, despite the increase in peptide concentration, the endogenous IGRP-specific 
CD8+ T cell population did not result in expansion of this population compared to PBS 
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(Figure 3-14, A). Interestingly, subcutaneous but not intravenous treatment with 6μg 
IGRP206-214/D3 in the spleen but not the PcLN or ILN, did result in an increase in PD-1 
expression (Figure 3-14, B). This was surprising as it would be expected that the highest 
PD-1 upregulation would occur in the ILN which drains the s.c. injection site. Analysis of 
IFN-g production (Figure 3-14, C) revealed reduced levels in 3μg IGRP206-214/D3 treated 
groups in the spleen and (s.c. and i.v.) ILN (s.c. only), with a similar trend in PcLN, though 
no statistical significance was reached. Intravenous treatment with IGRP206-214 only and 6μg 
IGRP206-214/D3 in SPL resulted in significantly elevated levels of IFN-g compared to 3μg 
IGRP206-214/D3 but not PBS treated mice. In summary, both s.c. and i.v. delivery of 3µg 
IGRP206-214/D3 resulted in low production of IFN-g. However, i.v. delivery of an increased 
peptide dose resulted in increased IFN-g production, whereas s.c. delivery did not. This 
could potentially argue for the overall safety of the s.c. route of delivery.  
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Figure 3-13. Increased amount of antigenic peptide boosts 8.3 cell proliferation and IFN-γ 
production. 
A. Proportion of IGRP-specific 8.3 cells. B. Level of PD-1 expression on 8.3 cells and C. 
Proportion of IFN-γ producing 8.3 cells in the SPL, PcLN and ILN 5 days after liposomal 
treatment. IFN-γ production measured after PMA/Ionomycin stimulation 5 days after transfer 
of 100,000 8.3 cells and treatment with liposomes. SEM is shown for each group, p value 
*≤0.05, **=0.009, ***=0.001, ****<0.0001. EL-empty liposome. 8.3 cells were gated from total 
CD8+ T cells using CD90.1 congenic marker. 
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Figure 3-14. Increased amount of antigenic peptide doesn’t boost cell proliferation or IFN-γ 
production in the endogenous IGRP-specific CD8 T cells. 
A. Proportion of IGRP-specific endogenous CD8 T+ cells. B. Level of PD-1 expression on 
endogenous CD8 T+ cells and C. Proportion of IFN-γ producing endogenous CD8 T+ cells 
in SPL, PcLN and ILN 5 days after liposomal treatment. IFN-γ production measured after 
PMA/Ionomycin stimulation 5 days after transfer of 100,000 8.3 cells and treatment with 
liposomes. SEM is shown for each group, p value *≤0.05, **=0.009, ***=0.001, ****<0.0001. 
EL-empty liposome. Tetr+ cells were gated from total CD8+ T cells and identified as IGRP 
tetr+ CD90.1neg. 
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3.2.8 Activation of the endogenous IGRP-specific CD8+ T cells is evident after 2 weekly 
liposomal injections. 
Before proceeding with the long-term liposomal treatment in NOD mice and assessing its 
therapeutic and preventative potential, we wanted to ensure that the delivered antigen does 
indeed have an effect on the endogenous population of IGRP-specific CD8+ T cells. Based 
on our previous observations in 8.3 cells, both intravenous and subcutaneous treatments 
produced comparative results with some evidence of proliferative response in the PcLN after 
subcutaneous treatment with IGRP206-214/D3 (Figure 3-10, A-B). Furthermore, the above 
data indicate that s.c. may be a more tolerogenic route evidenced by decrease in IFN-g 
production. Therefore, the subcutaneous treatment will be further discussed due to its wider 
therapeutic applications. 
Having previously used a single liposomal treatment we were unable to detect a change in 
proportion or activation status of endogenous IGRP-specific cells after 4 or 10 days. To date, 
reduction in IFN-g was the only evidence suggesting that a single liposomal treatment could 
induce anergy or unresponsiveness in the endogenous population. We decided to further 
test the effects of antigen availability. More precisely, rather than increasing the amount of 
antigen delivered in one shot, we delivered the same amount of IGRP206-214 (3µg) in multiple 
subcutaneous injections. Furthermore, no 8.3 cells were transferred in this experiment. 
Female NOD recipients aged 8-weeks received two IGRP206-214/D3 or PBS treatments (s.c.) 
on day 0 and day 7. Mice were sacrificed three days after the second treatment (day 10) 
and the spleen, ILN and PcLN collected. The proportion and expression of PD-1 and CD44 
on endogenous tetramer+ IGRP-specific CD8+ T cells was analysed using flow cytometry 
(Figure 3-15, A-D). There was a significant increase in both the proportion of IGRP-specific 
CD8+ T cells and their expression of CD44 in both the spleen and ILN of mice receiving two 
IGRP206-214/D3 liposome treatments compared to PBS. PD-1 expression was increased 
significantly in the ILN only in the liposome treated groups compared to PBS. In the PcLN 
there was no difference in the proportion of cells, PD-1 or CD44 expression on the IGRP-
specific cells between PBS and liposome treated groups. These data provide strong 
evidence to support the notion that persistent antigen presentation is required for the 
endogenous IGRP-specific CD8 population to respond and become activated. Based on 
these observations, I now proceeded with testing this model in both prediabetic and 
hyperglycaemic animals aiming to induce tolerance and terminate effector functions of 
IGRP-specific CD8+ T cells. 
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Figure 3-15. IGRP-specific CD8+ T cells expand and become activated after two 
subcutaneous treatments with IGRP206-214/D3.  
A. Experimental design. B. Proportion of IGRP-specific endogenous CD8+ T cells. C. PD-1 
expression on IGRP-specific CD8+ T cells. D.  CD44 expression on IGRP-specific CD8+ T 
cells in spleen, inguinal and pancreatic lymph nodes after IGRP206-214/D3 (n=5) or PBS (n=5) 
treatment. SEM is shown for each group, statistical analysis was performed using one-way 
Anova, p value *≤0.05, **=0.009, ***=0.001, ****<0.0001. 
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 Discussion  
 
In this chapter, I hypothesised that delivering liposomes encapsulating IGRP206-214 peptide 
and D3 to the DCs of pre-diabetic NOD mice would allow us to induce tolerance. This 
chapter focused on describing a proof of concept study undertaken in an animal model of 
T1D-susceptible NOD mice. Firstly, we successfully demonstrated the uptake of antigen by 
DCs and the subsequent upregulation of PD-L1 by total splenic DCs in all liposome treated 
groups. This suggests that the delivered dose of calcitriol was biologically active and that 
DCs remain in their tolerogenic state and allowing to progress further with investigation and 
activation status and proliferation potential of CD8+ T cells in response to treatment. IGRP206-
214/D3 liposomes did not increase PD-L1 or CD86 expression on the cross-presenting CD8+ 
DCs suggesting that they remain in a steady state. Furthermore, reduction of the DC 
numbers could be indicative of the CTL-mediated killing.  
Using IGRP islet antigen specific, highly diabetogenic CD8+ T cells from transgenic mice, 
we were able to confirm that our treatment results in the transient expansion of IGRP-specific 
8.3 cells followed by a large contraction in the population size of these cells. This relates to 
previous studies that showed that self-tolerance was maintained by antigen cross-
presentation on DCs in the draining lymph nodes. Davey et al., demonstrated the initial 
activation and expansion of OVA specific CD8+ cells in response to antigen followed by the 
deletion of these cells in a process termed cross-tolerance [226]. Furthermore, the 
expression of activation and negative regulation markers such as PD-1 (CD279) and LAG-
3 (CD223) was increased in response to the delivered antigen indicating successful antigen 
recognition and possible gain of an anergic or tolerogenic phenotype. Previous reports 
suggest that deletion of pathogenic CD8+ T cells is strongly associated with their inability to 
produce IFN-γ as well as downregulation of cytolytic molecules such as Granzyme A and B 
[227]. Whilst we have not tested the latter at this stage, our IFN-γ data show that pathogenic 
effector T cells are acquiring an anergic phenotype after liposomal treatment.  
Future investigation needs to focus on the phenotypic characterisation of DCs in order to 
determine whether a tolerogenic phenotype has been acquired. It has previously been 
reported that a non-targeted approach is less effective in the case of autoimmune 
encephalomyelitis (EAE), whereas targeting nanoparticles directly to monocyte derived 
inflammatory DCs using specially formulated nanoparticles yielded much more robust 
protection [228].  
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An important issue of antigen dosing was addressed, confirming that increasing the amount 
IGRP206-214 peptide to 6µg/mouse encapsulated in the liposome resulted in a marked 
increase in cell proportion as well as IFN-γ production. Whereas the levels of IFN- γ 
production upon administration of a lower concentration of peptide (3µg/mouse) were 
maintained at the level of PBS in 8.3 cells and reduced below that of PBS in endogenous 
population. This observation was particularly important in the PcLN since there was a 
striking reduction of IFN-γ in the 3μg IGRP/D3 treated group compared to PBS and other 
treatments. It needs to be acknowledged, however, that at the time of the experiment 
removal of free, non-encapsulated peptide in the 6 μg IGRP/D3 liposomes using column 
filtration was not performed. Therefore, at this stage we are unable to conclude whether the 
observed results were an artefact of free peptide circulating systemically.  
This chapter aimed to show that therapy with liposomes encapsulating IGRP206-214 peptide 
and calcitriol resulted in successful delivery of the liposomal contents to APCs was able to 
initiate antigen-specific CD8+ T cell activation. Whilst this proof of concept was clearly 
confirmed in transferred IGRP-specific Thy1.1 8.3 cells, assessing the response in 
endogenous IGRP-specific CD8+ T cells measured by their ability to proliferate and increase 
expression of activation and anergy markers was difficult after one liposomal treatment 
possibly due to low number of Tetramer+ cells. In order to address this, enrichment using 
magnetic beads could be considered. Moreover, other approaches have recently been 
described including the use of protein kinase inhibitor (PKI) to avoid TCR internalisation or 
ant-fluorochrome antibody to minimise the loss of tetramer during repeated washing [229].   
I also confirmed that endogenous IGRP-specific population failed to proliferate or increase 
activation markers in the absence of 8.3 cells ruling out the issue of potential competition. 
However, the encouraging finding of reduced IFN-g production by the endogenous IGRP-
specific CD8+ both in the presence and absence of 8.3 led to further investigation into the 
responsiveness of the endogenous population to treatment. We hypothesised that antigen 
dosing remains to be a cornerstone of the successful treatment and rather than increasing 
the amount of antigen within one delivery, the number of treatments was increased instead. 
This together with previous data showing reduced IFN-g production further suggests 
activation and anergy of endogenous CD8+ T cells. However, this requires further 
investigation and anergy assessment needs to be performed after multiple liposomal 
treatments. Initial observations showed that our therapy delivered intravenously resulted in 
a successful antigen recognition in the spleen and PcLN, whereas subcutaneous delivery 
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resulted in an antigen-specific T cell activation in the skin draining lymph nodes. 
Furthermore, the differences in antigen-presentation and tissue environments need to be 
appreciated [230]. A recent study highlighted the importance of lymph nodes for CD8+ 
effector T cell priming, whereas the role of spleen was less crucial [231]. Interestingly, I 
concluded that subcutaneous treatment also has proven to be successful in activating 
endogenous CD8+ T cells after multiple treatments and effectively reducing IFN-g 
production.  As the subcutaneous treatment offers more superior translational potential 
compared to the intravenous delivery, its efficacy and ability to induce tolerance will be 
further investigated. 
In the upcoming chapters multiple liposomal treatments and their therapeutic effects in 
female NOD mice will be discussed. Furthermore, the change in both DCs and T cell 
populations in response to the delivered antigen and calcitriol will be analysed.  
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Treatment with IGRP-Calcitriol Liposomes Halts 
Type 1 Diabetes Development in NOD Mice  
98 
 
 Introduction 
 
Previous chapters described the effects of antigen and calcitriol containing liposomes on 
IGRP-specific CD8+ T cells, both transgenic 8.3 and endogenous. It was concluded that the 
particles deliver their content to the dendritic cells which in turn process and present it to 
CD8+ T cells. IGRP-specific CD8+ T cells proliferated in response to the delivered antigen 
and the increase in expression of both anergy and activation markers have been noted.  
Furthermore, the i.v. and s.c. administration routes were compared. The s.c. delivery proven 
to be effective in activating endogenous CD8+ T cells and reducing IFN-g production in 
spleen and inguinal lymph nodes and is more favourable from the translational point of view. 
However, whilst I have no evidence of i.v. treatment activating endogenous CD8+ cells, its 
tolerogenic potential needs to be further explored. Interestingly, IFN-g in pancreatic lymph 
nodes was reduced in IGRP206-214/D3 treated groups compared to PBS. The route of 
administration of tolerising immunotherapy is subjected to much discussion. Previous 
studies report that i.v. administration of splenocytes coupled with autoantigens (Ag-SP) 
using ethylene carbodiimide (ECDI) successfully induced antigen-specific T cell tolerance in 
the autoimmunity setting in the experimental models of EAE and MS [232-234]. 
Furthermore, safe and biodegradable poly (lactic-co-glycolic acid) (PLG) nanoparticles also 
delivered i.v. have been shown to induce antigen-specific tolerance in EAE [235]. Despite 
these promising results, several safety concerns were raised regarding the toxicity of similar 
nanoparticles administered i.v. [236, 237]. Therefore, development of safer and more 
clinically relevant approach such as s.c. administration and/or reducing the antigen dose 
would be advantageous. Recently Casey et al. used PLG antigen-loaded nanoparticle 
coupled with TGF-b to show successful antigen-specific tolerance induction after s.c. 
delivery. The treatment resulted in antigen-specific T cell activation, reduction in expression 
of MHC II, CD80 and CD86. Furthermore, IL-12, IL-6 and IFN-g secretion was suppressed 
[238]. 
Here I explore the therapeutic efficacy of liposomes delivering IGRP206-214/D3 and IGRP206-
214 only at different stages of the disease development in mouse models of type 1 diabetes. 
The aim of this chapter is to establish whether the aforementioned liposomal treatment can 
delay or prevent T1D in female NOD mice and induce robust immunological tolerance.  
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 Results 
4.2.1 Subcutaneous delivery of liposomes delays T1D onset in the NOD-SCID accelerated 
diabetes model. 
 
In order to test potency of the liposomal treatment, we conducted experiments using the 
accelerated diabetes model in NOD-SCID mice as previously described [239] . It has been 
reported that diabetes can be induced by islet antigen specific T cells such as BDC2.5, G9 
or 8.3, recognising Chromogranin A, Insulin B chain and IGRP respectively [172, 240-243]. 
Successful diabetes transfer from TCR transgenic mice, however, requires for the cells to 
be activated prior to transfer [244]. We transferred 3x106 splenocytes from diabetic NOD/Lt 
female donors into NOD-SCID female recipients using previously described method [178]. 
Rapid induction of disease following diabetic splenocytes transfer is ascribed to homeostatic 
proliferation of pathogenic effector T cells targeting various antigens. Following the transfer, 
mice were treated with liposomes containing IGRP206-214 only, IGRP206-214/D3 or PBS s.c. or 
i.v. weekly for four weeks on days 0, 7, 14 and 21. Blood glucose was measured to monitor 
diabetes progression (Figure 4-1). Analysis of peripheral blood was performed 4 days after 
each treatment to evaluate the proportion of endogenous IGRP-specific CD8+ T cells 
throughout the course of the treatment (Figure 4-2). 
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Figure 4-1. Diabetes development in NOD-SCID mice is delayed after subcutaneous, but 
not intravenous delivery of IGRP206-214/D3 liposomes. 
Diabetic splenocytes (3x106) were transferred into NOD-SCID recipients and mice received 
4 weekly treatments with IGRP206-214 only, IGRP206-214/D3 containing liposomes or PBS. 
Diabetes incidence curve in mice treated A. subcutaneously (data is combined from two 
individual experiments) and B. intravenously. ns (not significant) when p>0.05, ∗p < 
0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. IGRP206-214/D3 s.c. n=11, IGRP206-214 s.c. n=4, PBS n=10; 
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IGRP206-214/D3 i.v. n=7, IGRP206-214 i.v. n=5, PBS n=5. Data is shown as a Kaplan-Meier 
survival curve, p value: ns (not significant) when p>0.05, ∗p < 0.05, ∗∗p < 0.01,	∗∗∗p < 0.001. 
 
  
Figure 4-2. Liposomal treatment prevents expansion of endogenous IGRP-specific tetramer 
positive effector T cells in subcutaneously treated NOD-SCID mice. 
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A. Experimental design. Proportion of IGRP-specific endogenous CD8+ T cells was 
measured in the peripheral blood of NOD-SCID mice after B. s.c. and C.  i.v. delivery.  3x106 
of diabetic splenocytes were transferred into NOD-SCID recipients and mice received 4 
weekly treatments on day 0, day 7, day 14 and day 21. Blood was collected on day 12 
following two treatments, day 19 following three treatments and day 26 after the final fourth 
treatment. ns (not significant) when p>0.05, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. 
Subcutaneous treatment with IGRP206-214/D3 liposomes resulted in delay of the disease 
development compared to IGRP206-214 (ns) only or PBS (p=0.0004) treated groups. The rate 
of the disease progression in the intravenously treated animals did not vary amongst the 
treatment groups. A gradual increase in the IGRP-specific endogenous CD8+ T cell 
population was observed in PBS treated mice in both s.c. and i.v. treatments. The proportion 
of IGRP-specific CD8+ cells increased significantly after the fourth s.c. treatment with 
IGRP206-214 only liposome. In contrast, IGRP-specific CD8+ T cells remained consistently low 
following IGRP206-214/D3 treatment. Intravenous treatment failed to suppress expansion of 
IGRP-specific CD8+ cells and a steady increase in the effector population was observed 
after administration of both IGRP206-214 only and IGRP206-214/D3 liposomes. Despite low 
numbers in the treated groups, these results suggest that effects of subcutaneous treatment 
on the pathogenic T cells need to be further explored. Moreover, it is necessary for this 
approach to be tested in spontaneous disease model. 
4.2.2 Subcutaneous treatment with IGRP/D3 containing liposomes slows down diabetes 
progression in pre-diabetic NOD mice. 
Following on from the study in NOD-SCID mice, I next tested the effects of both s.c. and i.v. 
delivered liposomes in a prevention study using 8-week old pre-diabetic NOD female mice 
(Figure 4-3). Animals received 4 weekly injections on days 0, 7, 14 and 21of IGRP206-214/D3, 
IGRP206-214 only or PBS and similarly to NOD-SCID mice, blood glucose monitoring was 
performed 2-3 times a week. T1D development was delayed significantly in IGRP206-214/D3 
s.c. treated mice compared to PBS, but not to IGRP206-214 only treatment. In the i.v. delivery 
no protection was noted as all three groups developed T1D at a similar rate. This result is 
consistent with the previous finding in NOD-SCID mice. Here no blood immunomonitoring 
data is available. However, based on earlier observations in the blood of treated NOD-SCID 
mice, it can be speculated that i.v. delivery results in increase of IGRP-specific endogenous 
CD8+ T cells. 
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Figure 4-3. Diabetes progression is delayed in NOD mice treated with IGRP/D3 
subcutaneously, but not intravenously.  
A. Diabetes incidence in NOD mice after subcutaneous treatment with IGRP206-214 (n=17), 
IGRP206-214/D3 (n=31) and PBS (n=30). B. Diabetes incidence in NOD mice after 
intravenous treatment, IGRP206-214 (n=12), IGRP206-214/D3 (n=12) and PBS (n=12). 
Treatment commenced at 8 weeks (56 days) of age and mice were treated weekly for four 
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weeks. Data is shown as a Kaplan-Meier survival curve, p value: ns (not significant) when 
p>0.05, ∗p < 0.05, ∗∗p < 0.01,	∗∗∗p < 0.001. 
It is widely accepted that successful immunotherapy for T1D is associated with reduced 
levels of insulitis [245]. As CD8+ T cells that are found in pancreatic islets infiltrates, one of 
the aims of our therapeutic approach is to reduce the level of insulitis. Furthermore, previous 
reports indicated the important role of vitamin D3 in suppressing the disease development 
and reducing the level of insulitis. Intraperitoneal administration of the active form of vitamin 
D, 1,25(OH)2D3 to prediabetic NOD mice resulted in a significant insulitis reduction [119, 
246]. Furthermore, high doses of dietary D3 have been reported to prevent T1D as well as 
reduced insulitis. However, concerns over calcaemic toxicity associated with administration 
of high doses of D3 were raised [246]. In order to assess the level of insulitis following a 
four-week s.c. treatment with IGRP206-214/D3, pancreata were collected from NOD female 
mice, processed as described in methods and islets scored for the presence of lymphocyte 
infiltration. Figure 4-4 (A) below illustrates the example of the scoring method used and the 
insulitis scoring calculated as the percentage of total islets as well as mean insulitis score 
are summarised below (Figure 4-4, B,C). 
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Figure 4-4. IGRP206-214/D3 treatment results in reduced lymphocyte infiltration in pancreata 
of 13-week-old NOD female mice. 
 A. Representations of H&E staining are shown 0=no insulitis, 1=peri-islet insulitis, 
2=intermediate insulitis, 3= over 50% insulitis, 4=complete insulitis; scale bar 200µm (100 
µm in picture 4). Tissues were collected 1 week after the final treatment, formalin fixed, 
paraffin embedded, and H&E stained. B. Insulitis score. C. Mean insulitis score in IGRP206-
214/D3 and PBS treated mice. Scoring was performed blindly. Minimum of 15 islets were 
scored per mouse. (n=5). Treatment for insulitis scoring was done independently to 
incidence study. SEM is shown, statistical analysis was performed using one-way Anova,  p 
value: ns (not significant) when p>0.05, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. 
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4.2.3 Subcutaneous liposomal treatment doesn’t slow T1D development when 
administered to young NOD mice.  
 
Pancreatic b cell destruction in NOD mice is initiated around three weeks of age and prior 
to T cell infiltration the influx of macrophages, dendritic cells and neutrophils into the 
pancreas occurs [247, 248]. Several studies identified the importance of these cells in the 
disease development and provided evidence by depleting phagocytic populations which 
resulted in lack of T cell infiltration and significantly delayed diabetes onset [249, 250]. The 
presence of both CD4+ and CD8+ T cells is required for disease progression and T cell 
infiltration begins at approximately 4-6 weeks of age [251]. The frequency of pathogenic T 
cells that escaped negative selection is low in younger mice, and as these T cells continue 
to encounter antigen and become activated, expand and cause damage to pancreatic b 
cells. Previously it has been reported that proportion of IGRP-specific CD8+ T cells in female 
NOD mice increases with age and these cells acquire effector phenotype in the pancreatic 
islets [252, 253]. Furthermore, human studies confirmed that some patients with long 
standing disease have increased number of IGRP-specific cells displaying a memory 
phenotype [253, 254]. We confirmed this by measuring the proportion of IGRP-specific CD8+ 
T cells in the pancreatic lymph nodes and pancreata of female mice at the age of 8, 11 and 
16 weeks shown in Figure 4-5 below. 
 
Figure 4-5.Proportion of IGRP-specific endogenous CD8+ T cells increases with age in the 
pancreatic lymph nodes of NOD mice. 
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Baseline levels of IGRP-specific CD8+ T cells in A. Pancreatic lymph nodes. B. Pancreas. 
Mice were sacrificed at the age of 8, 11 and 16 weeks. Tetramer + IGRP-specific CD8+ T 
cells ware gated on total CD8+ T cells. SEM is shown for each group, p value: ns (not 
significant) when p>0.05; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. 
The importance of early intervention for tolerance induction in T1D is apparent. In genetically 
predisposed individuals the peak of autoantibodies development occurs early in life, around 
9-24 months of age [3]. A recent study in NOD mice suggests that generation of autoreactive 
T cells occurs early in the development and ceases after weaning [255, 256]. Based on the 
above observation we decided to treat 5-week-old female NOD 45.2 mice at the early stages 
of lymphocyte infiltration to assess whether early intervention will provide more robust 
protection from the disease. NOD CD45 congenic mice have similar diabetes incidence wild-
type NOD [257]. Animals were treated subcutaneously for four weeks as previously 
described with IGRP206-214 only, IGRP206-214/D3 and PBS (Figure 4-6). 
 
Figure 4-6. Liposomal treatment in 5-week-old NOD mice doesn’t slow the disease 
progression. 
The subcutaneous treatment with IGRP206-214 (n=10), IGRP206-214/D3 (n=9) or PBS (n=9) 
was initiated at the age of 39 days and mice were treated weekly for four weeks. Data is 
shown as a Kaplan-Meier survival curve, p value: ns (not significant) when p>0.05, ∗p < 
0.05, ∗∗p < 0.01,	∗∗∗p < 0.001. 
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All treatment groups became diabetic at a similar rate in young mice and no disease 
protection has been achieved. We speculate that longer treatment might be necessary and 
targeted antigen-specific treatment will be more beneficial in older mice with expanded 
population of IGRP-specific pathogenic CD8+ T cells. We decided to test this hypothesis 
treating mice at onset of type 1 diabetes 10-16 weeks of age. As previously discussed, these 
animals have increased levels of IGRP-specific effector CD8+ T cells in blood and peripheral 
tissues and established insulitis. 
4.2.4 Subcutaneous IGRP206-214/D3 liposomal treatment delays T1D development when 
administered to hyperglycaemic female NOD mice. 
Treatment was initiated in hyperglycaemic mice when their blood glucose reached 11mmol/L 
on two consecutive readings and if initial blood glucose was ³16 mmol/L they were deemed 
diabetic and not included in the study. Mice were randomly allocated into the treatment 
groups and received biweekly subcutaneous injections of liposomes or PBS for 4 weeks (8 
injections in total) and non-fasting blood glucose monitoring was performed on average 3-4 
times/week at the same time of the day. Animals were culled when the blood glucose 
reached 28 mmol/L on 2 consecutive readings or due to ethical reasons. Mice treated with 
IGRP206-214/D3 liposomes developed diabetes slower compared to IGRP206-214 only, PBS or 
irrelevant peptide LLO/D3 treated mice (Figure 4-7). In the IGRP206-214/D3 treated mice 
blood glucose levels decreased after the initiation of treatment with some mice maintaining 
normoglycemia for the entire duration of treatment and beyond (Figure 4-8 A).The treatment 
with IGRP206-214 only liposome resulted in the gradual increase in blood glucose levels and 
mice did not survive longer than 40 days after the initiation of treatment (Figure 4-8 B).  Both 
LLO/D3 and PBS treated groups showed rapid rise in the blood glucose levels and disease 
progression (Figure 4-8 C, D). Consistent with our previous observations in both NOD-SCID 
and prediabetic NOD mice, IGRP206-214/D3 treatment of NOD mice at hyperglycaemia 
delayed type 1 diabetes development compared to control groups. Data from blood glucose 
readings confirm that mice treated with IGRP206-214/D3 liposomes are able to maintain 
normal blood glucose levels longer than IGRP206-214 only, irrelevant peptide or PBS treated 
group. 
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Figure 4-7. Treatment with IGRP206-214/D3 liposomes at onset delays diabetes development 
in hyperglycaemic NOD mice.  
Mice were treated with IGRP206-214 /D3 (n=14), IGRP206-214 only (n=7), LLO/D3 as an 
irrelevant peptide control (n=9) or PBS (n=14). Data is shown as a Kaplan-Meier survival 
curve, p value: ns (not significant) when p>0.05, ∗p < 0.05, ∗∗p < 0.01,	∗∗∗p < 0.001. 
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Figure 4-8. Liposomal IGRP206-214/D3 treatment normalises blood glucose in 
hyperglycaemic NOD mice. 
Graphs showing blood glucose monitoring in the individual mice treated with A. IGRP206-
214/D3, n=14; B. IGRP206-214 only, n=7; C. Irrelevant peptide LLO/D3, n=9; or D. PBS, n=14; 
at diabetes onset when blood glucose reached 16 mmol/L on two consecutive readings.  
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 Discussion 
 
A significant progress has been made in identifying and describing the diabetogenic 
antigens and their immunotherapeutic potential [258]. Exploiting the antigen-specificity and 
creating a targeted immunotherapy without a need for global immunosuppression would be 
the most desirable approach for treatment and prevention of type 1 diabetes and other 
autoimmune disorders [259]. Whilst there are no successful therapies to date, some 
approaches resulted in the reduction of disease progression, improvement in b cell function 
and C-peptide levels [260, 261]. 
Our liposomal treatment was tested in an accelerated diabetes model in NOD-SCID mice 
and spontaneous NOD model and in the IGRP206-214/D3 s.c. treatment group we observed 
a consistent delay in the disease progression. The i.v. delivery did not slow the disease 
progression which may be due the fact that systemic administration of antigen may have 
enhance effector memory T cell populations. Whilst we were unable to provide evidence of 
that after 4 or 10-day i.v. treatment (Chapter 3), the longer 4-week treatment failed to delay 
the disease development in both NOD-SCID and NOD mice. The expansion of IGRP-
specific CD8+ T cells in the peripheral blood of NOD-SCID mice during the i.v., but not s.c. 
treatment supports this notion. As demonstrated by Mellanby et al., upon transfer of diabetic 
splenocytes, a proportion of Tregs retain their autoreactivity suppressing function and 
treatment with anti-CD25 antibody accelerated the disease development [262]. Tregs 
functionality can be tested using Tregs expansion in vitro methods as well as testing their 
ability to produce immunosuppressive molecules such as IL-10 and TGF-b. Whilst there is 
no evidence to suggest that liposomal treatment induced Tregs, addressing these issues 
could further explain delay in the diabetes incidence after s.c. treatment we observe in NOD-
SCID recipients. 
Some of our previous data suggested that intravenous treatment may be more effective for 
disease prevention due to limiting expansion of pathogenic effector cells and reduction in 
IFN-g production. Therefore, the delay in diabetes of subcutaneously treated, but not i.v. 
treated NOD and NOD-SCID mice was surprising when indicated otherwise. Future studies 
need to be conducted to evaluate whether liposome trafficking and IGRP-specific T cell 
targeting in NOD-SCID mice was similar to that observed in NOD mice. The uptake could 
be significantly different in NOD mice due to the abnormalities in the lymphoid organs of 
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SCID mice associated with lymphopenia [263, 264]. Furthermore, it has been previously 
reported NOD-SCID mice have significantly impaired development of myeloid and dendritic 
cells and completely lack haemolytic complement due to a mutation in the Hc gene that 
plays important role in host defence against pathogens, inflammation and homeostasis [265, 
266]. A different mechanism of tolerance such as induction of regulation needs to be 
considered in this scenario as subcutaneous injection may have resulted in the local 
regulatory processes, induction of Tregs and subsequently delay in the disease onset [267]. 
This would support a notion that intravenous delivery focused on deletion wasn’t sufficient 
to eliminate pathogenic responses due to inability to induce Tregs. However, these 
preliminary findings need to be confirmed by more detailed mechanistic studies. 
We also tested the effects of s.c. delivered liposomes in a prevention study using 8-week 
old pre-diabetic NOD mice. We observed a delay in the disease development in mice treated 
with IGRP206-214/D3 compared to untreated groups. Whilst statistically significant, the effect 
size was relatively small. We hypothesised that initiating treatment at an earlier age could 
potentially exert protective effects due to restricted TCR diversity in younger mice and very 
low levels of lymphocytic infiltration. Kern et al. in their study reduced TCR diversity using 
transgenic TCR b chain. This resulted in a lack of both insulitis and diabetes development 
in these mice. [268]. Furthermore, other reports indicate that early intervention prevents 
pathogenic cells from expansion and acquisition of a memory phenotype [269, 270]  
However, s.c. treatment of young 5-week-old mice did not delay the progression of T1D. 
The IGRP-specific CD8+ T cells increase with age; this indicate that the timing of the 
treatment is crucial. If initiated too early, the effect of the antigen may not persist, and longer 
treatment needs to be considered as the antigen-specific effector T cell population expands. 
Furthermore, whilst a certain degree of deletion and anergy has been achieved in the earlier 
stages of treatment as demonstrated by reduction in proportion of 8.3 cells, in order to induce 
a more robust protection a longer or more frequent treatment may need to be considered. 
Another plausible explanation for poor treatment outcome is the expansion of T cell 
responses to other diabetogenic antigens or clonotypes. Previous studies showed a direct 
relationship between higher avidity clones and disease progression, demonstrating that islet 
infiltration is conditioned by islet antigen specificity. This was exemplified by in a study by 
Lennon et al. where GAD expression in the islets was required for accumulation of GAD-
specific T cells [271]. Furthermore, an earlier study by Yamanouchi et al., has shown that 
inhibition of MHC class I expression using the RIP-E19 transgene resulted in impaired CD8+ 
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T cell accumulation in the islets leading to reduced level of inflammation while having no 
effect on T cell cross-priming in the pancreatic lymph nodes [272]. However, another study 
argues that inhibition of MHC class I expression on b cells has no impact on insulitis but 
delays the disease progression and highlighting the fact that during early stage of the 
disease CD8+ T do not act in a b cell-specific manner, but instead a cross-presentation of 
islet antigen on MHC class I takes place [71, 273]. Furthermore, as demonstrated by Han et 
al., avoiding deletion of non-diabetogenic low-avidity clonotypes after targeting IGRP-
specific T cells was required for tolerance induction and disease protection occurred [180]. 
Therefore, there is a possibility that our treatment could have caused deletion of protective 
low-avidity clonotypes. We hypothesise that effectiveness of IGRP-specific liposomal 
treatment would yield a more profound effect in mice that exhibit higher proportion of IGRP-
specific cells such as older mice. Our treatment at hyperglycaemia confirmed that IGRP206-
214/D3 liposomes delivered s.c. delay diabetes development compared to IGRP206-214 only. 
LLO/D3 or PBS. Interestingly the effect of this treatment was no more robust compared to 
prevention study in pre-diabetic NOD mice. This potentially is attributable to aforementioned 
expansion of other antigen specificities. This can be tested by using tetramers to identify 
other antigens. To conclude, this study provides a helpful insight into antigen specific 
immunotherapy for type 1 diabetes in the murine models and administration of multiple 
antigenic peptides or combination treatment need to be considered for wider targeting. 
 Study limitations and future directions 
The studies done in both accelerated diabetes and spontaneous diabetes models did not 
assess the impact of irrelevant peptide (LLO) with or without calcitriol on the disease 
progression. The blood immunomonitoring in NOD-SCID mice was performed on a small 
number of mice. Furthermore, no blood immunomonitoring data is available for pre-diabetic 
NOD mice. The treatment of hyperglycaemic mice required daily monitoring for blood 
glucose and treatment and therefore to limit the exposure to additional stressors no blood 
collection was performed. The following chapter will investigate the mechanisms responsible 
for the disease protection observed after s.c. liposomal treatment in NOD mice. 
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The diabetes protection in IGRP206-214/D3 treated 
NOD mice occurs due to anergy of IGRP-specific 
CD8+ T cells 
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 Introduction 
Tolerance induction in an autoimmunity setting can be challenging. Deletion or anergy of 
pathogenic T cells or induction of regulatory T cell population are broadly the mechanisms 
that have been focused upon during development of therapeutic approaches. Whilst 
undesirable, immunosuppression remains the most common strategy for combatting 
autoimmune diseases by eliminating pathogenic T or B cells, reducing production of pro-
inflammatory cytokines or inhibition of antigen presentation. Moreover, targeting adhesion 
molecules LFA-1/ICAM-1 pathway has been employed to dampen effector T cell responses, 
activation and migration  [274, 275]. These approaches carry a significant burden of affecting 
cellular and humoral immunity increasing the risk of susceptibility to infections, virus 
reactivation or cytokine storm and malignancies [182, 276]. Furthermore, whilst some 
therapies such as anti-CD20 resulted in moderate success as measured by the delay in 
decline of beta cell function, their ability to restore tolerance long-term remains questionable. 
Therefore, development of antigen-specific approaches that do not require 
immunosuppression remain the most desirable to treat autoimmune disorders such as type 
1 diabetes. This chapter will explore the potential mechanisms of tolerance responsible for 
the disease protection described in the previous chapter.  
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 Results 
 
5.2.1 IFN-g production in 8.3 cells is reduced after liposomal IGRP206-214/D3 treatment. 
 
It is widely recognised that CD8+ T cells are main mediators of pancreatic b cell destruction 
in type 1 diabetes [41]. Therefore devising a therapy that can selectively delete cytotoxic T 
lymphocytes  can be of benefit in transplantation or autoimmune diseases  [277]. In order to 
test whether our liposomal therapy acts via deleting antigen-specific CD8+ T cells, we 
transferred 104 CD90.1+ 8.3 CD8+ T cells into 8-week-old NOD female recipients, followed 
by 4 weekly treatments with IGRP206-214/D3, IGRP206-214 or PBS. The number of transferred 
cells was intentionally low to assess whether they are deleted during the course of the 
treatment or indeed can be recalled after immunisation. Upon the completion of the last 
treatment, 7 days later the mice received a recall immunisation with IGRP206-214, Poly I:C 
and IFA intraperitoneally and 5 days later were sacrificed. The effectiveness of this 
immunisation was previously validated with 8.3 cells expanding significantly in PBS treated 
mice (0.5% of 8.3 cells from total CD8+ T cells compared to 0.02% in sham immunised 
mice).The proportion (Figure 5-1 A) and number (Figure 5-2 A) of transferred 8.3 cells were 
measured using flow cytometry. The expression of the proinflammatory cytokines and 
effector molecules IFN-g, granzyme B and TNF-a were measured after IGRP206-214 peptide 
and Brefeldin A (BD GolgiPlug) re-stimulation as per previously described protocol in 
Materials and Methods (Figure 5-1 B-D; Figure 5-2 B-D). 
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Figure 5-1.Transferred 8.3 cells display reduced effector function after 4 weekly injections 
with liposomes containing IGRP206-214 /D3 and IGRP206-214. 
A. Proportion of transferred CD90.1+ 8.3 cells (gated on total CD8+ T cells), B. Granzyme 
B, C. IFN-g and D. TNF-a producing 8.3 cells in SPL, PcLN and Pancreas. 8-week-old 
female mice received 104 MACS-purified 8.3 cells and treated with liposomes or PBS s.c. 
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for 4 weeks, n=5. SEM is shown for each group, statistical analysis was performed using 
one-way Anova, p value: ns=not significant, *≤0.05, **=0.009, ***=0.001. 
 
Figure 5-2. IFN-g production by 8.3 cells is reduced in SPL after 4-week treatment with 
IGRP206-214 /D3 liposomes. 
A. Absolute counts transferred 8.3 cells, B. Granzyme B, C.  IFN-g  and D. TNF-a producing 
8.3 cells in SPL, PcLN and Pancreas. 8-week-old female mice received 104 MACS-purified 
8.3 cells and treated with liposomes or PBS s.c. for 4 weeks, n=5. SEM is shown for each 
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group, statistical analysis was performed using one-way Anova, p value: ns=not significant, 
*≤0.05, **=0.009 
 
I observed a significant reduction in the proportion of 8.3 CD8+ T cells after IGRP206-214/D3 
and IGRP206-214 only treatment in the PcLN but not in SPL or pancreas compared to PBS. 
IGRP206-214/D3 treatment also resulted in reduction of Granzyme B and TNF-a production in 
splenic 8.3 T cells and not in PcLN or pancreas. However, IFN-g production was significantly 
reduced in animals treated with IGRP206-214/D3 and IGRP206-214 only in both SPL and PcLN 
and IGRP206-214/D3 in pancreas when compared to PBS. These results indicate that whilst 
the proportion of cells remained unchanged in spleen, their effector function was reduced 
significantly as demonstrated by decreased expression of Granzyme B, IFN-g and TNF-a. 
In the PcLN, the reduction in IFN-g in both IGRP206-214/D3 and IGRP206-214 only treated 
animals correlated with the reduced proportion of 8.3 cells after these treatments compared 
to PBS, whilst pancreatic 8.3 cells only showed decreased IFN-g production after IGRP206-
214/D3 treatment. The decline in absolute numbers of IFN-g producing 8.3 cells in the SPL 
after liposomal therapy was consistent with the decrease in proportions (Figure 5-1 C). 
Interestingly, the numbers showed a reduction in Granzyme B and TNF-a production after 
IGRP206-214/D3 treatment in PcLN compared to PBS but were not reduced in the SPL. 
Furthermore, the absolute number of 8.3 cells in PcLN and IFN-g production in both PcLN 
and pancreas was not statistically significant but showed the same trends as the proportions.  
The aforementioned observations provide a further link between 8.3 and endogenous IGRP-
specific T cell responses. Previously, in Chapter 3 it was established that whilst transferred 
8.3 cells proliferated and became activated in response to a single delivery of liposomes 
containing antigen, the endogenous IGRP-specific CD8+ T cells did not. However, we 
demonstrated that whilst there was no increase in cell proliferation, activation or expression 
of anergy markers observed, the endogenous IGRP-specific CD8+ T cell population 
produced significantly less IFN-g, suggesting that liposomal treatment can induce tolerance 
through reduction in IFN-g production. This finding resonates with the above observation 
and suggests that anergy or unresponsiveness could contribute to tolerance induction after 
liposomal treatment. Taken collectively, these findings suggest that after IGRP206-214/D3 
liposomal treatment the effector functions of IGRP-specific CD8+ T cells are reduced. 
However, no significant deletion of pathogenic IGRP-specific CD8+ T cells occurred as 
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demonstrated by the lack of change in the absolute numbers. This warrants further 
investigation to address the mechanisms responsible for the disease protection at or before 
the disease onset as demonstrated in the previous chapters.  
5.2.2 Splenocytes from mice treated with IGRP/D3 liposomes fail to suppress T1D when 
co-transferred with splenocytes from diabetic animals. 
 
The important role of regulatory T cells in the context of induction and maintenance of 
peripheral tolerance has been studied extensively over the past several decades since the 
initial discovery of CD4+CD25+ T cells [278]. Depletion of this subset in mice has been shown 
to result in autoimmunity [279-281] and on the contrary, boosting Tregs had beneficial 
effects in many autoimmune settings [282]. In fact, many studies have focused on 
developing therapies targeting induction of Tregs in both humans [283] and mice (REF). 
Some approaches were successful in preventing the disease development in NOD mice by 
inducing Tregs after administration of diabetogenic antigens [284-287] or other compounds 
such as dietary plant protein gliadin [288]. Furthermore, some studies explored the 
suppressive function of regulatory T cells and their ability to delay T1D when co-transferred 
with splenocytes from diabetic animals [289]. Our laboratory has previously shown that 
liposomal treatment with BDC2.5 mimotope/D3 significantly delays T1D when treated at 
onset. This delay is attributed to induction of ICOS and IL-10 producing antigen-specific 
Tregs (Bergot, et al., unpublished data). Furthermore, an important role of vitD3 in the 
maintenance of immune tolerance and induction of Tregs has been discussed previously 
[99]. Therefore, there is a possibility that D3 only liposomes may induce regulatory 
population and needs to be further investigated. Thymic-derived CD4+CD25+Foxp3+ 
regulatory populations are well studied and characterised for their immunoregulatory 
properties [290]. However, recently a CD8+ suppressor population is beginning to come to 
light [291].We were interested to test whether IGRP206-214/D3 treatment would induce any 
regulatory populations that were capable of dominant suppression of diabetogenic T cells.  
The following experiment was conducted to test whether our liposomal treatment induces a 
regulatory population with dominant suppressive ability. NOD mice (8 wo) donors were 
treated with IGRP206-214/D3, BDC2.5 mimotope/D3 liposomes or PBS once weekly for two 
weeks. Previous reports indicate that transfer of splenocytes from prediabetic animals 
results in slower disease development comparing to splenocytes from diabetic donors [239]. 
In order to assess whether the splenocytes from PBS treated mice would offer protection, 
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one group received splenocytes from PBS treated mice and an additional control group 
received only splenocytes from diabetic female NOD mice. Spleens were harvested and 
mixed with diabetic splenocytes at 1:2 ratio (5x106 of donor splenocytes and 107` of diabetic 
splenocytes) and injected into NOD-SCID mice. The blood glucose was measured daily to 
monitor disease progression. Figure 5-3 below shows diabetes survival curves in NOD-
SCID mice after reconstitution with splenocytes from treated and diabetic donors. 
  
Figure 5-3. Splenocytes from mice treated subcutaneously with BDC2.5/D3, but not 
IGRP206-214/D3 and PBS suppress the effector function of diabetic splenocytes when co-
transferred into NOD-SCID mice.  
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A. Experimental design. B. Kaplan-Meier survival analysis for animals treated with 107 
diabetic splenocytes only (red), n=5; 107 diabetic splenocytes and 5x106 BDC2.5mim/D3 
(green), n=5; 107 diabetic splenocytes and 5x106 IGRP206-214/D3 (blue), n=5; 107 diabetic 
splenocytes and 5x106 PBS (black), n=5. Data was analysed using log-rank Mantel Cox 
test, p value: ns=not significant, *≤0.05, **=0.009. D=diabetic splenocytes, iD3=IGRP206-
214/D3. 
 
In line with the previous observations in our laboratory, where robust protection from the 
disease and generation of Tregs occurred (Bergot, et al., unpublished data), this new data 
showed that splenocytes from mice treated with BDC2.5/D3 liposomes suppress the effector 
responses of transferred diabetic splenocytes. In contrast, while co-transfer of IGRP206-
214/D3 treated splenocytes and diabetic splenocytes delayed the disease development 
slightly compared to the group that received diabetic splenocytes only, the treatment failed 
to delay the disease incidence compared to PBS treated mice. Our data suggests that 
BDC2.5/D3 treatment suppresses the effector functions of splenocytes from diabetic mice 
and the induction of regulatory mechanisms is responsible for tolerance induction in this 
setting. Furthermore, based on the above observations it can be confirmed that IGRP206-
214/D3 treatment doesn’t induce regulation. 
5.2.3 IGRP206-214/D3 treatment results in reduction of CD8+ cross-presenting DCs and 
expression of co-stimulatory molecules. 
A combination antigen-specific immunotherapy which acts on antigen-specific T cells as well 
as uses immunomodulatory compounds to maintain tolerogenic status of DCs would be the 
most advantageous approach in treating or preventing autoimmunity. In our study, we aim 
to investigate the mechanisms responsible for induction of tolerance through potential 
anergy in in the IGRP-specific CD8+ T cells. Furthermore,  encapsulation of calcitriol within 
the liposomes aims to maintain DCs in a tolerogenic, immature state [292]. In order to assess 
the phenotype of DCs following the 4 week treatment regimen, we treated 8 week old female 
NOD mice s.c. with IGRP206-214/D3 liposomes or PBS and one week after the final treatment, 
the proportion (Figure 5-4 A) and expression of co-stimulatory molecules such as CD40, 
CD86 and co-inhibitory molecule PD-L1 (Figure 5-4 B-D) in spleen, pancreatic and inguinal 
lymph nodes were measured on DCs using flow cytometry. DC populations were identified 
based on MHC class II and CD11c expression and the following populations identified: 
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CD11c+CD8+ DCs, CD11c+CD11b+ DCs as well as CD11c-CD11b+. The absolute count 
(Figure 5-5 A-D) were assessed using Flow-Count Fluorospheres (Beckman Coulter).  
 
 
Figure 5-4. IGRP206-214 teatment leads to a decrease in proportion of DCs and reduced 
expression of CD40, CD86 and PD-L1 co-stimulatory molecules. 
A. Proportion of total CD11c+DCs, CD8+ DCs, CD11c+CD11b+ DCs and expression of B. 
CD40 C. CD86 and D. PD-L1 in and CD11b+ DCs in spleen, pancreatic and inguinal lymph 
nodes. Mice were treated with IGRP206-214/D3 or PBS for 4 weeks s.c. and sacrificed 7 days 
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after a final treatment; n=5. Standard error of the mean is shown for each group; statistical 
analysis was performed using one-way Anova; p value: ns=not significant, *≤0.05, **=0.009, 
***=0.001, ****<0.0001. 
 
 
 
Figure 5-5. IGRP206-214 teatment leads to decrease in absolute numbers of DCs and reduced 
expression of CD40, CD86 and PD-L1 co-stimulatory molecules.  
A. Absolute numbers of total CD11c+DCs, CD8+ DCs, CD11c+CD11b+ DCs  and 
expression of B. CD40, C. CD86 and D. PD-L1 in spleen, pancreatic and inguinal lymph 
nodes. Mice were treated with IGRP206-214/D3 or PBS for 4 weeks and sacrificed 7 days after 
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a final treatment; n=5. SEM is shown for each group, statistical analysis was performed 
using one-way Anova, p value: ns=not significant, *≤0.05, **=0.009, ***=0.001, ****<0.0001. 
 
Both the proportion and absolute numbers of analysed dendritic cell populations revealed a 
reduction of total splenic conventional DCs and decreased expression of CD40, CD86 and 
PD-L1 (absolute numbers only). Several studies described the role of vitamin D3 in the 
induction of DCs with a tolerogenic phenotype and reduction in expression of maturation 
markers such as CD40, CD80, CD86 and IL-12 as well as increase in production of IL-10. 
Whilst we have not tested IL-10 and IL-12 production on DCs, our data shows decreased 
expression of activation markers which is consistent with acquisition of a tolerogenic 
phenotype. The liposomal treatment had the most profound effect on CD8+ DCs resulting in 
significant reduction in proportion and numbers of this population in all analysed tissues as 
well as decreased expression of CD40 and CD86 in SPL and ILN, but not in PcLN and 
decreased PD-L1 expression in SPL but not in PcLN or ILN. The reduced expression of PD-
L 1 is a somewhat surprising finding as we would expect it to increase together with 
decreased expression of co-stimulatory molecules as part of tolerogenic DCs phenotype. It 
has been previously noted that type 1 diabetic patients have low levels of PD-L1 whereas 
overexpression led to T1D protection and Treg induction and inhibition of antigen-specific 
effector T cell responses [293, 294]. Based on the observations of DCs reduction in both 
proportions and absolute numbers, we can speculate that whilst calcitriol is playing a role in 
the maintenance of tolerogenic phenotype, there is a potential CD8+ T cell mediated killing 
of CD8+ DCs particularly is impacting their antigen presentation ability. 
5.2.4 IGRP-specific CD8+ T cells exhibit equal lytic activity in both treated and control 
groups. 
In order to examine the cytolytic capacity of IGRP-specific CD8+ T cells after a 4 week 
treatment with IGRP206-214/D3 or PBS, we performed a cytotoxicity assay using target cells 
from 7 week old NOD mice pulsed with IGRP206-214 peptide labelled with 5µM/L of CTV 
(CTVHIGH) mixed with non-pulsed cells labelled with 0.5 µM/L of CTV (CTVLOW) at 1:1 ratio 
and injected i.v. into the 12 week old liposome treated recipients. After 15 hours, animals 
were sacrificed and spleens, pancreatic and inguinal lymph nodes collected for flow 
cytometric analysis. The level of lytic activity is determined as the ratio between the target 
and control population decreases (Figure 5-6). It is of note, that one of the PBS treated mice 
became diabetic prior to receiving target splenocytes (indicated in red, Figure 5-6). There 
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was no difference observed in the lytic activity of lymphocytes from the diabetic animal 
compared to non-diabetic mice. Furthermore, based on the observation by Recino et al., 
hyperglycaemia has no effect on cytolytic killing or IFN-g production in vivo [295].  
 
 
Figure 5-6. IGRP-specific killing occurs equally in PBS and IGRP206-214/D3 treated mice 
in PLN, ILN and PcLN. 
Donor splenocytes from 7 week old NOD female mice were used as targets, 2x106 of cells 
were pulsed with IGRP206-214 peptide (1µg/ml) and labelled with CTV (5µMol/L). Control cells 
(2x106) were labelled with CTV (0.5µMol/L), mixed with targets in 1:1 ratio and injected i.v 
into tail vein of 12 week old NOD recipients previously treated with IGRP206-214/D3 or PBS. 
After 24 hours, spleens, pancreatic and inguinal lymph nodes were removed and analysed 
using flow cytometry. n=5. 
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I found that IGRP206-214/D3 treatment did not decrease the CD8+ T cells’ lytic ability. 
Interestingly, two out five animals treated with PBS show very low ability to kill IGRP206-214 
loaded targets, whilst the remaining mice including the diabetic one, have higher CTL killing. 
It has been previously shown that increase in islet-associated pathogenic T cells is directly 
linked to an increase of NOD mouse age and there is a high degree of variability of CTL 
activity. Furthermore, the killing mechanisms used may differ depending on animal’s age 
and the avidity of interaction between TCR, MHC and peptide [296]. In summary, these data 
suggest that CD8+ T cells in IGRP206-214/D3 treated mice retain their killing activity. However, 
further testing is required with possible reduction of killing time or altering concentration of 
peptide on target splenocytes.  
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 Discussion 
 
The aim of this chapter was to identify the mechanisms responsible for tolerance induction 
after IGRP206-214/D3 treatment. As demonstrated in Chapter 3, the treatment exerted disease 
protection in both prediabetic animals and animals treated at the onset of hyperglycaemia. 
Despite the effect size being small, we wanted to further understand the impact of our 
treatment on IGRP-specific CD8+ T cells. Particularly because we were unable to provide 
clear evidence of proliferation and activation of endogenous IGRP-specific CD8+ T cells in 
response to the delivered antigen after a single treatment. We did, however, see an increase 
in proliferation and expression of activation markers after two weekly treatments indicating 
a possible need for antigen persistence to initiate a clear response by the endogenous CD8+ 
T cells population.  
Peripheral deletion is a major mechanism of immune regulation [297, 298] and is responsible 
for elimination of pathogenic self-reactive lymphocytes that escaped thymic deletion. Whilst 
clonal deletion is the main mechanism in the thymus, clonal selection also takes place in the 
periphery [299] as evidenced by administration of soluble antigenic peptide into TCR-
transgenic mice in deletion of reactive clones [300, 301]. Furthermore, peripheral deletion 
can occur through a number of death receptors such as CD95 (Fas)/CD178 (FasL) 
interactions. Fas expression on wild-type OT-I CD8+ T lymphocytes cells has been shown 
to play an important role in their deletion [301-303]. A number of studies documented 
involvement of apoptotic splenocytes in prevention of autoimmunity [304, 305] or 
transplantation disorders [306] and detrimental effects of dysfunctional apoptotic machinery 
on the development of autoimmunity. It is well documented that in type 1 diabetes and other 
autoimmune conditions apoptotic clearance is defective [297, 307]. Furthermore, apoptotic 
lymphocytes serve as a source of antigen and can be successfully efferocytosed by APCs. 
This process (efferocytosis) doesn’t induce maturation of DCs and can be considered 
tolerogenic [166, 245, 297, 308]. 
Dendritic cells and their involvement in immune regulation has been of a huge interest in the 
last half a century. It is now greatly appreciated that DCs not only interact with naïve T cells 
but also have strong involvement in the effector phase of the immune response. The 
manipulation of dendritic cells in a wide range of therapies remains a much-researched area 
in both cancer and autoimmunity settings. The approaches such as preventing DCs 
129 
 
maturation or specific targeting of tolerogenic DCs have been explored in autoimmune 
disorders such as rheumatoid arthritis, lupus erythematosus and type 1 diabetes. 
Upon successful antigen uptake, DCs interact with CD4+ T cells in tissues resulting in 
activation of immune responses and increased production of cytokines [309]. Furthermore, 
DCs can activate CD8+ effector T cells. As apoptotic cells or infectious viruses are taken up 
by immature DC, cross-presentation of antigen via MHC class I can occur. It is noteworthy, 
however, that only CD8+ DCs possess cross-presentation ability  [91, 188, 310]. The concept 
of particular importance in relation to our study is that DCs capturing an antigen may become 
targeted by effector CD8+ T cells. Several studies have described the elimination of DCs 
pulsed with MHC class I peptides by CTL-dependent mechanism [311-313]. The idea of 
DCs killing needs to be further explored when continuous antigen presentation can be 
detrimental and further activation of CD8+ T cells needs to be prevented.  
In the current study, we designed several experiments to test the main mechanisms of 
tolerance such as deletion, regulation and anergy. Firstly, we demonstrated that after 
transfer of a small number of 8.3 cells and 4 weekly treatment with liposomes, the proportion 
of cells was decreased in the treated mice in PcLN only, but not in spleen or pancreas after 
recall. Whilst there is not enough evidence to support the fact that treatment resulted in 
deletion of pathogenic IGRP-specific effector T cells, a reduction in granzyme B and IFNg 
suggests that these cells exhibit an anergic phenotype. This observation is consistent with 
our previous finding where we saw a reduction in IFN-g production by the endogenous IGRP-
specific CD8+ T cells. Production of proinflammatory cytokines is one of the major 
mechanisms used by CTL apart from Fas and perforin pathways. Cytokines such as IFN-g, 
IL-1 and TNF-a have been implicated in the T1D progression [314, 315] by having effect on 
b cells through Fas upregulation [315], increased expression of MHC class I [316] 
chemokines [317] as well as induction of cytotoxicity [318-320]. One of the main 
mechanisms of killing used by CTL and natural killer cells occurs upon entry of Granzyme 
B and perforin into the target cell and the apoptosis is initiated [321]. One of the limitations 
of this study was assumption that all transferred 8.3 cells would become activate din 
response to either liposome delivered or endogenous antigen. However, the possibility that 
the longer period was required for the full deletion to be observed still exists. 
The ability of treated splenocytes to suppress the effector function of co-transferred diabetic 
splenocytes was tested in the NOD-SCID recipients. Whilst CD4+Tregs continue to be a 
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well-studied area, several studies focused on characterising CD8+ regulatory populations. 
Their role in immunological tolerance and prevention of autoimmunity [322] by supressing T 
cell help to B cells [323] or targeting effector CD4+ T cells in experimental allergic 
encephalomyelitis (EAE) model [324] has been discussed. Furthermore, there is no 
evidence to date showing that vitD3 plays role in the induction of CD8+ Tregs. We confirmed 
that only splenocytes treated with BDC2.5/D3 liposomes possessed a regulatory ability and 
successfully suppressed pathogenic T cells from diabetic splenocytes. IGRP206-214/D3 
treatment did not induce a regulatory population. This further confirms a requirement for 
CD4 epitope for induction of regulation. However, if induction of polyclonal [325] rather than 
antigen-specific Tregs [326] occurs, it may not be sufficient for disease protection. 
We observed a significant reduction of total splenic DCs and reduced expression of co-
stimulatory molecules such as CD40 and CD86. The expression PD-L1 was also down-
regulated on total splenic DCs population, PD-L1 is a ligand of PD-1 and an important 
regulatory molecule. Downregulation of PD-L1 may be associated with excessive activation 
of immune cells whilst increase in PD-L1 expression is linked to negative immune regulation 
and inhibition of T cell activation [210, 211, 327]. Furthermore, a reduction in cross-
presenting CD8+ DCs was observed in spleen, pancreatic and inguinal lymph nodes with 
similar reduction in co-stimulatory molecules as in total splenic DCs. Due to low proportion 
of DCs, the absolute numbers provide a clearer picture and also confirm the aforementioned 
observations.  
After a preliminary in vivo CTL assay was performed, we established that the killing rate was 
similar in both liposome treated and PBS control groups. This suggests that after a 4-week 
treatment IGRP-specific CD8 T cells retain their cytolytic ability and supports the fact that 
cross-presenting CD8+ DCs may be eliminated by effector CD8+ T cells. It is also noteworthy 
that this experiment requires repeating. 
In summary, our data suggests that IGRP/D3 liposomal treatment on the one hand 
anergises IGRP-specific CD8+ T cells resulting in the reduction of pro-inflammatory 
cytokines’ production, on the other it has a deleterious effect on both total DCs population 
as well as cross-presenting subset of DCs, impairing their ability for further antigen 
presentation and therefore proliferation of pathogenic IGRP-specific CD8+ T cells. Further 
mechanistic studies need to be performed in order to substantiate these claims. One of the 
limitations of this study is that we did not further investigate the mechanisms of potential DC 
killing such as perforin or Fas/FasL pathways. Furthermore, DCs phenotyping experiments 
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need to be repeated both after a 4-week treatment and after a shorter period of treatment to 
assess the phenotypic changes at the early stages of treatment. 
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The Effects of Targeting Multiple Islet Epitopes 
on Tolerance Induction in NOD Mice. 
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 Introduction 
 
Pathogenic CD4+ T cells play an important role in T1D development. They provide help for 
activation and proliferation of cytotoxic CD8+ T cells [328]. Chromogranin A is major antigen 
for diabetogenic CD4+ T cells clones in NOD mice [40] and humans [43]. One of the most 
extensively studied islet-specific clones is BDC2.5, a highly diabetogenic CD4+ T cell clone 
isolated from the lymph nodes and spleens of NOD mice [72, 174, 329]. The BDC2.5 clone 
was later determined to be specific for a chromogranin A derived epitope and MHC-II 
tetramers can be used to identify endogenous BDC2.5-like cells in vivo in NOD mice [40, 
330]. Similarly to IGRP-specific 8.3 cells, BDC2.5 CD4+ T cells from BDC2.5 transgenic mice 
are highly diabetogenic and if transferred into NOD.SCID recipients cause rapid disease 
progression [331].  
Recently our lab identified that intravenous treatment with liposomes containing a high-
affinity BDC2.5 mimotope (BDC2.5mim) peptide and D3 at the onset of hyperglycaemia 
significantly delays disease development compared to PBS treated animals (Bergot et al., 
unpublished data). This protection is attributed to an increase in antigen-specific regulatory 
Foxp3+ CD4+ T cells and Foxp3- Tr1 cells. The expansion of a regulatory population is 
responsible for tolerance induction and prevents the effector T cells attack (Bergot et al., 
unpublished data). Based on these findings, I decided to test whether combining IGRP206-
214/D3 and BDC2.5mim/D3liposomes in equal proportions would allow not only for 
inactivation of IGRP-specific CD8+ T cells but also induction of ChgA-specific Tregs ensuring 
more robust tolerance induction and subsequently greater protection from the disease. This 
chapter will investigate whether the delivery of both peptides will provide enhanced disease 
protection compared to a single antigen treatment.  
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 Results 
 
6.2.1 Treatment with mixed liposomes does not impact proliferation of IGRP-specific CD8+ 
T cells and their IFN-g and GzmB production. 
 
The efficacy of IGRP206-214/D3 and BDC2.5mim/D3liposomes mixed at equal proportions 
(referred to as 50:50 hereafter) was tested in 8-week-old female NOD mice. The animals 
received two weekly subcutaneous treatments with 100µL of IGRP206-214 /D3, 
BDC2.5mim/D3, 50:50 (mixture of 50µL of each individual liposome) or PBS. Three days 
after the second treatment, animals were sacrificed and spleen, pancreatic lymph nodes 
and pancreas collected. In this experiment I assessed proportion and absolute numbers of 
ChgA-specific CD4+ cells (Figure 6-2 A, C) and their IFN-g production (Figure 6-1 B, D). 
Furthermore, IGRP-specific CD8+ cells (Figure 6-2, B) as well as IFN-g and Granzyme B 
expression (Figure 6-2, C-D) and absolute numbers (Figure 6-2, F-H) were analysed using 
flow cytometry after PMA/Ionomycin stimulation. Of note, tetramer staining was performed 
prior to PMA/Ionomycin stimulation, there is still a possibility of staining becoming 
compromised due to internalisation of TCR. 
There was an equivalent, significant increase in both the proportion and absolute numbers 
of ChgA-specific CD4+ T cells in BDC2.5mim/D3 and 50:50 treated animals compared to 
PBS and IGRP206-214/D3 treated mice in the spleen and a slight increase in these groups in 
the PcLN, though the latter failed to reach statistical significance. The proportion of IFN-g 
production by the ChgA-specific CD4+ T cells remained unchanged in all treatments and 
tissues. The increase in absolute count of IFN-g producing ChgA-specific CD4+ T cells 
reflects the initial increase in both numbers and proportion of this population following 
ChgA/D3 and 50:50 liposomal treatment. The aim of this experiment was to assess the 
antigen-specific CD8+ and CD4+T cells and their ability to produce pro-inflammatory 
cytokines. The equivalent expansion of ChgA-specific T cells by BDC2.5mim/D3 and 50:50 
argues that the effect of the difference in delivered dose is negligible. The limiting factor of 
this experiment is that no data for Treg markers is available on this occasion. However, 
based on the aforementioned observations in our lab relating to the increased production of 
Tregs after BDC2.5mim/D3 treatment, the next logical step was to test the potency of the 
50:50 treatment in the diabetes incidence study. At this stage the effect of BDC2.5mim/D3 
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liposomes on IGRP-specific CD8+ T cells remains unclear, though the generation of 
BDC2.5mim-specific Tregs associated with BDC2.5mim/D3 treatment (Bergot, et al., 
unpublished data) may lead to bystander suppression of IGRP-specific cells explaining this 
decrease in absolute numbers. 
 
Figure 6-1. Subcutaneous treatment with mixed liposomes has the same effect on the 
ChgA-specific CD4+T cells as the BDC2.5mim/D3treatment alone.  
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A. Proportion of ChgA-specific CD4+ T cells. B. Proportion of IFN-g producing ChgA-specific 
CD4+ T cells C. Absolute numbers of ChgA-specific CD4+ T cells. D. Absolute numbers of 
IFN-g producing ChgA-specific CD4+ T cells in SPL, PcLN and Pancreas after 2 weekly 
treatments with IGRP206-214/D3, BDC2.5/D3, 50:50 or PBS. n=4, Standard error of the 
mean is shown for each group; statistical analysis was performed using one-way Anova; p 
value: ns=not significant, *≤0.05, **=0.009, ***=0.001, ****<0.0001. 
The proportion of IGRP-specific CD8+ T cells was not significantly different between any of 
the treatment groups, despite a trend towards an increase in the 50:50 treated group in the 
PcLN and BDC2.5mim/D3 treated group in the pancreas (Figure 6-2, B).Similarly, the 
absolute numbers of IGRP-specific cells in the liposome treated groups also did not increase 
compared to PBS (Figure 6-2, E). Whilst the sample size is small, and experiment needs to 
be repeated, these data suggests that IGRP206-214/D3 treatment may inhibit the accumulation 
of IGRP-specific effector T cells as further evidenced by the absolute numbers in PcLN 
where both IGRP206-214/D3 and BDC2.5mim/D3 treatment resulted in a reduction of IGRP-
specific CD8+ T cells. Moreover, in line with my earlier observations that IGRP206-214/D3 
treatment suppressed IFN-g production discussed in Chapter 4, IFN-g production (Figure 
6-2, C) by endogenous IGRP-specific CD8+ was reduced in the pancreas of the IGRP206-
214/D3 treated group compared to PBS but did not change relative to PBS in the spleen or 
PcLN. However, IFN-g was increased significantly in the spleen of BDC2.5mim/D3 treated 
animals compared to IGRP206-214/D3, 50:50 and PBS treatment, highlighting the differences 
in the mechanisms by which these treatments provide protection and reinforcing the idea 
that IGRP206-214/D3 treatment induces anergy of effector CD8+ T cells. Treatment with 50:50 
liposomes did not suppress IFN-g production which could be explained by a reduced amount 
of antigen. Alternatively, combining the antigens may interfere with tolerance induction. Both 
the proportion and absolute numbers of GzmB producing endogenous IGRP-specific CD8+ 
T cells ( Figure 6-2, D, G) remained at levels similar to PBS across all treatments and all 
analysed tissues. It is noteworthy, that animals were 10 weeks old and production of GzmB 
as a result of activation of effector CTL may be delayed. Furthermore, it has been previously 
reported that GzmB does not have a direct involvement in b cell destruction or Treg 
suppressive function [332, 333], therefore we need to further evaluate the role of GzmB in 
liposome treated mice. 
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Figure 6-2. Subcutaneous treatment with mixed liposomes doesn’t result in further reduction 
in IFN-g or GzmB production by IGRP-specific CD8+ T cells compared to IGRP206-214/D3 
treatment. 
A.  Experimental design. Proportion of B. IGRP-specific CD8+ T cells. C. IFN-g producing 
IGRP-specific CD8+ T cells D. Granzyme B producing IGRP-specific CD8+ T cells. And 
absolute numbers of E. IGRP-specific CD8+ T cells.  F. IFN-g producing IGRP-specific CD8+ 
T cells. G. Granzyme B producing IGRP-specific CD8+ T cells in SPL, PcLN and Pancreas 
after 2 weekly treatments with IGRP206-214/D3, BDC2.5/D3, 50:50 or PBS. n=4; SEM is 
shown for each group; statistical analysis was performed using one-way Anova; p value: 
p>0.05 is ns=not significant, *≤0.05, **=0.009. 
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6.2.2 Co-delivery of BDC2.5mim/D3and IGRP206-214/D3 liposomes at the onset of T1D does 
not improve the disease outcome compared to IGRP206-214/D3 treatment. 
 
Previously, in Chapter 4 it was described that subcutaneous treatment with IGRP206-214/D3 
at hyperglycaemia significantly delays disease progression compared to control groups, 
similar to BDC2.5mim/D3 treatment (Bergot, et. al, unpublished data). Here we tested the 
effect of the 50:50 combination treatment at the onset of hyperglycaemia. The blood glucose 
in female NOD mice was monitored continuously from the age of 10 weeks and once it 
reached ≥11mol/L on two consecutive readings the treatment was initiated. The animals 
were randomly allocated into treatment groups receiving 100 µL of liposomes containing 
either irrelevant control MHC class II hen egg lysozyme (HEL) peptide and calcitriol 
(HEL/D3) or a mixture of 50 µL IGRP206-214/D3 and 50 µL BDC2.5mim/D3 (referred to as 
50:50 below) or PBS (Figure 6-3). Blood glucose for disease monitoring was measured 
daily. A slight delay in the disease development in mice treated with 50:50 liposomes 
compared to PBS treatment was observed. However, the disease delay from the 50/50 
treatment was not greater than that of IGRP206-214/D3 treatment alone seen in the previous 
experiment described in Chapter 4. It is noteworthy that protective effect of BDC2.5mim/D3 
treatment alone at onset appeared larger than that of 50:50 treatment shown here 
(unpublished data) However, the treatments were not compared in the same experiment 
therefore presenting a major study limitation. In conclusion, whilst the treatment with 50:50 
liposomes does not accelerate the disease; its effects provide no further benefits compared 
to a single peptide liposomal treatment. 
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Figure 6-3. Subcutaneous delivery of IGRP206-214/D3 and BDC2.5mim/D3liposomes 
mixed at 1:1 ratio at onset of hyperglycaemia delays the disease development compared to 
PBS treated mice. 
Mice were treated with a mix of IGRP206-214/D3 (50µL) and BDC2.5mim/D3(50µL), n=10 
(pink); HEL/D3 (irrelevant MHC class II control peptide), n=12 (orange); or PBS, n=14 
(black), twice a week for four weeks following onset of hyperglycaemia. Grey area 
represents the duration of treatment. p value: p>0.05 is ns=not significant, *≤0.05. Data 
shown as Kaplan-Meier survival curve and analysed using log-rank Mantel Cox test. 
Treatment at onset presents several challenges, particularly intensive monitoring for an 
increase in blood glucose and initiating the treatment at an appropriate time which needs to 
be after the onset of hyperglycaemia but prior to established disease. I have previously 
discussed an increase in islet-specific T cells as NOD mice age. This increase relates to 
both CD4+ and CD8+ antigen-specific pathogenic T cells, however their response to therapy 
can be vastly different. Whilst CD4+-focused therapy induces regulatory T cell population 
and can be associated with the Treg -mediated suppression, therapy targeting CD8+ T cells 
relies on deletion of pathogenic T cells and/or induction of anergy. I have previously reported 
that subcutaneous IGRP206-214/D3 treatment delays disease development when 
administered to pre-diabetic NOD mice. Therefore, the 50:50 liposome therapy would need 
to be evaluated for its preventative potential and assessed whether generation of Tregs and 
elimination of pathogenic antigen-specific CD8+ T cells in pre-diabetic animals can be 
achieved and is sufficient to delay the T1D progression.  
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6.2.3 Subcutaneous treatment of pre-diabetic NOD mice with a mixture of 
BDC2.5mim/D3and IGRP206-214/D3 liposomes does not delay T1D development 
 
Following on from the previous study in hyperglycaemic mice, a prevention study in the pre-
diabetic 8-week-old NOD mice was conducted. Female mice were treated subcutaneously 
weekly for four weeks with PBS, a 50:50 mix of IGRP206-214/D3 and BDC2.5mim/D3 and 
HEL/D3 (Figure 6-4). Blood glucose was measured biweekly and measurements became 
more frequent as animals aged. There was no significant delay in T1D progression in 50:50 
treated mice compared to the control groups. One possible explanation for this is insufficient 
antigen dose throughout the treatment to allow the induction of Tregs and induction of 
anergy in pathogenic CD8+ T cells. Further investigation is required to assess whether a 
dose of antigen within the liposome, a number of injections delivered or potentially both of 
those variables need to be increased in order to achieve robust tolerance. 
 
Figure 6-4. Subcutaneous treatment of pre-diabetic mice with a mix of BDC2.5mim/D3 and 
IGRP/D3 liposomes doesn’t delay diabetes progression. 
Mice were treated weekly for four weeks with PBS (black), HEL/D3 (irrelevant MHC class II 
control peptide) (orange) and 50:50 made by mixing BDC2.5mim/D3 and IGRP/D3 at 1:1 
ratio (pink); n=20. p value: p>0.05 is ns=not significant, *≤0.05 Data shown as Kaplan-Meier 
survival curve and analysed using log-rank Mantel Cox test. 
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An important issue that needs to be addressed from these experiments described here is 
antigen dose. Previous experiments where a single liposome was used, the 100µL of 
liposomes was administered delivering 40ng of calcitriol and 3µg of peptide. However, after 
mixing the IGRP206-214/D3 and BDC2.5mim/D3 liposomes at 1:1 ratio, as 100uL of the mixed 
liposomes was delivered, the amount of delivered antigen was halved while the amount of 
calcitriol remained the same. Although the expansion of ChgA-specific cells was equivalent 
with BDC2.5mim/D3 and 50:50 liposome delivery, it is possible that the reduced dose of 
antigen was insufficient to trigger an equivalent tolerance induction in both IGRP-specific 
CD8+ as well as ChgA-specific CD4+ T cell populations as the control single antigen 
liposome treatments. This could explain the lack of disease prevention in the liposome 
treated groups compared to PBS. Therefore, to further test whether the lack of protection is 
indeed related to the antigen dose we engineered liposomes encapsulating 3µg of both 
IGRP206-214 and BDC2.5 peptides (6µg total) as well as 40ng of calcitriol (referred to as 
Dual/D3 hereafter). The concentration of peptides was confirmed to be 6µg per 100µL total 
using HPLC (not shown).  
 
6.2.4 Dual/D3 liposome treatment expands ChgA-specific T cells similar to BDC2.5mim/D3 
treatment but doesn’t induce ChgA-specific Tregs. 
 
The following experiment was designed to address aforementioned issue of reduced antigen 
dose within the 50:50 liposomes. Here, I compare the effects of two weekly s.c. treatments 
with IGRP206-214/D3, BDC2.5/D3, Dual/D3 liposomes and PBS in spleen, inguinal and 
pancreatic lymph nodes in order to establish whether simultaneous delivery of two 
diabetogenic peptides will induce an equivalent tolerogenic phenotype as single epitope. I 
hypothesised that in addition to anergy and reduced IFN-g production in IGRP-specific CD8+ 
T cells, an induction of Chg-A-specific Tregs can be achieved. Female NOD mice aged 8 
weeks were treated at day 0 and day 7 and sacrificed on day 10 (Figure 6-5, A). Ag-specific 
T cells were identified using Tetramers and staining for Treg and activation markers was 
performed and analysed using flow cytometry. 
Since the identification of an antigen-specific memory regulatory CD4+Foxp3+ T cells, there 
has been a growing interest in this population, particularly in the field of vaccine development 
[334]. As Bergot et al. described an increase in ChgA-specific Tregs following 
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BDC2.5mim/D3 liposome treatment (unpublished data), I wanted to investigate whether dual 
liposomes successfully induce an antigen-specific Treg population similarly to 
BDC2.5mim/D3 alone and whether they share the phenotypic characteristics of Tregs 
observed after BDC2.5mim/D3 treatment. The proportion and absolute numbers of ChgA-
specific CD4+ T cells and their Foxp3 expression was measured along with their expression 
of PD-1, CD44, CD39, CD73 and ICOS. (Figure 6-5 A-I). Surprisingly, Foxp3+ ChgA-specific 
CD4+ population did not expand after BDC2.5mim/D3 treatment as previously seen by 
Bergot et al. (unpublished data). The expression of PD-1 and co-expression of CD73 and 
CD39 also remained unchanged on the Foxp3+ population across all treatments, whereas 
CD44 was elevated in all tissues only reaching statistical significance in the spleen in all 
three liposome treated groups compared to PBS.  
Another molecule that was found to be indispensable for antigen-specific regulatory T cell 
survival and activation is the co-receptor CD28, inducible co-stimulatory molecule (ICOS) 
[335, 336]. A study conducted in BDC2.5 transgenic mice showed that Tregs found in 
pancreatic tissue express significantly higher levels of ICOS and IL-10 compared to lymph 
nodes and blocking ICOS results in rapid development of diabetes [337]. ICOS expression 
was significantly increased on the antigen-specific Foxp3+ population, particularly in the 
PcLN of BDC2.5mim/D3 and Dual/D3 treated groups compared to the IGRP206-214/D3 and 
PBS treatments. Interestingly, in the ILN ICOS was elevated in all treated groups including 
IGRP206-214/D3 while undetectable in PBS. These data demonstrate that BDC2.5mim/D3and 
Dual/D3 treatments may indeed induce ICOS+ ChgA-specific Tregs, however the 
experiment needs to be repeated in order to validate the induction of ChgA-specific Tregs 
and their ability to produce ICOS and IL-10. Furthermore, further investigation is required to 
address an ability of IGRP206-214/D3 liposomes to activate ChgA-specific T cells. 
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Figure 6-5. BDC2.5mim/D3 and Dual/D3 treatment fails to induce ChgA-specific Foxp3+ 
Tregs.  
8-week-old female NOD mice received two weekly subcutaneous injections with IGRP206-
214/D3 (i-D3), (n=5); BDC2.5mim/D3(BDC-D3), (n=5); Dual, (n=5), liposomes or PBS (n=5) 
and culled on the tenth day. Spleen, inguinal and pancreatic lymph nodes were collected.  
A. Experimental design. B. Proportion and C. Absolute numbers of ChgA-specific CD4+ T 
cells from the total CD4+ population. D. Proportion and E. Absolute numbers of the 
ChgA+Foxp3+ population. Proportions of F. PD-1 positive ChgA+Foxp3+ population. G. 
CD44 positive ChgA+Foxp3+ population H. CD73 and CD39 positive ChgA+Foxp3+ and I.  
ICOS positive ChgA+Foxp3+ population. Standard error of the mean is shown for each 
group; statistical analysis was performed using one-way Anova; p value: ns=not significant, 
*≤0.05, **=0.009, ***=0.001, ****<0.0001. 
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In order to fully appreciate the extent to which antigen-specific treatment affects the effector 
populations, regulatory markers on the non-Foxp3 expressing ChgA-specific CD4+ T cells 
were also analysed (Figure 6-6 A-D). PD-1 expression was elevated on Foxp3- ChgA-
specific T cells in all tissues following BDC2.5mim/D3and Dual/D3 treatments compared to 
PBS. Interestingly, PD-1 was also upregulated by IGRP206-214/D3 treatment in the ILN. CD44 
was upregulated by all liposome treatments in the spleen and ILN but not PcLN compared 
to PBS. Th co-expression of the regulatory markers CD73 and CD39 was significantly 
increased in the ILN in both BDC2.5mim/D3and Dual/D3 treated animals compared to both 
PBS and IGRP206-214/D3 treated mice. In the spleen, these two treatments also resulted in 
CD39/CD73 upregulation in comparison to IGRP206-214/D3 but not PBS; and no difference 
was observed in the PcLN. Lastly, the expression of the Treg activator ICOS was increased 
in the ILN in all three liposome treated groups compared to PBS. In summary, these data 
suggest that ChgA-specific CD4+ T cells increase expression of regulatory molecules 
following both BDC2.5mim/D3and Dual/D3 treatments. Whilst there is no difference 
between BDC2.5mim/D3and Dual/D3 treatments, this warrants further investigation into the 
potency and superiority of Dual/D3 liposomal treatment compared to a single treatment. This 
can be achieved by directly comparing the suppressive ability of T cells from treated 
splenocytes as previously descried in Chapter 5. 
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Figure 6-6. ChgA+Foxp3 neg CD4+ T cells show increase in activation and anergy markers 
after subcutaneous liposomal treatment with BDC2.5mim/D3and Dual/D3. 
Female NOD 8-week-old mice received two weekly subcutaneous injections with IGRP206-
214/D3 (i-D3), (n=5); BDC2.5mim/D3(BDC-D3), (n=5); Dual, (n=5), liposomes or PBS (n=5) 
and culled on the tenth day. Spleen, inguinal and pancreatic lymph nodes were collected 
and the proportion of A. PD-1 expression on ChgA-specific Foxp3 neg CD4+ T cells from 
the total ChgA+ population B. CD44 expression on ChgA+Foxp3 neg population C. CD73 
and CD39 expression on  ChgA-specific Foxp3 neg CD4+ T cells from the total ChgA+ 
population D. ICOS expression of expression on  ChgA-specific Foxp3 neg CD4+ T cells 
from the total ChgA+ population. Standard error of the mean is shown for each group; 
statistical analysis was performed using one-way Anova; p value: ns=not significant, *≤0.05, 
**=0.009, ***=0.001, ****<0.0001. 
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6.2.5 PD-1 and CD44 expression by IGRP-specific CD8+ T cells is equally upregulated 
after both IGRP206-214/D3 and Dual/D3 liposome treatments. 
 
In the experiment described above, the proportion of IGRP-specific CD8+ T cells and their 
expression of PD-1 and CD44 (Figure 6-7 B-D) was measured.  Interestingly, a significant 
increase in the proportion of splenic IGRP-specific CD8+ T cells following Dual/D3 liposome 
delivery was noted, whilst no significant increase was seen in any other tissues or treatment 
groups. While the IGRP206-214/D3 treatment with two liposomal injections failed to induce 
expansion of the IGRP-specific population, CD44 expression was significantly increased 
after both IGRP206-214/D3 and Dual liposome treatment, with the former being consistent with 
single liposome delivery outcome. Interestingly, after two shots there was evidence of PD-1 
upregulation in ILN after both IGRP206-214/D3 and Dual/D3 liposome treatment. Previously 
when phenotypic surface markers on the endogenous IGRP-specific CD8+ T cell population 
after a single delivery of liposomes were analysed, no significant changes were observed. 
Whilst after a single treatment these cells had an increased expression of CD44 and reduced 
production of IFN-g, they did not increase in frequency in response to the delivered antigen, 
nor showed increase in expression of anergy markers such as PD-1, TIM3 or LAG3. 
Therefore, I investigated the effects of two weekly treatments and showed that the increase 
in antigen availability was positively correlated with PD-1 expression, confirming the notion 
of anergy or unresponsiveness of antigen-specific population.  
These data together in combination with my earlier observations in IGRP206-214/D3 treated 
groups confirms a successful antigen recognition by IGRP-specific CD8+ T cells and despite 
the lack of proliferation their apparent activation and display of anergic phenotype following 
the treatment. However, in Dual/D3 treatment there is currently no evidence of tolerance 
induction and increase in the frequency of IGRP-specific CD8+ T cells remains a concern.  
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Figure 6-7. Two treatments with liposomes containing both IGRP206-214/D3 and 
BDC2.5mim/D3 results in an increase in IGRP-specific CD8+T cell numbers and 
upregulation of their activation and anergy markers. 
8-week-old female NOD mice received two weekly subcutaneous injections with IGRP206-
214/D3 (i-D3), (n=5); BDC2.5mim/D3(BDC-D3), (n=5); Dual/D3, (n=5) liposomes or PBS 
(n=5) and culled three days after the final injection. Spleen, inguinal and pancreatic lymph 
nodes were collected and both A. Proportion and B. Absolute numbers of IGRP specific 
CD8+ T cells from the total CD8 population were calculated. C.  Expression of PD-1 and D.  
CD44 on IGRP-specific endogenous CD8+T cells. Standard error of the mean is shown for 
each group; statistical analysis was performed using one-way Anova; p value: ns=not 
significant, *≤0.05, **=0.009, ***=0.001, ****<0.0001. 
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6.2.6 Suppression of diabetes transfer following BDC2.5mim/D3 liposome treatment is 
abrogated by both dual and 50:50 liposome treatment strategies 
 
We have previously compared the regulatory and suppressive effects of splenocytes pre-
treated with IGRP206-214/D3, BDC2.5mim/D3 liposomes or PBS after co-transfer with diabetic 
splenocytes into NOD-SCID recipients and seen that BDC2.5/D3 liposomes could suppress 
diabetes transfer. Here, we posed a similar question focusing on comparison of the efficacy 
of 50:50 mixed liposomes containing 1.5 µg of each antigen per dose and ‘dual’ liposomes 
containing 3 µg of each antigen per dose. Diabetic splenocytes were mixed with splenocytes 
from female NOD mice pre-treated with either a 50:50 mix, Dual/D3, BDC2.5mim/D3 
liposomes or PBS (two weekly treatments) at a ratio of 2:1 and delivered i.v. into NOD-SCID 
female recipients. Blood and/or urine glucose was measured daily for diabetes progression. 
The Kaplan-Meier survival curves for individual groups are shown in Figure 6-8. The 
animals that received only splenocytes from diabetic mice rapidly developed disease and 
there was a significant delay in the disease development between these animals and the 
ones received BDC2.5mim/D3, 50:50 and Dual pre-treated splenocytes. Interestingly the 
group that received splenocytes from PBS treated mice also showed a slight delay in the 
disease progression indicating that a certain level of protection was transferred. It is possible 
that Tregs transferred from PBS treated mice aged between 8 and 10 weeks still displayed 
some suppressive ability [289]. Neither 50:50 nor Dual/D3 liposomal treatment delayed 
diabetes progression to the extent of BDC2.5mim/D3 derived cells when compared to PBS. 
Therefore, it appears neither of these treatments are sufficient to offer both Treg-mediated 
suppression and inactivation of CD8+ effector T cells. In summary, these data show that only 
BDC2.5mim/D3 treatment results in optimal induction of Tregs and addition of IGRP206-214 
peptide provides no further benefit and is potentially detrimental due to an expansion of 
IGRP-specific CD8+ T cells. 
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Figure 6-8. Splenocytes from animals treated with BDC2.5mim/D3 liposomes successfully 
suppress effector function of diabetic splenocytes, whilst both 50:50 and Dual liposomes fail 
to do so. 
A. Experimental design. B. Kaplan-Meier survival curves for NOD-SCID mice that received 
107 splenocytes from diabetic NOD mice (red), n=10; a mix of 107 diabetic splenocytes and 
5x106 splenocytes from PBS treated NOD mice (black),n=9 ; a mix of 107 diabetic 
splenocytes and 5x106 splenocytes from IGRP206-214/D3/BDC2.5mim/D3 mix (50:50) treated 
NOD mice (blue), n=5; a mix of 107 diabetic splenocytes and 5x106 splenocytes from Dual 
liposomes treated NOD mice (orange), n=5; a mix of 107 diabetic splenocytes and 5x106 of 
splenocytes from BDC2.5mim/D3 treated NOD mice (green), n=5; Data is combined from 
two separate experiments. p value: ns=not significant, *≤0.05, **=0.009. Data was analysed 
using log-rank Mantel Cox test. 
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6.2.7 BDC2.5mim/D3 but not Dual/D3 liposome treatment upregulates PD-L1 expression 
on CD8+ DCs. 
 
I have previously reported that 4-week s.c. treatment with IGRP206-214 resulted in a reduction 
in CD8+ DC numbers, suggesting a possible CD8+ T cell-driven elimination of cross-
presenting DCs. I now investigated whether dual liposome treatment also results in loss of 
CD8+ DCs or induces a tolerogenic phenotype from a DC perspective. NOD mice (8-week-
old females) received two weekly subcutaneous treatments with IGRP206-214/D3, 
BDC2.5/D3, Dual/D3 or PBS. Spleen, ILN and PcLN were collected 24 hours after the 
second injection (Day 8) and CD86 and PD-L1 expression was analysed on both total 
CD11c+ DCs and cross-presenting CD8+ DCs (Figure 6-9). The proportion of CD11c+ DCs 
remained unchanged across all tissues and treatments with an exception of splenic 
conventional DCs in BDC2.5mim/D3treated mice where a slight decrease was noted 
compared to PBS and CD8+ DCs in the ILN where a slight increase in their proportion 
compared to IGRP206-214/D3 treated mice was observed. CD86 expression remained at a 
similar level to PBS treated mice across all treated groups in all analysed tissues. 
Interestingly, PD-L1 expression provided a further insight into the difference between 
BDC2.5mim/D3and Dual/D3 liposome treatment. PD-L1 expression on both total and CD8+ 
DCs in the BDC2.5mim/D3treated animals was significantly higher compared to IGRP206-
214/D3, Dual/D3 and PBS in the ILN, and compared to IGRP206-214/D3 and PBS in the PcLN. 
Splenic PD-L1 levels remined unchanged amongst all treated groups. The interaction 
between PD-1 and PD-L1 is of great importance in the autoimmunity setting and tolerance 
[338] and an increase in PD-L1 expression is associated with negative immune regulation  
[210, 211]. The current data suggests that BDC2.5mim/D3 treatment provides more robust 
protection than 50:50 or Dual/D3 treatment via induction of more functional Tregs and 
increased expression of PD-L1 on DCs. Furthermore, it is apparent from the recent data that 
inclusion of IGRP206-214 epitope dampens these responses as well as increases the 
proportion of CD8+ effector population. 
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Figure 6-9. Subcutaneous liposomal treatment with BDC2.5/D3, but not IGRP206-214/D3 
or Dual/D3 causes an increase in PD-L1 expression on total CD11+ DCs and CD8+DCs. 
Female NOD 8-week-old mice received two weekly subcutaneous injections with IGRP206-
214/D3 (i-D3), (n=5); BDC2.5mim/D3(BDC-D3), (n=5); Dual, (n=5), liposomes or PBS (n=5) 
and culled on the eighth day. Spleen, inguinal and pancreatic lymph nodes were collected 
and the proportion of A. Total CD11c+ DC population gated from MHC class II+ cells B. 
CD86 expression on total CD11+ DCs C.  PD-L1 expression on CD11c+ DCs D.  Proportion 
of cross-presenting CD8+ DCs out of total CD11c+ DCs, E. CD86 expression on CD8+ DCs 
F.  PD-L1 expression on CD8+ DCs was calculated. Standard error of the mean is shown 
for each group; statistical analysis was performed using one-way Anova; p value: ns=not 
significant, *≤0.05, **=0.009, ***=0.001, ****<0.0001. 
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 Discussion 
 
This chapter explored the possibility of using a combination of diabetogenic antigens and 
calcitriol encapsulated within liposomes to maximise their therapeutic effect. The effects of 
IGRP206-214/D3 treatment has been discussed extensively throughout the previous chapters, 
and it was established that whilst it inactivates pathogenic CD8+ T cells and plays a role in 
the reduction of proinflammatory cytokines production, the overall effectiveness is still 
limited. The discussion of detailed mechanisms and effects resulting from 
BDC2.5mim/D3liposomal treatment were beyond the scope of this study. However, the 
apparent benefits described by Bergot et al. included the generation of ChgA-specific Tregs 
and a significant delay in disease progression when treatment is started at the onset of 
hyperglycaemia (unpublished data) posed an obvious question about combining the two 
treatments in an attempt to induce more robust tolerance. by tolerising a wider range of 
antigen-specific T cells and potentially employing different mechanisms to do so. 
Furthermore, translational aspects of multi- peptide immunotherapy need to be evaluated. 
It is likely that in humans a longer peptide containing both CD4 and CD8 epitopes will be 
used in order to both inactivate pathogenic CTL responses as well as induce regulatory 
populations [339]. Therefore, this study can contribute to better understanding of 
mechanisms of tolerance induction when different antigenic peptides are administered 
together. Furthermore, provision of CD4 help can interfere with induction of tolerance and 
addition of calcitriol to liposomes might prevent activation of antigen-specific T cells [340]. 
This was further investigated in the context of our treatment. 
Initially, to assess the potency of both liposomes together, a simple mixing of IGRP206-214/D3 
and BDC2.5mim/D3liposomes at 1:1 ratio was performed. This, however, resulted in a 
reduced antigen delivery, halving their amount compared to previous experiments where 
100µL of liposomes containing 3µg of peptide and 40ng of calcitriol was administered. 
Interestingly, however; whilst the ChgA-specific CD4+ T cells expanded similarly in both 
BDC2.5mim/D3and 50:50 treated groups, there was a slight increase of IGRP-specific CD8+ 
T cells, suggesting a possibility of CD4+ T cell help to induce CD8+ effector responses. This 
was further confirmed by even more pronounced effect on IGRP-specific T cell expansion 
after Dual/D3 liposomal treatment. CD4 T cell help during priming is an important aspect for 
forming immunological memory and T cell expansion after secondary encounter with 
antigen. Upon CD8+ T cell priming in the presence of CD4+ helper T cells, CD8+ T cells 
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undergo clonal expansion while those that did not receive help can also initiate cytotoxicity 
and pro-inflammatory cytokine release, they do not undergo clonal expansion [341, 342].  
An interesting concept emerged several decades ago proposed that CD4+ T cells that 
express CD40L engage with DCs via CD40-CD40L pathway resulting in ‘DC licensing’. This 
results in activation of DCs which in turn activate effector CD8+ T cells. The importance of 
CD40 was highlighted in the original model [343-345] and since it has been proposed that 
CD4+ help can still occur in the event where the APC doesn’t express CD40. Furthermore, 
the importance of close proximity between CD4+ and CD8+ was highlighted and the role of 
DC was described to initiate that contact [346]. The model described in our study relies on 
the DCs presenting both CD4 and CD8 epitopes simultaneously. Interestingly, the treatment 
at hyperglycaemia showed a delay in disease progression with 50:50 treatment. At this stage 
it is unclear which mechanism was responsible for this protection and further investigation, 
particularly into the Treg markers is required. It can be speculated that Tregs or the type 1 
regulatory cells (Tr1) [347] have expanded after treatment rendering it protective. However, 
the effectiveness or sustainability of Tregs may have been compromised due to reduction in 
PD-L1 expression and/or increase in IGRP-specific CD8+ T cells. The importance of PD-L1 
in the induction and maintenance of Tregs has previously been demonstrated. It plays a vital 
role in sustaining the Foxp3 expression and therefore suppressive function of Tregs [348]. I 
have noted that there was an increase in IGRP-specific CD8+ T cells in the PcLN after 50:50 
treatment, however IFN-g and GzmB production were not altered suggesting that the effector 
function of the CD8+ T cells was not impacted. Admittedly, one of the limitations of this 
experiment is that Foxp3 expression on CD4+ T cells wasn’t measured and an assessment 
of Treg induction couldn’t be made. The IFN-g production by ChgA-specific CD4+ T cells in 
BDC2.5mim/D3and 50:50 treated groups did not increase compared to IGRP206-214/D3 and 
PBS.  
The main objective of the combination therapy was to enhance the effects of IGRP206-214/D3 
therapy by inducing regulatory mechanisms that BDC2.5mim/D3 treatment had to offer. The 
reduced antigen availability seen in 50:50 liposomes needed to be corrected and therefore, 
a Dual/D3 liposome was devised where the amount of antigen was the same as in the single 
peptide treatment. However, this further disproved the benefits of this combination therapy 
as the IGRP-specific CD8+ T cell population expanded even further. Furthermore, when the 
suppressive ability of T cells from liposome treated splenocytes to suppress diabetes 
transfer was tested the only liposomal therapy to induce regulation was BDC2.5mim/D3 and 
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in this scenario significantly delayed the disease progression in NOD-SCID recipients. This 
could be explained by further expansion of the transferred IGRP-specific CD8+ T cells 
skewing the balance towards effector T cells. In future, this can be corrected by sorting CD4+ 
T cells and testing their suppressive capability in the presence of anti-CD3 and ant-CD28 
stimulation. As previously mentioned Bergot, et al. described a successful induction of Tregs 
after the BDC2.5mim/D3 treatment. In this study no increase in Foxp3 expression after 
treatment was seen. Therefore, further investigation and repeat of the experiments 
assessing the Treg markers is necessary.  
The current study has also began addressing the antigen dosing in the multi-epitope 
liposomal delivery. Initially, it was speculated that reducing the antigen in a 50:50 delivery 
contributed to the lack of protection in pre-diabetic animals. However, treatment of 
hyperglycaemic mice resulted in the similar level of protection as did the IGRP206-214/D3 
treatment. Whilst the reduced antigen availability may still be of importance here, I have not 
sufficient evidence to confirm that. The increase of IGRP-specific CD8+ T cells seemed to 
be more pronounced after two treatments with Dual/D3 liposomes compared to 50:50 
treatment. However, the experiments differed in design and weren’t performed together. The 
aforementioned adoptive transfer of pre-treated splenocytes and splenocytes from diabetic 
animals into SCID recipients showed that neither 50:50 nor Dual/D3 liposomes induced 
regulatory mechanisms. This, however, did not address a question of dosing and needs to 
be further investigated. A direct comparison of 50:50 and Dual/D3 liposomal treatments as 
well as reduced dose of IGRP206-214/D3 and BDC2.5mim/D3 and their ability to induce Tregs 
or anergy of IGRP-specific CD8+ T cells needs to be made in the same experiment. This will 
allow to test the potency of these liposomes. 
The final piece of the puzzle that argues against combining both epitopes into a liposomal 
therapy was the reduction in PD-L1 expression after Dual/D3 treatment compared to 
BDC2.5mim/D3 treatment. Ansari et al., demonstrated the importance of PD-1-PD-L1 
pathways in the development of autoimmunity and maintenance of tolerance [338, 349]. PD-
L1 blockade in 10-week-old female NOD mice resulted in rapid disease development [349]. 
Recent study in EAE demonstrated that reduction in PD-L1 expression on DCs resulted in 
the exacerbation of the disease. Furthermore, PD-L1 expressed on CD11c+ DCs has been 
described to inhibit the differentiation of T follicular helper cells (Tfh) and T follicular 
regulatory cells (Tfr). More specifically, this study demonstrated, that PD-1 expression 
played role in inhibiting the activation of MOG-specific CD4+ T cells [350]. Moreover, the 
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loss of PD-L1 on DCs caused increase of Tfh cell in the blood, resembling observations in 
PD-L1 deficient mice [351]. In Chapter 5 I showed that a 4-week long IGRP206-214/D3 
treatment resulted in a reduction in the DC population and subsequent reduction in PD-L1 
expression in splenic CD8+ DCs. Here, however, the proportion of both total and cross-
presenting CD8+ DCs remained unaffected after two liposome treatments, but PD-L1 
expression after Dual/D3 treatment did not increase to the extent seen after BDC2.5mim/D3 
treatment. It can be speculated that addition of vitamin D3 increased the ability of DCs to 
convert CD4+ T cells into IL-10 producing antigen-specific Tregs. Also, an increase in PD-
L1 expression may also be associated with vitD3 treatment as demonstrated previously by 
Unger, et.al. [99]. The lack of upregulation in the IGRP206-214/D3 treated groups can be 
associated with aforementioned killing of DCs and requires further investigation. 
In summary, the combination treatment has been proven to be a “double-edged sword’ 
where inclusion of CD4 peptide results in activation of CD8+ T cells rather than the intended 
induction of Tregs whereas addition of CD8 peptide causes increase of IGRP-specific CD8+ 
population, reduction of PD-L1 and potential killing of DCs. 
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Concluding Remarks 
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 Antigen-specific Immunotherapy: The Once and Future Therapy for T1D. 
 
7.1.1 Current study 
 
The aim of the journey this thesis embarked upon was to further understand the challenges 
of ASI for type 1 diabetes and bring us closer to designing a tolerising immunotherapy with 
a specific focus on CD8+ T cell tolerance. The importance of the delivery vehicle and delivery 
route as well as careful consideration of antigenic peptide(s) to be targeted and co-delivery 
of an immunomodulatory compound all needed to be assessed. Liposomes have been 
widely used clinically as drug delivery systems with an excellent safety record and have the 
capacity to encapsulate both hydrophobic and hydrophilic compounds [352]. This delivery 
system boasts versatility required for our antigen-specific tolerising immunotherapy delivery 
targeting CD8+ T cells in NOD mice.  
It is now well appreciated that effector CD8+ T cells play a major role in destruction of b cells 
and therefore, designing a therapy aiming to induce islet-specific CD8+ T cell tolerance is a 
challenge worth undertaking. IGRP has been described as a major diabetogenic antigen in 
NOD mice and IFN-g producing IGRP-specific CD8+ T cells have been found in human T1D 
patients [353]. Another important piece of our therapy ‘puzzle’ is the APC-T-cell interaction. 
DCs and other APCs present islet-antigens and mediate T cell activation and subsequent 
pancreatic tissue destruction in T1D. Therefore, enforcing DCs to maintain their tolerogenic 
immature state associated with low expression of MHC class II and co-stimulatory molecules 
such as CD80 and CD86 may well be critical for effective antigen-specific immunotherapy 
[354]. The immunomodulatory agent calcitriol, an active form of vitamin D, 1,25(OH)2D3, 
has been widely studied over the past several decades due to its immunoregulatory and 
anti-inflammatory potential and due to its role in inhibition of NF-kB activation [292, 355]. 
With the use of transgenic 8.3 mouse models I have shown that liposomes encapsulating 
IGRP206-214 and D3 efficiently deliver their contents to APCs 24 hours post-injection resulting 
in successful presentation of antigen to T as seen in the proliferation and increase in 
activation markers on 8.3 T cells 4 days after delivery. The endogenous IGRP-specific 
population did not proliferate or showed increase in expression of activation markers after a 
single liposomal treatment. To investigate this further, the amount of IGRP206-214 peptide was 
increased to 6µg/mouse compared to 3µg/mouse. However, increasing the peptide 
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concentration did not increase proliferation or activation markers of the endogenous IGRP-
specific CD8+ T cell population. However, the production of IFN-g was significantly increased 
in the group treated with 6µg IGRP206-214/D3 liposomes compared to IGRP206-214/D3. As the 
increase in IFN-g production is not a favourable outcome of the treatment, increasing the 
peptide concentration was ruled out as a candidate for tolerance induction. I have further 
shown that the endogenous IGRP-specific CD8+ T cell population required multiple 
liposomal treatments to respond to antigenic stimulation. And whilst no population expansion 
was observed, both CD44 and PD-1 expression was upregulated after two weekly 
subcutaneous treatments and reduction in IFN-g was noted even after a single delivery of 
liposomes. Whilst I did not note increase in activation of T cells after one liposomal 
treatment, there is a possibility that markers used were not sensitive enough to detect early 
activation. In order to address this in the future CD69 as an early activation marker can be 
used [356]. Moreover, it has long been appreciated that T cell clone avidity directly impacts 
responses to antigenic stimulation. The IGRP-specific 8.3 T cells display high avidity and 
therefore can be efficiently activated in response to antigen. However, the endogenous 
IGRP-specific CD8+ T cell population comprises of clones with a wide range of avidities and 
may have decreased sensitivity to peptide MHC complex and therefore did not respond in 
the same manner as the transferred cells [357, 358]. In future, TCR profiling and use of 
multimers could be considered to address difference in avidity and efficiency of responses 
to antigen. 
The route of delivery is also a very important factor that needs to be considered as the 
pharmacokinetics and mechanisms of action may differ depending on the route of 
administration. Certainly, the subcutaneous delivery of therapeutic agents is a preferred 
option by both patients and healthcare professionals. This is due to the fact that it is less 
invasive than intravenous, easy to administer and whilst it may not be applicable to all 
therapies, the possibility of self-administration is greatly beneficial to patients [359]. During 
the course of this study, IV and SC routes were initially compared with later experiments 
performed using SC delivery only. I have demonstrated that whilst liposomal content gets 
successfully delivered to splenic and pancreatic lymph nodes DCs after systemic IV 
treatment, its efficacy may be compromised by induction of effector CD8+ T cells. It was 
evident in both NOD-SCID and pre-diabetic NOD mice as the IV treatment did not delay the 
disease development. Furthermore, when assessing liposome efficacy after a single 
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treatment, there was sufficient evidence to suggest that i.v. delivery is in any way 
advantageous compared to s.c. treatment.  
One of the major issues with murine disease incidence studies is the low sample number 
and lack of appropriate randomisation. The animals in this study were randomly allocated to 
treatment groups in both prediabetic and onset stages of the disease. I demonstrated that 
subcutaneous delivery of liposomes containing IGRP206-214/D3 delayed disease 
development in NOD-SCID mice, prediabetic and hyperglycaemic NOD mice compared to 
IGRP206-214 only or PBS treated animals. In NOD-SCID mice, treatment was initiated after 
splenocytes were transferred from diabetic NOD donors and a significant delay in the 
disease development was observed after subcutaneous but not intravenous treatment, 
further supported by the blood immunomonitoring data. My observations revealed that there 
was no increase in the endogenous IGRP-specific CD8+ T cells in the peripheral blood of 
s.c. IGRP206-214/D3 treated NOD-SCID mice compared to IGRP206-214 only and PBS 
treatment where the proportion of endogenous tetramer+ population increased during the 
course of the treatment. It is noteworthy, however, that after re-constitution of cells analysis 
of peripheral blood can be challenging due to the risk of lymphopenia development. The 
disease protection in NOD mice was attributed to inactivation and anergy of IGRP-specific 
CD8+ T cells as well as elimination of CD8+ cross-presenting DCs resulting in reduction of 
DC-T cell interactions and lack of further antigenic stimulation. Moreover, it has been 
previously been reported that generation of IGRP-specific regulatory CD8+ T cells 
successfully prevented T1D development in NOD-SCID mice when transferred with 
splenocytes from diabetic mice [360]. However, in the current model there was no evidence 
to support induction of regulatory populations as demonstrated in NOD-SCID model after 
transfer of pre-treated and diabetic splenocytes.  
There was a clear indication in outcome of the incidence studies that encapsulation of 
calcitriol within the liposomes has a beneficial tolerogenic effect. The disease was delayed 
in both pre-diabetic and hyperglycaemic animals treated s.c. with IGRP206-214/D3 but not with 
IGRP206-214 only. The limiting factor was that no D3 only or irrelevant peptide together with 
D3 administration was assessed. However, as later demonstrated during treatment at 
hyperglycaemia irrelevant peptide and D3 (LLO/D3) did not delay the disease development 
and mice became diabetic at a similar rate to PBS treated animals. Throughout this study I 
tried to demonstrate the effects of D3 on DCs during both short term and long-term 
treatments. Whilst the results require further confirmation, early evidence suggests that DCs 
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exhibit tolerogenic phenotype as demonstrated by the increase of PD-L1 on total DCs after 
BDC2.5mim/D3 treatment. This further supports inclusion of vitamin D3 within the liposomes 
due to their ability to induce Tregs [99].  
I previously discussed that delivery of BDC2.5/D3 liposomes induced production of antigen-
specific IL-10 and ICOS producing Tregs (unpublished data). Whilst the CD4-specific 
treatment is beyond the scope of this thesis discussion, I decided to utilise previous findings 
and deliver both CD8 and CD4 epitopes together with calcitriol, hypothesising that the 
effects of treatment will be maximised through both induction of Tregs and reduction of CD8+ 
T cell cytotoxicity. Despite the fact that this work requires completion, the evidence I have 
presented suggests that addition of a CD4 epitope in either 50:50 or dual liposomes doesn’t 
induce Tregs required for disease suppression nor does it offer more robust tolerance 
induction compared to a subcutaneous treatment with IGRP206-214/D3. The former was 
evidenced through the experiments where splenocytes from liposome treated and diabetic 
mice were co-transferred in NOD-SCID recipients and the only splenocytes capable of a 
Treg-mediated suppression were splenocytes treated with BDC2.5/D3 liposomes and 
surprisingly not 50:50 or Dual/D3 liposomes containing both CD4 and CD8 epitopes. On the 
contrary, the treatment resulted in the increase of antigen-specific effector CD8+ T cells. One 
possibility that can be further explored here is initiation of treatment with BDC2.5mim/D3 
prior to administration of IGRP-specific treatment. This would allow robust Tregs induction 
followed by antigen-specific targeting of pathogenic CD8+ T cells. 
A recent study described a possibility of inducing antigen-specific CD4+ and CD8+ T cell 
responses using tailorable nanoemulsion (TNE) to target tumour antigens to cross-
presenting DCs [361]. As approach described in this study utilised non-specific targeting, 
therefore a possibility of targeted delivery to a specific population of DCs may need to be 
considered in the future. In T1D, the development of a multi-epitope DNA vaccine has 
recently received a lot of attention due to simplicity of its production, relatively low cost and 
effectiveness [362]. To date plasmid DNA (pDNA)-encoded proinsulin and GAD65 have 
been tested and treatment resulted in prevention or delay of T1D development in NOD mice 
[261, 363, 364]. As with other ASI therapies where a single antigen is used, the issue of 
epitope spreading is not being addressed and therefore restricts successful therapy 
outcomes. Dastagir, et al. have recently described the use of a DNA construct expressing 
epitopes from a range of b cell antigens and its ability to successfully and efficiently stimulate 
different antigen-specific CD4+ and CD8+ T cells [339]. The use of mimotopes with a superior 
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antigen-specific T cell engagement ability compared to native sequences, as well as 
intracellular differential MHC targeting were utilised to ensure high-affinity antigen 
presentation [365-367]. This group’s work further investigated the effects of DNA construct 
delivering multiple epitopes and demonstrated a broader involvement of antigen-specific 
CD4+ and CD8+ T cells resulting in protection from T1D in NOD mice [339]. Similar to my 
investigation of the effects of Dual liposomes, they found did not observe a significant 
increase in antigen-specific Foxp3+ Tregs. However, CD73 and PD-1 expressions were 
upregulated suggesting that tolerance may be achieved through anergy [339]. Another 
recent peptide immunotherapy study MultiPepT1De investigated the safety profile 
intradermal delivery of multiple b-cell antigens in subjects with recent onset of T1D and an 
HLA-DRB1*0401 genotype. Early reports indicate that therapy was well tolerated, and no 
exacerbation of the disease observed compared to controls [368]. However, the trial 
outcomes have not yet been finalised and yet to be published. At this stage the Dual 
liposomal treatment described in this thesis doesn’t appear to be therapeutically superior 
compared to a single epitope. There was no disease exacerbation noted and some level of 
protection was achieved in hyperglycaemic mice. Therefore, further investigation is required. 
The observations in aforementioned studies are very encouraging and therefore a further 
evaluation of the mechanisms of multi-peptide liposomal treatment is required. The diagram 
below (Figure 7-1) provides a brief summary of the observed outcomes do date after a s.c. 
liposomal treatment using single epitopes IGRP206-214, BDC2.5mim (courtesy of Dr Bergot, 
unpublished data) and combination of IGRP206-214 and BDC2.5mim. 
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Figure 7-1. A schematic representation of liposomal delivery mechanism of action and effect 
on target T cell populations.  
Hydrophilic antigenic peptides are encapsulated within a core (yellow represents MHC class 
I peptides and green - MHC class II peptides) and hydrophobic compounds such as 
immunomodulator calcitriol (pink) within a shell of a liposome. After uptake by DCs, antigens 
are processed through MHC molecule and presented to (1) CD8+ T cells rendering the 
antigen-specific CD8+ T cells unresponsive or anergic as evidenced by induction of PD-1 
and reduction in production of IFN-g. (2) CD4+T cells inactivating antigen-specific CD4+ T 
cells and inducing IL-10 producing antigen-specific Tregs (Bergot, et al., unpublished data). 
(3) Combination of both CD4 and CD8 epitopes has led to the increase of antigen-specific 
effector CD8+ T cells as well as lack of Treg induction and reduction of PD-L1 on DCs 
indicative of their maturation. 
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 Future directions and study limitations 
 
Liposomal therapy is a promising approach for delivering antigen-specific and anti-
inflammatory treatment to induce tolerance and prevent autoimmunity. This work has paved 
the way for further investigation into the mechanisms of tolerance induced by liposomal 
treatment targeting antigen-specific CD8+ T cells. The study described here also provides 
an important information about targeting CD4 epitopes and may have applicability to other 
diseases than T1D.   
As there are a wide range of diabetogenic antigens that can serve as potential candidates 
for this therapy and be encapsulated within liposomes, the next logical step would be to test 
these possibilities. In the current age of personalised medicine, screening for a response to 
a particular antigen and designing an individual therapy could be an attractive option. It 
would be necessary to test other CD8 multiple epitopes both in isolation and in combination 
for their ability to induce tolerance. A possibility of constructing a multi-epitope vaccine could 
also be further explored. However, a particular attention should be paid to multiple epitopes 
interfering with tolerance induction as demonstrated in Dual and 50:50 liposome treatment 
in this study.  Furthermore, the reduction of IFN-g production by IGRP-specific CD8+ T cells 
was identified as one possible mechanism responsible for delay in T1D development in NOD 
mice. Therefore, using IFN-g knock-out mice or IFN-g blocking antibody together with 
liposomal treatment would be a good way to confirm this further. Moreover, a detailed 
investigation into DC subsets is required to confirm whether the of these cells killing indeed 
occurs. One possibility would be to perform an in vivo elimination assay using antigen-
loaded DCs [312].  
Another important factor to be considered is the association between MHC class I 
expression, islet infiltration and T1D development that has been studied extensively over 
the past several decades, though its mechanisms remain poorly understood [27, 369-371]. 
In humans the degree of inflammation varies between pancreatic lobes and whilst some are 
not affected, others display increased insulitis preceded by overexpression of MHC class I 
[370]. Human pancreas is generally inaccessible for investigation and analysis of MHC class 
I expression on the donor tissues using laser-capture microdissection can be technically 
challenging [372] and therefore assessment of murine pancreas can be performed. The IFN-
g production was reduced after liposomal treatment and therefore MHC class I expression 
may be downregulated. One of the future directions of the study described in this thesis 
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could be to assess the MHC class I expression on murine pancreatic islets and to further 
evaluate the effects of liposomes on insulitis and disease development [373].  
Finally, the crucial importance of APCs in the context of antigen-specific therapy as well as 
their role during the disease development cannot be ignored. [362]. Recent study in EAE 
demonstrated tolerance induction after i.v. administration of soluble myelin antigen. The 
treatment resulted in the expansion of immature CD11c+CD11b+ DCs characterised by the 
low expression of co-stimulatory molecules such as CD80, CD86 and CD40  and increased 
production of IL-10, IL-27 and TGF-b [374]. Furthermore, IL-27 expression in DCs has been 
described to reduce the induction of effector Th1 and Th17 cells in EAE. Another molecule 
shown to be of importance to mediate these effects was ENTPD1 (CD39) [375]. Therefore, 
it is necessary to conduct a detailed investigation into DC subsets by possibly depleting total 
DCs or individual subsets and assessing the phenotypic characteristics and expressions of 
aforementioned molecules after a liposomal treatment. 
 
 Conclusion 
This thesis highlighted the benefits and challenges of ASI in T1D. Whilst it brings us closer 
to understanding the mechanisms that aid disease protection in NOD mice after the 
liposomal treatment, it needs to be appreciated that even multiple deliveries of a single 
peptide together with calcitriol may not be sufficient for a long-term robust tolerance 
induction. Liposomal treatment with IGRP206-214/D3 delayed the development of T1D, 
however the effects of this treatment appear to either ‘wear off’ with time or other epitopes 
become prominent and cause disease. Longer treatment may need to be considered; 
however, this partly defeats the purpose of antigen-specific immunotherapy where a short-
term treatment is hoped to induce long-term effects without a need for daily insulin injections. 
Moreover, a careful consideration and design of combination therapy may be required as it 
was demonstrated in this study when both BDC2.5 and IGRP206-214 peptides encapsulated 
together did not induce tolerance, but on the contrary increased the proportion of IGRP-
specific CD8+ T cells. It is likely that future T1D therapy will have to be a multi-step process 
addressing regulation, inflammation and effector T cell responses at different time points. 
As personalised treatment becomes a cornerstone of modern medicine, we can be confident 
that a nanoparticle-based approach such as liposomal therapy discussed in this thesis will 
rise to the challenge and create possibilities to tailor treatments for T1D. 
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Please check all details below and inform the Animal Welfare Unit within 10 working days if anything is incorrect.
Activity Details
Chief Investigator: Professor Ranjeny Thomas, The University of Queensland Diamantina Institute
Title: Pathogenesis and treatment of type 1 diabetes
AEC Approval Number: UQDI/217/15/NHMRC/JDRF
Previous AEC Number: UQDI/429/12/NHMRC/JDRF
Approval Duration: 13-Jul-2015 to 13-Jul-2018
Funding Body: JDRF, NHMRC
Group: Health Sciences
Other Staff/Students: Hanno Nel, Ali Baradaran, M Arifur Rahman, Diahann Jansen, Daphne Montizaan, Irina 
Buckle, Michelle Kappler, Lisa Nagl, Jennie Tyler, Kamil Sokolowski, Zaied Bhuyan, 
Richard Linedale, Karen Herd, Lisa Craig, Lauren Windt, Muralidhara Maradana, Emma 
Hamilton-Williams, Ryan Galea, Kendall Hepple, Linda Rehaume, Ben Harvie, Anne-
Sophie Bergot, Suman Yekollu, Nathan Boase, Nishta Ramnoruth, Emily Duggan, Kylie 
Hengst, Brian Tse, Natalie Goh, Filip Nesic
Summary
Subspecies Strain Class Gender Source Approved Remaining
Mice - genetically 
modified
BDC12-4.1 Adults Mix Institutional 
Breeding Colony
216 216
Mice - genetically 
modified
NOD Adults Mix Commercial 
breeding colony
2160 2022
Mice - genetically 
modified
G9C8 Adults Mix Institutional 
Breeding Colony
264 264
Mice - genetically 
modified
NOD 8.3 Thy1.1 Adults Mix Commercial 
breeding colony
128 98
Mice - genetically 
modified
NOD Thy1.1 x 
BDC2.5
Adults Mix Commercial 
breeding colony
68 68
Mice - genetically 
modified
NOD 
CD45.1/CD45.2
Adults Mix Commercial 
breeding colony
72 72
Mice - genetically 
modified
NOD CD45.2 Adults Mix Institutional 
Breeding Colony
420 420
Mice - genetically 
modified
BDC2.5 Thy1.1 Adults Mix Institutional 
Breeding Colony
60 60
Mice - genetically 
modified
BDC4.1 Adults Mix Institutional 
Breeding Colony
180 180
Permits
Location(s): PA Hospital Translational Research Institute (TRI)
Cumbrae-Stewart Building
Research Road
Brisbane Qld 4072 Australia
Animal Welfare Unit
UQ Research and Innovation
The University of Queensland
+61 7 336 52925 (Enquiries)
+61 7 334 68710 (Enquiries)
+61 7 336 52713 (Coordinator)
animalwelfare@research.uq.edu.au
uq.edu.au/research
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Mice - genetically modified (NOD, Mix, Adults, Commercial breeding colony)
10 Jul 2015 Initial approval 1680 1680
17 Dec 2015 Mod #7 60 1740
31 Dec 2015 Use in 2015 (from 2016 MAR) -138 1602
21 Apr 2016 Mod #9 420 2022
Mice - genetically modified (G9C8, Mix, Adults, Institutional Breeding Colony)
10 Jul 2015 Initial approval 144 144
31 Dec 2015 Use in 2015 (from 2016 MAR) 0 144
21 Apr 2016 Mod #9 120 264
Mice - genetically modified (NOD Thy1.1 x BDC2.5, Mix, Adults, Commercial breeding colony)
10 Jul 2015 Initial approval 48 48
7 Aug 2015 Mod #2 change of strain 0 48
17 Dec 2015 Mod #7 20 68
31 Dec 2015 Use in 2015 (from 2016 MAR) 0 68
Mice - genetically modified (NOD CD45.2, Mix, Adults, Institutional Breeding Colony)
21 Apr 2016 Mod #9 420 420
Mice - genetically modified (NOD CD45.1/CD45.2, Mix, Adults, Commercial breeding colony)
10 Jul 2015 admin ajustment (initial approval) 72 72
Mice - genetically modified (NOD 8.3 Thy1.1 , Mix, Adults, Commercial breeding colony)
10 Jul 2015 Initial approval 48 48
17 Dec 2015 Mod #7 20 68
31 Dec 2015 Use in 2015 (from 2016 MAR) -30 38
21 Apr 2016 Mod #9 60 98
Mice - genetically modified (BDC4.1, Mix, Adults, Institutional Breeding Colony)
21 Apr 2016 Mod #9 180 180
Mice - genetically modified (BDC12-4.1, Mix, Adults, Institutional Breeding Colony)
10 Jul 2015 Initial approval 216 216
31 Dec 2015 Use in 2015 (from 2016 MAR) 0 216
Mice - genetically modified (BDC2.5 Thy1.1, Mix, Adults, Institutional Breeding Colony)
21 Apr 2016 Mod #9 60 60
Description Amount Balance
Approval Details
Provisos
Personnel Proviso:
Michelle Kappler is listed as a participant on this project. According to our records, we have not received a response 
regarding  this nomination. These participants cannot work on an approved project until they have confirmed involvement 
via electronic signature or, via email notification being sent to the Animal Welfare Unit Administration Officer 
awu.aec.hs@research.uq.edu.au
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Please note the animal numbers supplied on this certificate are the total allocated for the approval duration
1. When ordering animals from Animal Breeding Houses
2. For labelling of all animal cages or holding areas.  In addition please include on the label, Chief Investigator's name and 
contact phone number.
3. When you need to communicate with this office about the project.
It is a condition of this approval that all project animal details be made available to Animal House OIC.
(UAEC Ruling 14/12/2001)
The Chief Investigator takes responsibility for ensuring all legislative, regulatory and compliance objectives are satisfied 
for this project.
This certificate supercedes all preceeding certificates for this project (i.e. those certificates dated before 11-May-2016)
Please use this Approval Number:
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Research Road
Brisbane Qld 4072 Australia
Animal Welfare Unit
UQ Research and Innovation
The University of Queensland
+61 7 336 52925 (Enquiries)
+61 7 334 68710 (Enquiries)
+61 7 336 52713 (Coordinator)
animalwelfare@research.uq.edu.au
uq.edu.au/research
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